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ABSTRACT 
 
 
In 1999, Saskatchewan Health sanctioned licensed pharmacists in the 
province to initiate Exception Drug Status (EDS), also referred to as prior 
approval, requests on behalf of their patients.  The objectives of this study 
were to obtain pharmacists’ opinions about the benefits of the EDS program 
to stakeholders, and to identify factors associated with pharmacists initiating a 
request.  
 
In the fall of 2004, a census of community-pharmacy managers in 
Saskatchewan was conducted using a postal questionnaire, consisting of an 
introductory letter, two survey mailings and one reminder card.   The 
questionnaire consisted primarily of seven-point Likert scale questions, and 
was analyzed using descriptive statistics and frequencies, followed by non-
parametric analysis using Mann-Whitney U and Kruskal-Wallis tests; post-hoc 
analysis was carried out using the Bonferroni test. 
 
A response rate of 82.6% was achieved.  Those living in Saskatoon or 
Regina made up 39% of respondents, with another 39% located in centres of 
less than 5,000 people.   
 
A majority of respondents (63%) agreed or strongly agreed the EDS program 
benefited patients and the Drug Plan (64%).  Only 15%, 37% and 39% of 
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respondents agreed or strongly agreed EDS benefits pharmacists, physicians 
and the health care system respectively. 
 
Factors that were important or very important to pharmacists in deciding 
whether they would initiate an EDS request on behalf of their patient were: 
the ability of the pharmacist to obtain the required information to initiate the 
EDS request (77%); their ability to contact the prescribing physician (70%); 
and patient centred concerns such as the ability to pay (74%) or the patient 
had exceeded their deductible (66%).  However, time (39%) was not as 
important relative to other factors in whether the pharmacist would apply for 
EDS on behalf of their patient.   
 
The majority of respondents agreed or strongly agreed that changing the 
policy in 1999 was beneficial to patient care (71%), while it also contributed 
substantially to their administrative workload (87%).   
 
The results of this study indicate community pharmacy managers in 
Saskatchewan acknowledge that the Exception Drug Status process is 
beneficial for their patients.  While pharmacists were supportive of the 
benefits of an EDS program, their apprehensions towards the program lie in 
the administrative processes, particularly in obtaining the required 
information, from physicians, to submit a claim.  There is also concern with 
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the methods pharmacists must use to apply for EDS, which can be 
burdensome and prolong the administrative process. 
 
To enhance pharmacists’ support for the program it may be necessary to 
develop strategies designed to reduce the administrative workload associated 
with the program, and to streamline the efficient communication of required 
information between the prescriber and pharmacist.  Alternatively, financial 
compensation to pharmacists for their expertise and efforts might be 
considered; although this would not address the workload and communication 
concerns of pharmacists, it does provide recognition for their professional role 
in securing appropriate drug therapy for their patients. 
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1. INTRODUCTION 
1.1 General Background 
 Health care operates in an ever changing environment.  Within this 
environment is the profession of pharmacy and the interconnected factors 
that aid, hinder and shape pharmaceutical care.  As health care delivery 
evolves, so too does pharmacy practice.  Pharmacy has advanced from a 
time when apothecaries ground and created in-exact compounds to the 
current state where pharmacists are integral to the delivery of sophisticated 
drug products and services.  Within this dynamic environment are many 
obstacles including the challenges of appropriate drug utilization, cost control, 
affordability, and access to effective pharmaceutical agents.   
To address these issues, public and private drug plans have 
developed various management strategies.  However, some of these 
strategies become sources of contention between payers, patients and health 
care providers; particularly those policies that restrict what may be prescribed 
or dispensed.  While these strategies may limit access to required drugs, 
patients may also find it more difficult to qualify for financial assistance.  
Pharmacists are increasingly required to perform additional administrative 
tasks before they can dispense the medication to the patient [1].  As well, 
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pharmacists often find themselves in the difficult position of mediating 
between the physician, patient, drug plan, and conflicting expectations.     
Escalating growth in drug utilization and costs has also “escalated 
demand for pharmacists that has outpaced supply” [2].  As a result, the 
average community pharmacy in Canada filled over 43,000 prescriptions in 
2002, compared to just under 36,000 in 1995 [3]; a growth of 20.8 percent.  At 
the same time the number of community pharmacies also grew, up from 
6,527 in 1995 to 7,296 in 2002 [3]; a growth of 11.8 percent.   
 
1.2 Statement of Problem 
 
 As drug utilization rates continue to grow, so too do the costs of 
providing prescription drug coverage for both public and private insurers.  As 
well, “irrational use of cost-effective medicines reduces their effectiveness 
and their cost-effectiveness [4].”  Over time this has led to the use of various 
managerial methods, such as restrictive formularies, to control the utilization 
of prescription medicines while maintaining access to effective therapy 
through the use of policies such as Saskatchewan Health’s Exception Drug 
Status (EDS) program.    
In Saskatchewan, the EDS program has been an area of concern due 
to the potential for reduced access that might occur as the result of 
administrative delays in completing the necessary paperwork.  To improve 
access, beginning in 1999, Saskatchewan Health sanctioned licensed 
pharmacists in the province to apply for EDS (also referred to as prior/special 
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authorization) on behalf of their patients.  Prior to 1999, only those 
practitioners licensed to prescribe in the province were able to initiate such 
requests.   
While allowing pharmacists to initiate the EDS request appears to be a 
logical step toward improved access to appropriate drug therapy for patients, 
it raises the concern that this policy change might be overburdening 
pharmacists, with a shifting of administrative duties and workload from 
physicians to pharmacists.   
Recently [1997], restrictive formularies, special authorizations and 
increased cost-sharing have been introduced to curb escalating 
expenditures.  While some costs have been reduced through the 
development of these plans, the administrative costs of implementing 
these changes and explaining them to patients has shifted to the 
pharmacists [5]. 
   
 Finally, in July 2004, Saskatchewan Health began implementation of a 
Maximum Allowable Cost (MAC) policy, also referred to as reference-based 
pricing, beginning with Proton Pump Inhibitors (PPIs).  With this change in 
policy, the pharmacists’ role in the administration of the Drug Plan further 
increased.   
 
1.3 Purpose of Study 
 
 Since the sanctioning of licensed pharmacists to initiate EDS requests 
in 1999, research has not been conducted within the province pertaining to 
how the policy has affected community pharmacy practice.  This study sought 
to obtain the opinions of community-pharmacy managers with regard to 
Saskatchewan Health’s EDS program, and the affect the policy has on 
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community pharmacy.  A secondary rationale for the study was to gain 
baseline knowledge from community-pharmacy managers towards 
Saskatchewan Health’s Maximum Allowable Cost (MAC) policy, and the 
effect of the policy on community pharmacy. 
 
1.4 Research Questions 
 
 To address these issues, the following research questions were posed: 
1. In the opinion of community-pharmacists, which stakeholders benefit 
from Saskatchewan Health’s Exception Drug Status (EDS) program? 
 
2. To what extent do pharmacies in Saskatchewan participate in the EDS 
program? 
 
3. Under what circumstances will a pharmacist initiate an EDS request?  
 
a. Is the initiation of an EDS request part of the continuum of care 
pharmacists provide to their patients?   
b. Do pharmacists have access to all the information necessary to 
initiate an EDS request? 
c. Is additional administrative workload a factor when initiating an 
EDS request? 
 
4. How is the new Maximum Allowable Cost (MAC) policy affecting the 
administrative workload of pharmacists?   
 
a. Has the number of EDS requests initiated by pharmacies 
changed since the implementation of MAC? 
b. Do pharmacists have sufficient information on MAC to allow 
them to adequately explain the policy to patients? 
c. Since the implementation of MAC, have pharmacists been 
spending more time with patients explaining the Drug Plan?  
 
 
1.5 Significance of Study 
 
 The significance of this study lies in gaining baseline knowledge from 
community-pharmacy managers with regard to Saskatchewan Health’s EDS 
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and MAC policies.  This knowledge may be used to help inform those who 
implement such policies, primarily government sponsored drug plans, by 
relaying the opinions of those who carry out this administrative duty. 
 
1.6 Relevant Terms and Definitions 
 
FORMULARY: a catalog of therapeutically effective drugs of demonstrated 
quality that have been approved for coverage/reimbursement under a given 
drug plan [6]. 
OPEN FORMULARY: a listing of pharmaceutical preparations available to be 
prescribed in a given setting. 
CLOSED FORMULARY: a listing composed of pharmaceuticals that have 
been approved for reimbursement at a preconceived level. May also be 
referred to as a Restricted Formulary, Limited Use List, or Preferred 
Medicines List. 
PRIOR AUTHORIZATION: “a cost-control policy that restricts the use of 
services by requiring pharmacies to obtain advance approval before 
dispensing certain drugs, usually effective drugs for which there are less 
costly therapeutic alternatives” [7].  May also be referred to as Special 
Authorization/Approval, Prior Approval or Exception(al) Drug Status. 
REFERENCE-BASED PRICING: a base price is established for each 
therapeutic class through an evaluation process and if the patient wishes to 
acquire a pharmaceutical other than the base, the patient is required to pay 
the difference unless the physician or pharmacist has obtained prior 
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authorization for the more expensive medication.  May also be referred to a 
Maximum Allowable Cost. 
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2. LITERATURE REVIEW 
 In reviewing Saskatchewan Health’s Exception Drug Status (EDS) 
program and the role of community pharmacists, the relevant literature is 
presented in the following manner.  First, an overview of the changing nature 
of health care in Canada.  This is followed by a review of the formulary 
system, along with a summary of the objectives of a formulary system.   
 The fourth section reviews the characteristics of the main types of 
formularies (open and closed), as well as their underlying mechanisms.  This 
is followed by a synopsis of the drug review process in Canada and 
Saskatchewan.  Alternatives and complements to formularies are covered, 
followed by resistance to the formulary concept.   
Once matters pertaining directly to the formulary system have been 
addressed, other related issues will be explored, such as administrative 
workload.  Next, the issue of remuneration is focused on, followed by 
automated adjudication.  The literature review concludes with a summary of 
the issues presented. 
 
2.1 The Dynamic Nature of Health Care 
 
 Medicare, or the publicly funded part of the Canadian health care 
system, as defined by the Canada Health Act (CHA), is based on five 
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principles: public administration, comprehensiveness, universality, portability, 
and accessibility [8].  Although the CHA is a federally funded program, each 
province administers the services that are part of the Act through transfer 
payments.  Medicare and the CHA are meant to ensure all Canadians receive 
first dollar care for all necessary physician and hospital services.   
Notable by their absence, most prescription drugs are not covered 
under Medicare.  Individual provinces exercise full discretion over any publicly 
funded program that might be made available; the result is a patchwork of 
coverage, with most prescriptions not publicly funded.  Thus, despite the 
objective for a publicly funded health care system, deficiencies in the CHA 
allow private enterprises to offer pharmaceutical insurance [9].   
When Medicare was implemented in 1948 in Saskatchewan, and 
nationwide in 1964, pharmaceutical care and drug therapy played a minor 
role in health care [10].  The prevailing strategy was towards treating 
diseases once onset had occurred, instead of prevention, and may have led 
to a failure to appreciate the important role pharmaceutical preparations 
would play in future health care.   
Health care in Canada has evolved to its current state through various 
transformations. This evolution began with two open-ended, cost-sharing 
programs where funds were transferred to the provinces from the federal 
government: the Hospital Insurance and Diagnostic Services Act of 1958 that 
insured in-hospital care, and in 1968 with the Medical Care Act which insured 
all physician services [11].  In 1977, there was an adjustment in the transfer 
   8
payment mechanism to block funding, which linked a formula that took into 
account various measures, such as increases in population and gross 
domestic product [11].   
The final change came in 1984 with the adoption of the CHA which 
prohibited any direct charges or deductibles for services insured under the 
CHA [8, 11-14].  This allowed the federal government to withhold transfer 
payments to the provinces if the province violated the regulations of the CHA.  
However, a recent Supreme Court ruling has determined that it is 
unconstitutional for provinces to restrict access to medically necessary 
procedures [15, 16].  Therefore, if the ruling stands, private insurers may 
enter the system to cover medically necessary procedures, such as hip 
replacement surgery.  Only time will tell if this ruling is challenged and/or 
overturned and whether there will be changes to the interpretation of the CHA 
by the provinces as a result.   
Throughout the 1990s, the federal government cut transfer payments 
to the provinces in order to balance federal budgets.  As a result, provincial 
governments reduced spending on health care, most notably to hospitals, and 
began to consolidate hospitals under regional authorities [13, 14].  This shift 
in funding resulted in procedures being pushed out of the hospital to be 
performed in out-patient settings and/or using other technologies, such as 
prescription medications, to reduce the time and money spent in hospitals.   
As health care becomes less focused on hospital and physician care 
… and more on community care and drugs …, less and less services 
fall under the rules of Medicare [14].   
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 Not surprisingly, with changes in how health care was provided, 
utilization rates and expenditures for prescription drugs began to increase [2, 
3, 17].  To control this growing area of health care expenditure, at least in 
terms of its effect on public expenditures, provincial governments began to 
look for ways to reduce prescription drug coverage for some or all of their 
beneficiaries; for example, by providing coverage only to seniors and children 
in poor families, or increasing co-payments and deductibles. 
In Saskatchewan, where the government implemented the provincial 
drug plan in the mid-1970s, all costs were covered publicly, with the 
exception of a dispensing fee [14, 18].  Today, while residents are still 
“covered” by the provincial drug plan, most beneficiaries must meet an 
annual, income-based deductible (3.4% of household income [6]) before 
receiving any financial support from the government; approximately one-
quarter of beneficiaries receiving a prescription in a given year will receive a 
financial benefit through the provincial drug plan [6].  Ironically, the very 
policies that restrict the coverage of prescription medications can also 
contribute to reduced patient adherence and in the long run increase costs to 
the health care system [19] and other sectors of society. 
 
2.2 The Formulary System 
 
Regardless of the nature of the funding mechanism in a health care 
system, whether public or private, a common characteristic is the use of 
formularies.  Formularies are found in both ambulatory and hospitals settings.  
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The basic premise of a formulary is to provide a listing of pharmaceutical 
agents that are available in a given health care setting/region [20].   
Formularies are thought to be an effective way to improve the efficacy 
and efficiency in the health care environment, without sacrificing the health 
and welfare of patients [21].  Recently, formularies have started to serve a 
more ‘administrative’ purpose for clinical reasons, such as reducing adverse 
drug events [22].  Formularies have also evolved from merely listing available 
agents, to providing a method for containing and monitoring costs and 
expenditures [7]. 
While there is some debate as to the primary purpose of a formulary, 
they are an important factor in decisions affecting the therapeutic treatment of 
patients.  There are seemingly too many pharmaceuticals on the market, with 
some being inferior to others, and others having a higher initial drug cost 
and/or replicating the therapeutic worth of an existing and proven agent.  
Thus, invariably, some agents will be excluded from the formulary. 
Economic considerations also limit the number of agents as the initial 
cost of some agents are seen as too large to a health care system and/or 
drug plan to cover all pharmaceuticals available.  With the costs of 
medications rising rapidly, due in part to new, more efficacious agents, it is 
increasingly important to ensure that drugs be prescribed as rationally as 
possible; yet physicians’ choices of drugs frequently fall short of the ideal 
circumstance of precise and cost-effective assessment [23].   
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2.3 Objectives of a Formulary System 
Formularies have been developed in response to specific forces which 
have affected pharmaceutical utilization and costs.  Specifically, this is 
in response to an increase in the aging population requiring more 
drugs, inflation in the acquisition cost of drugs, increasing utilization, 
and the introduction of new technology [24].   
 
If carefully designed, a formulary can assist prescribers in choosing the 
safest, most effective pharmaceutical agent [25].  However, formularies are 
continuously being challenged as to their benefit and detriment in the health 
care arena.  The intent of formularies is to identify pharmaceuticals that are 
the most therapeutically suitable and cost-effective in order to provide for the 
health interests of a particular patient population [26].  Naturally, this is an 
inherently difficult task [20].     
It must be recognized that medications and their applications are often 
complex, especially when considering the fact that an agent may have 
therapeutic worth outside its labeled indications.  Formulary systems seek to 
establish a standard of care in pharmaceutical therapy, as opposed to a mere 
compilation of pharmaceuticals [27].  However, groups assigned to develop 
and maintain formularies, such as pharmacy and therapeutic committees, 
may disagree as to the worth of a pharmaceutical; whether considering 
efficiency, effectiveness, initial and future costs, or any topic brought about in 
deliberations.   
Drug formularies, when implemented and administered correctly, can 
be crucial methods for delineating and directing prescribing to the most 
appropriate drugs; however, complete recognition of their potential has been 
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burdened by insufficient comparative data on drug efficacy/safety and limited 
resources for formulary development.  Use of a carefully planned formulary 
theoretically provides the foundation for guiding prescribers in choosing the 
safest and most effective agents for treating particular medical conditions 
[25].   
In an ideal situation, an effective formulary would include the following 
components: 
Basic Objectives 
 
1. Specify drugs of choice as determined by relative safety and efficacy. 
 
2. Include second-line alternatives in categories where needed. 
 
3. Minimize therapeutic redundancy by excluding superfluous/inferior 
preparations. 
 
4. Maximize cost effectiveness and benefits by excluding more expensive 
agents when possible without compromising patient care. 
Operational Requirements 
 
1. Content and procedures determined by representative group of 
knowledgeable health care professionals. 
 
2. Deletion/addition decisions based on criteria consistent with scientific 
information that supports basic objectives. 
 
3. Newly marketed products added when evidence of unique therapeutic 
contribution is accumulated. 
 
4. Nonformulary orders permitted only under well-controlled protocol. 
 
5. Communication methods support user productivity and understanding. 
 
6. Adequate administrative support [25]. 
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2.4 Formulary Types 
 Individually, formularies and formulary systems are as varied as the 
institutions that establish them.  However, most ascribe to a number of 
common characteristics.  Below are the two principle formats (open and 
closed) to which most formulary systems generally conform.   
Of note, regardless of the type of formulary, there is often some form of 
a co-payment or deductible that must be paid up front by the patient.  A co-
payment may come as a set fee per prescription, such as $3.00, or a set 
percentage of the prescription cost, such as 35%.  A deductible will be in the 
form of the patient paying up to a set amount annually or semi-annually, such 
as $400 per year, or a percentage of their income, such as 3.4% in 
Saskatchewan.  After this limit has been reached, the patients’ benefits will 
start to take effect, or the drug plan will pay all, or a greater portion of 
prescription costs.   
 
2.4.1 Open Formularies 
 
An open formulary fundamentally serves the purpose of allowing the 
prescriber to know what is available for pharmaceutical therapy; the 
prescriber is encouraged to use the formulary to prescribe from, but in most 
instances the drug plan will reimburse the patient for non-formulary 
medications [28].  In some settings, if the prescriber chooses to prescribe a 
drug that is not on the formulary, the patient will incur the total cost of the 
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prescription.  There is no prior authorization mechanism in place with an open 
formulary. 
 None of the public drug plans in Canada operate as open formularies 
[29].  Open formularies are in place where competition for beneficiaries exists, 
such as in the United States, but may also be present within Canada through 
private drug plans.   
One study that looked at open formularies found that moving from a 
restricted/closed formulary, to an open formulary resulted in 720 entities being 
prescribed following relaxation in restrictions, as opposed to 397 entities 
under a restricted formulary [30].  Despite almost doubling the number of 
different pharmaceuticals prescribed, the entities prescribed once restrictions 
were relaxed only accounted for 8% of total drug claims.   
In another study, the relaxing of formulary restrictions resulted in a 
45.1% increase in the number of different pharmaceutical products 
prescribed, but again just an 8% increase in terms of total claims [28].  There 
was also an increase in the utilization of prescription, physician and outpatient 
services, while at the same time a decrease in utilization of inpatient services 
[28].   
One needs to be cautious when examining the effects of formulary 
systems, as changes in coverage of pharmaceuticals may have a direct 
impact on the utilization of other health services.  However, in a system as 
complex as health services, where numerous variables factor into patient 
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outcomes, it may be difficult to attribute cause and effect to one treatment 
mode or policy. 
 
2.4.1.1 Tiered Lists 
 
A tiered prescription list is a type of formulary that is based on the open 
formulary model.  This system works by having tiers of drugs that are 
reimbursed at differing levels.  As each tier of drugs becomes less desirable 
to insure by the drug plan, the co-payment increases for the patient.  The 
reasons for placing a drug in one tier over another will hinge on factors such 
as whether the manufacturer provides rebates for their drugs, or one drug is 
therapeutically similar and financially less costly than another [31]. 
 
2.4.2 Closed Formularies 
 
 A closed formulary is a list of pharmaceutical agents that have been 
approved for reimbursement at a predetermined level.  This register allows 
patients to obtain the pharmaceutical after receiving a prescription from a 
physician for those agents included in the formulary.  However, this type of 
formulary, by design, eliminates or reduces financial reimbursement for many 
drugs currently available for use in Canada.   
Prescription medications that would be of use for some indications may 
be eliminated due to the potential for inappropriate use in other indications or 
the cost to the payer is seen as too large.  As a way to address this problem, 
prior authorization is an essential feature of many closed formularies.   
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Occasionally, there are patients who do not respond in a positive 
manner to the listed formulary drugs; in order to account for these 
cases, methods of authorization for use of non-formulary drugs should 
be developed [24]. 
 
2.4.2.1 Prior Authorization 
Prior authorization is a cost-control policy that restricts the use of 
services by requiring pharmacies to obtain advance approval before 
dispensing certain drugs, usually effective drugs for which there are 
less costly therapeutic alternatives [7].   
 
In Saskatchewan, the prior authorization program is for 
pharmaceuticals labeled Exception Drug Status (EDS) by the Saskatchewan 
Formulary Committee.  EDS drugs are subject to the same co-
payment/deductible structure as regular formulary preparations, with the 
exception of high cost drugs where the drug plan covers the cost for the 
patient when they cannot afford the cost; this is usually for chronic medication 
use for disease states such as Alzheimer’s and Multiple Sclerosis.  For 
example, two drugs to treat Multiple Sclerosis, Betaseron ® and Copaxone ®, 
were not originally covered in Saskatchewan due to their high cost, but were 
eventually insured [32].    
There are typically seven reasons that EDS is placed on a 
pharmaceutical: 
1. The drug is ordinarily administered only to hospital in-patients, but is 
being administered in the ambulatory setting due to unusual 
circumstances. 
 
2. The drug is not ordinarily prescribed or administered in the province, 
but is being prescribed because it is required in the diagnosis or 
treatment of an illness, disability, or condition rarely found in the 
province. 
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3. The drug is infrequently used because formulary products are usually 
effective, but are contraindicated or found to be ineffective due to the 
clinical conditions of the patient. 
 
4. The drug has been deleted from the formulary, but is required by 
patients previously stabilized on the drug. 
 
5. The drug has potential for use outside its labeled indication. 
 
6. The drug has the potential for the development of widespread 
inappropriate use. 
 
7. The drug is more expensive than those already listed on the formulary 
and only offers an advantage in a limited number of indications [6]. 
 
Formularies and prior approval programs also look to influence 
prescribing decisions, and many times are used interchangeably and/or 
complimentary to one another [26].  Information commonly requested when 
submitting a claim for prior authorization includes the diagnosis for the patient 
requiring the medication, prior drug therapies initiated for the particular 
condition, and the response to previous therapies.   
As an administrative tool, prior approval programs require the 
prescriber, or pharmacists in Saskatchewan beginning in 1999, to obtain prior 
consent in order for their patient to be reimbursed for the prescription in 
question [21].  Via an Internet search of provincial and territorial government 
websites (Appendix L), Newfoundland and Labrador is the only other province 
that has granted authority to pharmacists to initiate prior authorization 
requests.   
With prior authorization requests in Canada, there is no emergency 
supply of the drug in question before approval is obtained; however, 
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programs do reimburse the patient if the request is approved by backdating 
the approval to the date when the request was made.  There are programs 
elsewhere, such as the Iowa Medicaid program, which allow up to a 72 hour 
emergency supply of the medication [33].   
Prior authorization often creates increased administrative workload for 
those involved in obtaining the drug approved for the patient.  A Canadian 
survey of community pharmacists found that prior authorization programs 
were the third most significant issue in terms of administrative services; the 
most significant was having to explain drug plans to patients, followed by the 
insurer not reimbursing a full professional fee [5].   
Bacovsky and Virani reported that physicians in some provinces, 
including Saskatchewan, are able to charge the patient a fee for filling out 
prior authorization requests, as completing these forms is not considered to 
be part of what is reimbursed for a consultation [34].   
In Saskatchewan, physicians are remunerated for EDS submissions 
for Alzheimer and Multiple Sclerosis medications.  However, these drugs 
require the physician to perform tests before applying for EDS status, and 
may also include on-going monitoring of the patient.  As well, through the 
Medical Services Division of Saskatchewan Health, physicians are 
compensated ($4) for information requests made by pharmacists [35].  
Therefore, compensation by Saskatchewan Health is only provided to 
physicians if information is requested by the pharmacist, or the indication for 
the EDS drug is restricted and only physicians may apply for EDS.   
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2.4.2.2 Reference-based Pricing 
 
 Reference-based pricing is a policy that borrows components of open 
and closed formularies.  However, reference-based pricing has come about in 
systems where a closed formulary has been in place; they can also co-exist 
within a drug plan.   
There are some drug plans, such as British Columbia’s PharmaCare 
[10], that employ a reference-based pricing and low-cost acquisition program.  
Beginning July 1, 2004, the Government of Saskatchewan started to 
gradually introduce this mechanism, one therapeutic class at a time beginning 
with Proton Pump Inhibitors (PPIs).  Under this system, a base price is 
established for a therapeutic drug class through an evaluation process, 
usually some form of drug quality assessment.  If the patient wishes to 
acquire a pharmaceutical other than the base, the patient is required to pay 
the difference unless the physician or pharmacist has obtained prior approval 
for the more expensive medication.  Although a restricted formulary is not 
technically in place, this system encourages the selection of less expensive, 
equally effective agents.  In effect, the policy is structured to work like a 
closed formulary.     
Although there is a sense of involvement by the patient in choosing 
their pharmaceutical therapy, this type of program may increase the 
administrative burden on the health care system.  Patients are given the 
choice of having complete coverage for the reference-based drug, or paying 
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the difference to obtain a more expensive one.  However, the vast majority of 
patients do not have the information or training to make a clinically informed 
decision. 
Even though patients can access information to gain insight as to what 
is available through various mediums such as the Internet, it is often 
necessary to discuss available options with their health care professional.  As 
a result, physicians and pharmacists will continue to play an important, expert 
role in final product selection.  As well, the pharmacist or physician may be 
required to submit a prior authorization request on behalf of their patient to 
have a drug that is more costly, in terms of the drug itself, than the reference-
based drug.  This inevitably increases the administrative workload of the 
pharmacist and/or physician submitting the request.   
Within closed formularies, a form of reference-based pricing exists 
within most drug plans in Canada [36].  This is because these plans 
implement therapeutic substitution.  Therapeutic substitution allows 
pharmacists and physicians to switch from the prescribed medication, to one 
that is either bio-equivalent or therapeutic equivalent: bio-equivalent is 
switching between products that have the same ingredient drug and have the 
same bioavailability as the prescribed drug, where as therapeutic equivalent 
is switching the prescribed drug with a drug listed in the same therapeutic 
category [37]. 
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2.5 Drug Review Processes 
 
2.5.1 Saskatchewan Formulary Review Process 
 A formulary is a catalog of therapeutically effective drugs of 
demonstrated quality that have been approved for coverage under a given 
drug plan [6].  There are presently 19 different public formularies that exist in 
the country under the direction of federal, provincial or territorial governments.  
Altogether the public plans account for roughly 34% of prescription drug 
spending in Canada [17].  In addition, there are numerous private insurance 
plans.  However, these private plans tend to lend their composition to 
decisions made by the formulary committee, or a similar body, of the province 
or territory the patient resides in. 
The goal of a formulary is to provide health care providers and patients 
with a listing of prescription medications that will be reimbursed at a 
prearranged level.  To establish this process, drug plans form groups of 
health care experts, including physicians, pharmacists, economists, and may 
incorporate other stakeholders such as nurses, to objectively analyze the 
clinical and economic implications of each submission.  The factions brought 
together to ultimately compile the drug formulary is commonly referred to as 
the formulary committee, or pharmacy and therapeutics committee.   
In Saskatchewan, there are two committees that work together and 
make recommendations to the Minister of Health on what should and should 
not be included in the formulary; these groups are the Drug Quality 
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Assessment Committee (DQAC), and the Saskatchewan Formulary 
Committee (SFC).   
The mandate of the DQAC is to: 
o Evaluate manufacturer submissions for consideration for coverage of 
new drugs and report its findings to the Saskatchewan Formulary 
Committee; 
 
o Review available manufacturing documentation including clinical 
documents, scientific studies reports and published literature; and 
 
o Evaluate comparative bioavailability studies and/or comparative clinical 
studies to determine compliance with accepted standards for 
interchangeability [6].   
 
The mandate of the SFC is to: 
o Recommend to the Minister of Health additions and deletions to the 
Saskatchewan Formulary; 
 
o Consider economic information including utilization patterns, as well as 
clinical assessment by the DQAC assessment; 
 
o Provide advice in compiling and maintaining the Saskatchewan 
Formulary; 
 
o Identify those products that are interchangeable (different brands of 
the same drug that are equivalent in therapeutic effectiveness and 
quality); and 
 
o Conduct reviews of new drug products and re-evaluation of listed 
products based on new information about use, efficacy and cost [6]. 
 
After the DQAC and the SFC have reviewed the submissions, 
recommendations are made to the Minister of Health who ultimately decides if 
the pharmaceutical will be placed on the Saskatchewan Formulary and the 
stipulations to its use if need be.   
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2.5.2 The Common Drug Review 
 
Beginning in September 2003, the Common Drug Review (CDR), 
which operates as a branch of the Canadian Coordinating Office for Health 
Technology Assessment (CCOHTA), began operations.   
The CDR is a single process for reviewing new drugs and providing 
formulary listing recommendations to participating publicly-funded 
federal, provincial and territorial (F/P/T) drug benefit plans in Canada. 
All jurisdictions are participating except Quebec [38].   
 
A review is completed on all available clinical evidence, as well as a 
pharmacoeconomic evaluation. 
Being a relatively new venture, the impact of the CDR has yet to be 
evaluated.  Saskatchewan Health has begun to adapt to the changes present 
since the implementation of the CDR, in order to reduce overlap in evaluation 
procedures.   
 
2.6 Resistance to the Formulary Concept 
 
As with any policy that restricts the clinical freedom of health care 
professionals, the formulary concept has its critics.  Comments commonly 
expressed towards formularies are:  
o they interfere with the clinical freedom a physician possesses;  
o they sacrifice patient care to cost control by limiting the preparations 
available for which the patient is insured;  
o widespread use equals drug of choice if the agent is used in other 
regions and/or countries;  
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o that a specialist knows best what to prescribe their patient, not a 
diverse committee of health care professionals; and  
o education requires experience with a multitude of drugs in order to 
learn when to prescribe appropriately [25].   
Objective data on clinical trials is often not available, especially within 
the first two years a pharmaceutical is on the market.  Therefore, formularies 
can be put in place, or are in place, to restrict the use of preparations with 
insufficient clinical results, those which provide little or no therapeutic benefit 
over other agents, and/or proven preparations already on the formulary [32].  
Formularies may limit the clinical freedom of a physician, but this freedom 
should be balanced with the clinical and costing evidence used to compile 
formularies.   
“It is a common misconception that drugs are placed on a formulary on 
the basis of cost alone” [24].  The idea of sacrificing patient care to cost 
control is a narrow focus on a much larger issue.  Some may argue that this is 
due to increased drug utilization in patient treatment; however, what must not 
be lost is that newer, patented medicines are expensive and continue to flood 
the market, with many being of questionable therapeutic worth compared to 
older, established drugs [39].  Between 1990 and 2001, prescription drug 
spending in Canada rose by an average of 9% per year, with 12% of 
expenditures in health care occurring from the provision of pharmaceuticals 
[17].  Therefore, if formularies were simply in place to contain costs, one 
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would be safe to assume that this trend of rising drug expenditures would not 
be so.   
In presenting the idea that widespread use equals drug of choice, one 
needs to consider the economic implications of attempting to cover and stock 
every available pharmaceutical preparation on the market.  It just is not 
sensible, especially economically, to cover every available preparation for a 
given disease, when the majority will have little to no therapeutic advantage 
over others.  A decision needs to be made via a pharmacy and therapeutics 
committee on what best meets the needs of all involved; patient, physician, 
and insurer.   
Looking at the idea that a specialist knows best what to prescribe to 
her/his patient may be true, but with the diverse nature of patients seen, the 
specialist would have to be present in many cases to make the proper 
diagnoses.  However, this is not feasible since patients require a primary care 
physician to refer him/her to a specialist and many times the waiting list to see 
a specialist is numerous months.  What is good for one patient, or even the 
majority, is not the case in all encounters.  An informed decision needs to be 
made in pharmaceutical therapy; simply relying on the adage that the 
specialist knows best is an ill-advised approach to take in patient care within 
the current health care model [40].  Also, a diverse committee of health care 
practitioners are able to make an informed judgement on what to include in 
the formulary via reviewing all available information on the drug in question.   
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When looking at the idea that in order to become educated on various 
pharmaceutical preparations, the pharmacy and therapeutics committee has 
done much of the work for physicians by obtaining the most accurate, up-to-
date information available.  Many times the information available to a 
pharmacy and therapeutics committee is more diverse and complete than the 
information available to physicians.  Also, there is nothing holding back the 
physician from prescribing a drug, so long as it has been approved for sale in 
Canada by Health Canada.  But, the onus of payment will then fall solely on 
the shoulders of the patient in allowing physicians to educate themselves in 
varying pharmaceutical therapies.  This is unless the physician applies for 
prior authorization and has tried other preparations that were ineffective or of 
sub-optimal effect for the patient, and the application is accepted.   
As a result of the continuing resistance to the formulary concept, there 
has been movement to make the decisions affecting formularies more 
transparent [41]; improving the chance to submit input from interested 
stakeholders, as well as allowing individuals the opportunity to witness the 
selection process.  The latter idea faces some scepticism because what is 
discussed within a formulary committee meeting is not ‘common knowledge’ 
to the public and many wish to keep it this way to maintain privacy of the 
manufacturer who has a decision before the committee.   
Within committee meetings, such as the DQAC and SFC, discussing 
recommendations for inclusion into a formulary are sensitive and highly 
confidential.  In reality, if a preparation is not approved for coverage within a 
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drug plan, the result may not only be a detriment to the pharmaceutical 
manufacturer in lost revenues, but also the representative that may lose their 
job due to little or no need to promote the drug in the region.  One must also 
consider the possible effects on patient care and future health care costs.   
Formularies also exist to ideally improve prescribing decisions towards 
reducing the number of adverse drug reactions and/or hospitalizations due to 
drug interactions or inappropriate use.  If accurately developed, implemented 
and utilized, the formulary can be a risk-limiting factor [27].  What must not be 
lost in the shuffle is that formularies also look to increase the cost-
effectiveness not only of pharmaceuticals, but also in the entire therapeutic 
treatment of patients.   
The most expensive drug is not always the most effective clinically and 
vice versa.  Transparency and disseminating of decisions made by formulary 
committees should be available to educate and gain acceptance to the 
formularies merit for all stakeholders, but most importantly by the prescriber 
[40].  This can be done with final decisions and the reasoning behind the 
recommendation, but will in all likelihood not include specifics discussed 
within committee meetings.   
Some have argued that restrictions and regulations, as opposed to 
other methods such as education, are simpler and more effective strategies 
for improving prescribing practice.  While formularies have been found to be a 
valuable means of reducing inappropriate use of some medications, for many 
medications the problem is misuse of an otherwise effective agent [23].  In 
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2001, Saskatchewan listed almost 3,000 pharmaceuticals on the formulary, 
on top of over 500 Exception Drug Status preparations [18].  A formulary 
therefore lists what is ‘covered’ under a drug plan, but does not provide in-
depth information to the prescriber on the indications of the pharmaceuticals 
listed.   
 
2.7 Alternatives and Complements to Formularies 
 
In the past, formularies were primarily found in the hospital and in-
patient setting.  More recently, they are commonly found in the out-patient 
setting.  To help ensure quality pharmaceutical care, as well as fiscal 
responsibility, formularies and other administrative measures to change ways 
in which pharmaceuticals are prescribed have emerged. 
The changing nature of health care technology impacts the quality of 
care patients receive [23].  Various approaches are used to increase the 
efficiency and effectiveness of these new technologies, as well as to 
communicate the risk and benefits.  The methods used include academic 
detailing, prescribing guidelines and audit-and-feedback. 
Changes in the methods currently in place to communicate risks of 
pharmaceuticals need to be addressed [42].  Currently labelling of drugs by 
pharmaceutical firms, as required through Health Canada, aim to disseminate 
risks associated with use of the drug, as well as serving to fulfill a legal 
requirement.  Many times the contraindications and warnings may be lost in 
the plethora of information contained in the product specifications.  An 
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improvement in the partnership between pharmacists and prescribers, 
together with respect for the knowledge and strengths each has, increases 
the chance of optimal drug therapy [43] that ultimately benefits everyone, 
from those who fund health care, to the most important player, the patient. 
There is a changing role of the formulary system towards a method of 
drug-use controls, whether in terms of costs or therapeutic merit, coupled with 
an increasing role of educating prescribers in the goal of optimal drug therapy 
[44].  Transition continues from a listing of what is available and 
recommended for use, to a means in helping to ideally promote appropriate 
and cost-effective use of pharmaceuticals.  There has also been an 
expanding role within the health care segment towards increasing education 
in the direction of prescribers and other stakeholders, many times by 
pharmacists, about pharmaceuticals via what is commonly referred to as 
academic detailing [23, 45-48].  
Academic detailing was first developed and reported on in 1983 by 
Avorn and Soumerai [45], and is described as a program of one-on-one 
interactive educational outreach provided by an individual who has been 
trained to discuss prescribing decisions with physicians in a manner likely to 
induce evidence-based practice change [47].  Evidence has shown a positive 
correlation between educational programs, such as academic detailing, 
towards general practitioners with improvement in attitudes, prescribing habits 
and costs [48].     
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Similar to academic detailing, practice and/or prescribing guidelines 
are in place to help inform, while at the same time educate, prescribers in 
decisions leading to pharmaceutical therapy.  However, much like 
formularies, guidelines are in place and the prescriber is the one who 
ultimately decides whether to consult/use them or not.  Many guidelines are 
not written to the audience of the practicing physician, but instead are 
focused on scientific knowledge that may be hard to transfer into the practice 
setting [46].  The prescriber is the defining indicator as to the impact, positive 
or negative, that guidelines, formularies and such will have on the health care 
system [49].  
Access to timely information by primary health care providers needs to 
be coupled with practice guidelines, academic detailing and such if there is 
going to be significant change in the prescribers’ behaviour and practice [50].  
If needed information is not available within 30 seconds then guidelines are 
ineffective in the clinical situation; the probability that prescribers will adapt 
their prescribing decisions increases as guidelines enhance their credibility 
and simplicity of use [51].   
Another strategy designed to increase appropriate prescribing is audit-
and-feedback.  This intervention looks at the drug therapy given to a patient, 
or numerous patients, and the results are discussed between the prescriber 
and another health care professional and compared against predefined 
criteria [46].  This intervention, much like academic detailing, relies on the 
physicians’ willingness to participate.    
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2.8 Administrative Workload 
 
Physicians are vital to the development, implementation and utilization 
of the formulary.  The importance of physicians’ in formulary development is 
tacitly acknowledged by the fact that physicians are well represented on the 
advisory committees in all Canadian provinces [52].  The only other groups 
with substantial representation on formulary development committees are 
pharmacists, as would be expected, and government officials due to the 
nature of formulary systems in Canada.   
 In essence, physicians and their representative bodies exert significant 
control over the selection of pharmaceutical therapies that will be accessible 
to patients.  In order to assist and maintain the quality of care patients receive 
in a system where a formulary exists, it is vital that the involvement and 
support include the prescriber [53].  “Ultimately, the individual prescriber 
retains control over his or her prescribing decisions” [27].   
The administration and managerial demand not only of clerical and 
administrative staff, but also of physicians, pharmacists, nurses and others in 
the day-to-day operations of health care, detract from time, and one would 
assume care that is available to the patient.  Sixty percent of family 
physicians reported spending 10% - 25% of their time billing and conducting 
paperwork and another 21% said more then one-quarter of their time is 
exhausted on such duties [54].  This percentage will only increase as more 
responsibilities are expected of physicians, not to mention other primary care 
providers, through formulary systems and other mechanisms such as prior 
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authorization.  The escalating pressures family physicians are facing in 
Canada are predicted to increase as the profession ages, coupled with more 
than four million Canadians already without a family physician [54].   
Collier questioned how many patients knew where physicians received 
their training, as well how long it has been since the physician received their 
formal training in medical school [55].  Due to the increasing workload 
physicians are faced with in times of contraction in health care budgets, it is 
the pharmaceutical industry that many times disseminates information on 
preparations.  This may in turn lead to implications to the health care provided 
to patients because the benefits are the focus of the industry, with risks being 
minimized or not discussed at all.   
As the rate of drug utilization continues to climb, so do the pressures 
on pharmacists for their time.  Throughout Canada there is a shortage of 
pharmacists leading to greater demands on those already practicing [5].  
Pharmacy technicians play an important role in relieving some of the time 
pressures, but the scope of his/her duties are limited, with a pharmacist still 
required to review most of the work completed by a pharmacy technician.  
Some pharmacies are beginning to use a tech-check-tech system where 
pharmacy technicians check each others work, instead of requiring the 
pharmacists to check a pharmacy technician’s work.  However, there remains 
a limit to what a pharmacy technician can perform without the participation of 
a pharmacist.   
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With pharmacists being the most accessible health care practitioner 
available to patients, many times cognitive services are sought out.  Coupled 
with this demand are administrative duties such as therapeutic substitution 
and prior authorization programs.  As well, prior authorization programs are 
time-consuming and expensive [37], and carry an administrative burden [21]. 
Since 1999, pharmacists in Saskatchewan have been authorized to 
initiate a prior authorization request on behalf of a patient.  One would 
assume that this relieves some administrative duties from physicians, and 
places the responsibility on pharmacists.  As well, pharmacists across 
Canada have “complained about their increasing workloads due to prior 
approval processes.  Valuable time is required to explain the policies, 
facilitate obtaining prior approval and providing interim supplies” [34].   
As of 2001, approximately 60% of EDS requests in Saskatchewan 
were initiated by pharmacists [56].  In fact, in cases of special claims (prior 
authorization), “it would appear that physicians are off-loading workload onto 
pharmacists.  The pharmacists in turn must provide this administrative service 
without the reassurance that the claim will be accepted” [5].   
In Saskatchewan, if the EDS claim is not approved for coverage by 
Saskatchewan Health and the patient is not prescribed a formulary drug, 
where a dispensing fee could be collected, then the pharmacist is not 
provided a fee for their service [57].  Pharmacies do not receive any fees for 
initiating an EDS request on behalf of their patient; therefore, the only 
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remuneration a pharmacy will receive is the dispensing fee if a prescription is 
dispensed.   
In a review of conclusions constructed during an optimal drug therapy 
symposium, management techniques, which rely on regulatory means, were 
reported to be generally ineffective [50].  These regulatory means, such as 
formularies and prior authorization, have been in response to 
pharmaceuticals that are many times overprescribed and/or have the 
tendency to be abused [58].   
 
2.9 Remuneration 
 
In Canada the vast majority of physicians are paid on a fee-for-service 
basis.  Therefore, in order to obtain a desirable salary, physicians are by 
default encouraged to see as many patients as possible in the shortest time 
frame.  “Because Canada’s fee-for-service system provides financial 
incentives to see as many patients as possible, prescribing drugs may be 
used as a strategy to end patient visits” [59].  Consequently when 
administrative duties are presented that require time away from patient 
consultations, the primary source of a physicians’ remuneration, resistance is 
present.   
Regulations imposed by governments, provincial licensing bodies and 
relevant professional associations, corporate practices, and inertia in 
fee systems are serious barriers to the kind of change needed to both 
relieve the current excess demand for pharmacists and to provide 
health care services at reduced costs for all Canadian consumers [60].   
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Community pharmacists in Canada are commonly paid on an hourly 
basis.  In order for a pharmacy to receive payment for pharmacists’ services, 
dispensing fees are the major, and many times the only source of revenue 
aside from sales of store front items such as over-the-counter products.  This 
is unless the pharmacy is to charge the patients directly for pharmaceutical 
services provided that lie outside of the current fee structure provided by 
Saskatchewan Health.  Therefore, when administrative duties are required, 
such as initiating prior authorization requests and contacting physicians for 
clarification on a prescribing decision, revenue is in essence being lost; this is 
exacerbated by the absence of remuneration for performing such duties.   
The payment structure for community pharmacists does not encourage 
the cognitive services that pharmacists are trained and able to do, which 
benefit the patient and the health care system as a whole [61].  The British 
National Health Service has proposed “a change in the remuneration system 
that rewards services provided and not just the volume of prescriptions 
dispensed” [62].  To date in Saskatchewan, no such plans are said to be 
under consideration.   
A move towards pharmaceutical care, such as providing cognitive 
services, has been growing in popularity since the late 1980s and has 
transformed pharmacists’ job requirements away from one that was primarily 
based on dispensing duties [63].   As well, approximately 31% of all 
prescriptions and 72% of new prescriptions require administrative services; 
with a mean of 174 prescriptions requiring such services a week per 
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pharmacy, this translates into an average cost of over $28,000 each year per 
pharmacy [5]. 
 
2.10 Automated Adjudication 
 
 Currently in Canada, automated adjudication of prior authorization 
requests in public drugs plans is non-existent.  However, most provincial drug 
plans anticipate developing and implementing an automated system [64].  
More specifically, the Quebec Department of Health and Social Services 
highlighted the need to reduce the administrative bureaucracy involved in 
prior authorization requests through such measures as submitting requests 
via the Internet [65].  Many managed care organizations in the United States 
have implemented online adjudication as part of their prior authorization 
programs [1].  Evaluation of such systems is not available, and the sparse 
literature on automated adjudication is descriptive in nature. 
The automated, online adjudication process is in place to streamline 
requests for prior authorization and encourages use of the most cost effective 
prescription medication [66].  In this system, various forms and/or prompts are 
in place for a restricted medication, and are linked directly with the point-of-
sale system within the pharmacy.  The health care professional applying for 
prior authorization must fill in the required fields to have the claim processed 
automatically.  If the system deems the information to warrant approval, then 
the request is approved without any interjection from the drug plan.  However, 
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if the claim does not meet the online system requirements, it is not approved 
and a drug plan representative then evaluates the claim. 
The automated adjudication system seeks to standardize and 
streamline the prior approval process.  Human contact from the drug plan is 
reduced to only the claims that are unique.  As well, the claimant is notified 
automatically as to whether the medication is going to be reimbursed, with the 
exception of requests requiring drug plan analysis. 
 
Figure 2.1 Automated Adjudication Process 
 
2.11 Summary 
 
 As a whole, health care is a continuously evolving entity.  When 
addressing issues related to pharmaceutical therapy, one needs to recognize 
the interconnected factors that impact and are impacted by policies governing 
Source: [1] 
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coverage of prescription drugs.  The effects of pharmaceutical policy are far 
reaching and influence how and what therapies a patient will receive while 
using the health care system. 
 No matter how one approaches the health care spectrum, physicians 
are the dominant profession.  However, physicians must work in unison with 
other health care professionals, such as pharmacists and nurses, and 
practice within environments shaped by other stakeholders, most notably the 
financiers of health care who form and implement the policies that dictate how 
health care is delivered.   
 One policy that influences the way in which a physician practices his or 
her profession is the formulary system.  Formularies are a management 
technique used to influence prescribing, from an economic and clinical 
perspective, and the choice of what pharmaceutical to prescribe, if prescribing 
is warranted, is impacted by this policy.   
 As drug experts, pharmacists play a key role in the drug therapy of 
patients.  By authorizing pharmacists to apply for EDS on behalf of his or her 
patient, Saskatchewan Health acknowledged this expertise to a greater 
extent.  However, this acknowledgment may come as more of a burden than 
a benefit to the profession of pharmacy due to the administrative 
requirements encompassed within the policy.   
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3. METHODOLOGY 
3.1 Study Design 
 
 The study design was a mail questionnaire.  A modified Tailored 
Design Method [67] was utilized to ensure the writing of questions, 
construction of the questionnaire and survey implementation were carried out 
in a manner to maximize response rate.   
For simplicity of response by community-pharmacy managers, the 
instrument was designed primarily using a seven-point Likert scale, consisting 
of 5 pages of questions, with an average of 8 questions on each page.  The 
elements not consisting of seven-point Likert scale questions were comprised 
of open-ended questions focussing on the operations of the pharmacy, such 
as the number of prescriptions filled per week, the dynamics of the pharmacy 
in which the respondent operated, and the respondent himself/herself.   
“Surveys of patients and health professionals may be perceived by the 
target respondents as having relatively high saliency, … a relatively long 
questionnaire on a health-related topic may therefore be acceptable” [68].  
Although the questionnaire was not lengthy, it could not be classified as short 
either, with time to complete the survey being under fifteen minutes.  The 
objective was to balance length with the need to cover the subject in a 
comprehensive manner.   
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The questionnaire was designed to obtain a subjective understanding 
of community-pharmacy managers’ perceptions of the EDS program. 
Dispensing has a number of interrelated components that to varying 
degrees take up a pharmacist’s time.  In effect, pharmacists have 
diverse “workloads” and attempts to control just one aspect may 
overlook something that is potentially important [69].   
 
Although some may question using subjective measures to study 
pharmacists’ workload, studies have shown that this form of data collection 
(mail survey) can be accurate [5, 70], is less intrusive than direct observation 
or work sampling, and allows research to be conducted on a larger sample 
[70, 71].  This research project was designed to obtain data on the 
behavioural nature of pharmacy practice. 
When dealing with prescription volume, community pharmacists were 
able to recall and report numbers that were found to be within ten percent of 
actual, objective numbers [5].  Therefore, questions pertaining to recall of 
prescription volume and/or workload that were part of this research project, 
although subjective, are felt to have relative accuracy. 
With modest literature on the subject matter of the questionnaire, the 
questionnaire looked to gain an overview of perceptions from community-
pharmacy managers to help formulate areas of saliency that would potentially 
deserve further investigation; therefore, subjective research was warranted 
[72].  As well, the focus of the research was on community-pharmacy 
managers’ perceptions, and not necessarily objective data one would 
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achieve, for example, by analyzing drug claims data captured at the point-of-
service terminals in pharmacies. 
 
3.2 Study Population 
 
  There are approximately 1,200 pharmacists in the province of 
Saskatchewan, and approximately 346 community-based pharmacies [73].  In 
September 2004, a list was received from the Saskatchewan College of 
Pharmacists consisting of all 346 community pharmacies in the province. This 
list was arranged to identify the pharmacy and its manager, as well as the 
mailing address.  A census was carried out of the 346 community-pharmacy 
managers.  A census of community-pharmacy managers was used to reflect 
the dynamics present in each store, and therefore was skewed towards older, 
more established professionals who were in the position of management 
and/or owner.   
 
3.3 Measures 
 
 The measures used in this study were selected for the purpose of 
understanding the environment of various community pharmacies and their 
day-to-day operations, as well as gaining an initial perspective on the new 
Maximum Allowable Cost policy that began July 1, 2004.  Described below 
are the measures that encompassed each section of the questionnaire, 
separated by sections.   
Part A –Saskatchewan Health’s EDS Program: Items in this section 
focused on EDS stakeholders and the benefits each might obtain from the 
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EDS program.  Those groups identified as having a vested interest in the 
prior authorization process are: patients, pharmacists, physicians, drug plans, 
and the health care system as a whole [21, 22, 25, 39, 74].     
Health care centres on the patient.  In regard to prior authorization 
policies, patients have a stake in the medications that are included as part of 
the policy, as opposed to not being included in a closed formulary, as well as 
the costs of the drugs to the patient.   
Another important stakeholder in any prior authorization program is the 
physician.  In most jurisdictions, physicians are the principle health care 
profession that is responsible for initiating prior authorization requests on their 
patients’ behalf.  As health care systems evolve, so do the methods of 
administering and managing the delivery of health care.  As a result, 
pharmacists are an increasingly integral part of prior authorization programs.  
In Saskatchewan, this is most evident with the sanctioning of pharmacists to 
initiate EDS requests.   
Within the mix of stakeholders lies the drug plans that develop and 
administer prior authorization programs, from a policy and implementation 
perspective, with the aid of other stakeholders.  The drug plan is looking to 
manage the costs associated with prescription medications, but is also 
seeking to improve the chances of delivering optimal drug therapy to patients 
through the management technique of prior authorization.   
The final stakeholder is the health care system as a whole.  The health 
care system’s consideration in prior authorization is in how the system is 
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affected by the decisions made with regard to policy; this would be in terms of 
health outcomes, and the resources that are saved and/or used in other 
sectors of the health care system as a result of policy decisions. 
Part B – Participation in Saskatchewan Drug Plan’s EDS Program: 
Items in this section addressed the circumstances surrounding an EDS 
request and the volume of requests received by the pharmacy [5, 75].  In 
essence, questions in this section were included to act as independent 
comparative factors to be used in the analysis of responses to measures in 
other sections of the questionnaire.  Items in this section included the volume 
of restricted and non-formulary prescriptions per week, the percentage of 
these prescriptions received that are submitted for prior authorization 
coverage, the percent submitted by the pharmacy as opposed to the 
prescribing physician, and the percent submitted by the pharmacy resulting 
from a request by the prescribing physician.   
Part C – Factors Surrounding the Initiation of an EDS Request: This 
section was devoted to understanding the circumstances under which a 
community pharmacist initiates an EDS request.  Specifically: time, patient 
ability to pay, the initiators familiarity with the policy, and the ability to obtain 
the required information [50, 58, 69, 76]. 
Time is a finite resource.  Pharmacists are limited in the amount of 
services they are able to provide in a given day by the pressures of time.  
Therefore, with the shortage of pharmacists in Canada comes the increased 
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need for efficiency with what is and can be provided.  Administrative duties, in 
particular, often reduce the time available for clinical activities.   
Patients are the focal point in providing health care services.  Despite 
the concept of universal health care in Canada, there are areas where 
patients’ are required to pay out-of-pocket expenses for certain services 
and/or technologies; in the community setting, prescription drugs are one 
such area.  The shift to reducing or all together eliminating the need for in-
patient services has resulted in patients paying for prescription drugs when 
they used to be covered via the Canada Health Act in the in-patient setting 
[13].  Therefore, the ability of the patient to pay for their prescription factors 
into whether or not a pharmacists’ energy should be put into applying for prior 
authorization.   
Whether a pharmacist will apply for prior authorization may centre on 
his or her knowledge of the policy itself.  If the pharmacist is unfamiliar with 
the policy, one of two possible scenarios may play out: first, the pharmacist 
applies for prior authorization, not knowing what is required and/or if the 
medication will be covered, resulting in uncertainty; second, the pharmacist is 
familiar with the program and will only apply if there is the likelihood of 
success as not all applications are approved (the medication will be covered 
by the drug plan).   
With many prior authorization programs, the prescriber is the sole 
health care professional that applies for coverage [37]; therefore, they have 
access to the information required by the drug plan to assess the application.  
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In Saskatchewan pharmacist are authorized to apply for EDS on behalf of 
patients, yet they do not always have the necessary information required by 
the drug plan.  Therefore, the submission hinges on the pharmacists ability to 
obtain the required information from the prescriber, which is not always 
provided. 
Part D – Appropriateness of Procedures used for Obtaining EDS: 
Items in this section sought to understand community-pharmacy managers’ 
opinions on the procedures used to submit an EDS request.  In particular, 
questions addressed whether: the respondent finds it difficult to apply for 
EDS, they have access to the required information, and they receive 
notification of the submission being accepted or rejected  [7, 39, 74, 77]. 
The difficulty in applying for EDS and if the pharmacist has the 
required information to submit the claim relate to factors that influence 
whether a pharmacist will submit the claim, which were alluded to in Part C.  
However, Part C looked at influencing factors on whether or not the 
pharmacist will apply for EDS, while this section concentrated on the 
appropriateness of the procedures in place.  In looking at whether notification 
of acceptance or rejection is received, interest focused on the communication 
between the Drug Plan and the pharmacist.  Currently, the policy does not 
stipulate that the pharmacist will be notified, even when the pharmacist 
submits the claim.   
Part E – About the EDS Program: This section addressed the 
circumstances surrounding an EDS request in the community-pharmacy.  
   46
Focus centred on: whether staff pharmacists had adequate information on the 
EDS program, the importance of pharmacist initiated EDS, the benefits of the 
policy change to patient health care, and the administrative workload as a 
result of EDS [2, 62]. 
The first question looked at whether all pharmacists within the 
respondents store had the appropriate information on administering the EDS 
program.  The second question addressed if pharmacists feel that initiating an 
EDS request is an important service they now provide to patients.   
With part of the reasoning behind administrative measures such as 
prior authorization to improve patient outcomes, the third question was 
addressing whether the respondent felt the change in policy benefits patient 
health care.  The last question in the section was direct in addressing if the 
policy change had significantly increased the administrative workload of 
pharmacists.   
Part F – Maximum Allowable Cost: This section looked to appreciate 
the experiences of community-pharmacy managers’ and their staff since the 
MAC policy began to be phased in July 1, 2004.  Emphasis was on: the 
information provided to pharmacies, the preparedness in addressing 
questions on MAC, time spent explaining the Drug Plan to patients, the 
change in EDS requests since the implementation of the policy, and the 
effects of the policy on patients access to the appropriate drug therapy [39, 
78, 79]. 
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The first item addressed whether Saskatchewan Health provided 
adequate information to pharmacies on the MAC policy.  The second 
question, which progressed logically from the first, was measuring whether 
pharmacists were prepared to answer questions on the policy.  And the third 
question addressed whether the time spent explaining the Drug Plan in 
general had changed since the implementation of the MAC policy. 
With the MAC policy decreasing the number of prescription drugs 
covered by the Drug Plan, changes might be seen in the number EDS 
requests; therefore, a question addressing this issue was included.  There is 
also the chance that restrictive policies such as MAC impair the ability of a 
patient to receive the appropriate drug therapy, and the final question sought 
to gain insight into this issue.   
Part G – The Pharmacy: Items in this section were in place to value the 
dynamics behind the pharmacy setting in which the respondent operates.  
Information was gathered with regard to: the area, location and type of 
pharmacy, the number of pharmacists and pharmacy technicians in the 
respondents store, the proximity of the prescribing physician, prescription 
volume, and the hours the dispensary was open.   
Part H – The Pharmacist Completing the Questionnaire: Items in this 
section were to capture the demographics of the respondent.  In particular, 
information sought was the gender, age, position and years in current position 
of the respondent. 
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Part I – Additional Comments: This section was an open-ended 
question where the respondent was free to add any additional comments that 
he/she felt were relevant to the subject matter of the questionnaire.  The 
responses in this section were not a part of the data analysis, but were in 
place to add to the discussion on the findings of the survey. 
 
3.4 Data Analysis 
 
 Content validity was strengthened through pre-testing with five 
community-pharmacy managers.  The validity of the questionnaire was further 
enhanced through review by the Acting Director of Pharmaceutical Services 
and Acting Executive Director of Saskatchewan Health’s Drug Plan and 
Extended Benefits Branch, and the Executive Director and Board Members of 
the Representative Board of Saskatchewan Pharmacists. As well, an expert 
in Market Research and Questionnaire Design reviewed and provided 
feedback on the structure of the questionnaire.   
Due to the fact that this was a descriptive study, the statistical analysis 
was relatively straight forward.  Therefore, analysis using descriptive statistics 
was conducted to explore means, medians, modes, standard deviation, 
ranges, etc.  Results are displayed below according to the sections of the 
questionnaire.   
With the vast majority of the data being ordinal in nature, comparative 
statistical analysis was carried out using non-parametric tests.  In particular, 
the Mann-Whitney U Test and Kruskal-Wallis One-Way Analysis of Variance 
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were used rather than the parametric methods, respectively, of an 
Independent t-Test and Analysis of Variance (ANOVA).  The Mann-Whitney U 
Test and Independent t-Test are used to compare the mean value of two 
groups; where as the Kruskal-Wallis and ANOVA tests are used to test the 
mean value of more than two groups. 
As a method for post-hoc analysis of more than two groups of non-
parametric data, the Bonferroni test was used, as opposed to the Scheffe 
method which is used when analyzing post-hoc parametric data.  The 
Bonferroni test was used to identify statistically significant differences (p < 
0.05) between respondents when comparing factors.   
Exploratory factor analysis was used to identify relationships between 
variables and consider the possibility of multi-item constructs.  Factor analysis 
identifies questions with similar or related responses, creating a single scale 
from multiple measures that allows further analysis of a single, more complex 
scale.  Comparative analysis was carried out on those constructs that were 
identified and demonstrated content validity and inter-item reliability 
(Cronbach’s alpha < 0.700).  Subsequent multi-item constructs were analyzed 
using comparative parametric tests (Independent t-test and one-way 
ANOVA). 
 
3.4.1 Qualitative Analysis and Themes 
 
Sections I and J of the questionnaire asked respondents open-ended 
questions to allow an opportunity to provide opinions and/or suggestions 
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regarding the EDS and MAC policies.  Due to the fact that these two 
questions were asked to gain general knowledge, and were not seeking 
answers to specific questions, their analysis was quite limited [80, 81].  The 
analysis was restricted to developing common themes that were present 
when compiling responses.   
 
3.5 Questionnaire Distribution and Data Collection 
 
One week prior to the questionnaire being sent out, an overview of the 
research and the reasons for the survey were sent to the sample (Appendix 
B).  This gave the subject an idea of the reasoning behind the research being 
conducted, why they were selected for the research project, the importance of 
a high response, and methods of dissemination on the research findings.   
The first wave of questionnaires (Appendix A) were mailed out one 
week after mailing the overview letter.  The questionnaire was sent along with 
a cover letter (Appendix C) and a pre-stamped return envelope.  Two weeks 
after the first wave of the survey had been sent out a reminder postcard 
(Appendix D) was mailed to those that had not responded.   
With the EDS program being a part of the daily routine of community 
pharmacists, it was anticipated that the response would be above 40% (> 140 
respondents).  “Surveys on health-related topics typically achieve better 
response rates than those on more general issues” [68].   
Surveys completed by pharmacists that involve recall similar to this 
survey have achieved response rates between 30% [82] to 52.4% [5, 83].  In 
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particular, the response rate of pharmacists in Saskatchewan for research 
conducted by Loh and colleagues was 61.2% [5].  However, to achieve a 
response rate above 40% a second wave was planned for and mailed out two 
weeks after the reminder postcard and included a cover letter (Appendix E) 
and pre-stamped return envelope.  Four weeks after the second wave of the 
survey was sent out, data collection concluded.  Each questionnaire was 
coded for administrative purposes.   
The timeline for conducting the research was: 
October 18th, 2004:  Overview of research mailed out 
October 25th, 2004:   First wave of survey mailed out 
November 8th, 2004:  Reminder postcard mailed out 
November 22nd, 2004:  Second wave of survey mailed out 
December 20th, 2004: Data collection concluded 
 
3.5.1 Non-responder Questionnaire 
 
 Despite the high response to the questionnaire, a non-responder 
survey was implemented, although not a part of the original research 
protocol, to investigate whether there were differences between responders 
and non-responders.  A total of 50 non-responder questionnaires were mailed 
out on March 7th, 2005.  The mailing included a one-page questionnaire 
(Appendix F), a cover letter (Appendix G), and a pre-stamped return 
envelope.  This was a one-time mailing, with no follow-up.  Data collection 
concluded April 15th, 2005. 
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3.6 Data Entry 
 
The analytical plan commenced once the data from all respondents 
had been compiled into a database using the Statistical Package for Social 
Sciences (SPSS© 13.0 for Windows).  The variables were labelled and coded 
in a logical pattern beginning with the first question on the questionnaire.   
 
3.6.1 Recoding 
 
 Once all the data was entered into SPSS, it was recoded for analysis 
purposes.  Collapsing and recoding of data was done to allow for an easier 
interpretation of the displayed results by those viewing the research.  All 
recoding was done before the analysis for this study.   
Where sections had seven-point Likert scale questions, these 
response categories were collapsed to create a five-point Likert scale.  The 
responses categories of Strongly Agree and Agree were collapsed into one 
category, as well as Disagree and Strongly Disagree being condensed into 
one category.  The response categories of Very Important and Important 
were collapsed into one category, as well as Unimportant and Very 
Unimportant being condensed into one category.  And the response 
categories of Greatly Increased and Increased were collapsed into one 
category, as well as Greatly Decreased and Decreased.   
 Interval and ratio data in Section B, G and H of the questionnaire were 
recoded into ordinal scales to allow analysis between independent and 
dependent variables throughout the questionnaire.   
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3.7 Ethical Considerations 
 Due to the nature of the research requiring input from community-
pharmacy managers, ethics approval was required.  Therefore, an application 
was submitted to the University of Saskatchewan Behavioural Research 
Ethics Board in July, 2004.  Approval was granted (BEH 04-175) on August 
27th, 2004 (Appendix H).   
An ethics application for a non-responder survey was submitted to the 
University of Saskatchewan Behavioural Research Ethics Board in December 
2004.  Approval for the non-responder portion of the research was obtained 
on January 6th, 2005 (Appendix I). 
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4. RESULTS 
This section begins with an overview of the response rate and 
demographic characteristics of respondents.  This is followed by analysis of 
the four research questions and sub-questions that are addressed in the six 
sections of the questionnaire.   
 
4.1 Response Rate 
 
From the original mailing list of 351 community-pharmacy managers 
and owners provided by the Saskatchewan College of Pharmacists, 5 were 
excluded due to duplication of contacts; therefore, the first mailing consisted 
of 346 questionnaires.  After the initial mailing and reminder card, 219 
questionnaires were returned, for a response rate of 63.3% (219/346).   
At this time it became apparent that some of the questionnaires mailed 
out could not be completed due to: pharmacy closure (1), pharmacy located 
on a First Nations reserve which dealt solely with Non-Insured Health Benefits 
patients (1), and satellite pharmacies that did not dispense medications (11).  
Therefore, the list of 346 was further reduced for a final study population of 
333.   
Four weeks after the second mailing, data collection closed with 
another 60 questionnaires being received for a second round response rate 
of 52.6% (60/114).  After data collection concluded, 4 additional 
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questionnaires were received, but were not included in the analysis.  Of the 
279 eligible questionnaires received, 275 were completed for a final response 
rate of 82.6% (275/333). 
 
4.1.1 Non-responder Response Rate 
 
 Of the 50 non-responder questionnaires mailed out, 15 were returned 
(30%).  All returned questionnaires were completed fully, with the exception of 
3 questionnaires where the responders choose not to enter his or her age.   
 
4.2 Demographic Characteristics 
 
Demographic characteristics were collected and are displayed in Table 
4.1.   Each characteristic is displayed according to the percentage and 
number of respondents in each category. 
Of the 275 respondents, 100 were female and 173 were male; 2 
respondents did not state gender.  In terms of community size, 105 
respondents resided in Saskatoon/Regina (53 females; 52 males), 61 
respondents resided in locations with a community size between 150,000 and 
5,000 inhabitants (21 females; 40 males), and 107 respondents resided in 
centres of less than 5,000 residents (26 females; 81 males). 
 There were 109 respondents that reported their age, with a mean of 44 
years, a range of 24 – 76 years, and a median 43 years (data not displayed).  
A total of 207 respondents answered the question on the length of time in 
their current position, which had a mean of twelve years, with 87.4% of 
respondents indicating owner or pharmacy manager as their position. 
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Table 4.1 Demographic Summary 
 
Variable 
Total 
Responses 
  N (%) 
Gender   
Female 100 (36.4) 
Male 173 (63.1) 
Total 273 (99.3) 
Position*   
Owner 100 (36.4) 
Pharmacy Manager 135 (49.1) 
Pharmacist 30 (10.9) 
Other 4 (1.5) 
Total 269 (97.9) 
Area   
Commercial 110 (40.0) 
Residential 70 (25.5) 
Mixed 95 (34.5) 
Total 275 (100) 
Location**   
Stand Alone Building 141 (51.3) 
Strip Mall 43 (15.6) 
Enclosed Mall 36 (13.1) 
Medical Building/Complex 48 (17.5) 
Other 7 (2.5) 
Total 275 (100.0) 
Type^   
Independent 115 (41.8) 
Banner 38 (13.9) 
Chain 23 (8.4) 
Franchise 31 (11.2) 
Grocery Store 44 (16.1) 
Department Store 11 (4.1) 
Mass Merchandiser 7 (2.5) 
Other 4 (1.4) 
Total 273 (99.3) 
Proximity to Prescriber^^   
Same Location 58 (21.2) 
Next Door 24 (8.9) 
Close By 72 (26.3) 
Somewhat Removed 109 (39.6) 
Distant 8 (2.9) 
Total 271 (98.6) 
Community Size   
Saskatoon or Regina 107 (38.9) 
5,000 – 150,000 People 61 (22.2) 
< 5,000 People 107 (38.9) 
Total 275 (100.0) 
 
 
 
* Collapsed Pharmacist and 
Other into one category 
(Other) for analysis 
 
 
 
 
 
 
 
 
 
** Collapsed Strip Mall and 
Enclosed Mall into one 
category (Mall), as well as 
Medical Building/Complex 
and Other into one category 
(Other) for analysis 
 
 
^ Collapsed Department 
Store, Mass Merchandiser 
and Other into one category 
(Other) for analysis 
 
 
 
 
 
 
^^ Collapsed Same Location 
and Next Door into one 
category (Same Location), as 
well as Somewhat Removed 
and Distant into one category 
(Removed) for analysis  
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On average, responding pharmacies employed 2.8 pharmacists per 
store, or 2.4 full-time equivalents per store.  A total of 70.4% of responding 
pharmacies employed 3 or fewer pharmacists, with 79.8% of responding 
pharmacies employing 3 or fewer full-time equivalent pharmacists (data not 
displayed).   
On average, pharmacies employed 1.4 pharmacy technicians per 
store, or 1.0 full-time equivalent per store.  A total of 88.9% of responding 
pharmacies employed 3 or fewer pharmacy technicians, with 94.8% of 
responding pharmacies employing 3 or fewer full-time equivalent pharmacy 
technicians (data not displayed).     
 Of the respondents, 266 (96.7%) reported the number of hours their 
dispensary was open per week.  A total of 41 (15.4%) were open 40 hours or 
less per week, 59 (22.2%) were open 40.5 – 50 hours per week, 54 (20.3%) 
were open 50.5 – 60 hours per week, 58 (21.8%) were open 60.5 – 80 hours 
per week, and 54 (20.3%) were more than 80 hours per week.  There were 
36.4% of responding pharmacies open up to 50 hours per week, with 22.9% 
open over 80 hours per week.  In total, the average responding pharmacy 
was open 62 hours per week (data not displayed).     
A total of 264 (96.0%) respondents reported the number of 
prescriptions their pharmacy fills per week: 35 (13.3%) filled 250 or fewer 
prescriptions per week, 71 (26.9%) filled 251 – 500 prescriptions per week, 
56 (21.2%) filled 501 – 750 prescriptions per week, 47 (17.8%) filled 751 – 
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1000 prescriptions per week, and 55 (20.8%) filled more than 1000 
prescriptions per week.  As a whole, the average responding pharmacy filled 
738 prescriptions per week (data not displayed).   
 
4.2.1 Non-responder Demographics 
 
 All 15 respondents reported their gender: 3 were female and 12 were 
male (Table 4.2).  In terms of community size, there were 6 respondents that 
resided in Saskatoon/Regina (1 female; 5 males), 3 respondents residing in 
locations where the community size was between 150,000 and 5,000 
inhabitants (1 female; 2 males), and 6 respondents residing in centres of less 
than 5,000 residents (1 female; 5 males).   
There were 12 respondents that reported their age, with a mean of 45 
years, a range of 32 – 63 years, and a median of 44 years (data not 
displayed).  All 15 respondents reported their current position, with 5 listing 
Owner, 9 responding Pharmacy Manager, and one Pharmacist.   
 In statistically analyzing responders and non-responders, the p-value 
was set at p < 0.05.  As displayed in Table 4.2, there were no statistically 
significant differences between responders and non-responders.  Despite no 
statistically significant differences, the results are to be approached with 
caution as the high response rate on the original questionnaire limited the 
possible number of responses to the non-responder questionnaire.  
Therefore, responses by one respondent to the non-responder questionnaire 
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may have a greater impact than would be the case if the number of 
responses were larger.   
Table 4.2 Non-responder and Responder Demographic Summary 
Variable 
Total Non-
responder 
Responses 
Total 
Responder 
Responses p Value 
  N (%) N (%)  
Gender       
Female 3 (20.0) 100 (36.4) 
Male 12 (80.0) 173 (63.1) 
Total 15 (100.0) 273 (99.3) 
0.271 
Position*       
Owner 5 (33.3) 100 (36.4) 
Pharmacy Manager 9 (60.0) 135 (49.1) 
Pharmacist 1 (6.7) 30 (10.9) 
Other 0 (0.0) 4 (1.5) 
Total 15 (100.0) 269 (97.9) 
0.847 
Proximity to Prescriber^       
Same Location 2 (13.3) 58 (21.2) 
Next Door 0 (0.0) 24 (8.9) 
Close By 6 (40.0) 72 (26.3) 
Somewhat Removed 5 (33.3) 109 (39.6) 
Distant 0 (0.0) 8 (2.9) 
Total 13 (86.7) 271 (98.6) 
0.479 
Community Size     
Saskatoon or Regina 6 (40.0) 107 (38.9) 
5,000 – 150,000 People 3 (20.0) 61 (22.2) 
< 5,000 People 6 (40.0) 107 (38.9) 
Total 15 (100.0) 275 (100.0) 
0.981 
* Collapsed Pharmacist and Other into one category (Other) for analysis 
^ Collapsed Same Location and Next Door into one category (Same Location), as well as Somewhat 
Removed and Distant into one category (Removed) for analysis  
 
 
4.3 Responder/Non-responder Comparison 
 
 Table 4.2 displays demographic comparisons between responders and 
non-responders.  Table 4.3 displays the remaining six questions that were the 
same between the responder and non-responder questionnaires.  Statistical 
significance was set at p < 0.05.  As displayed, there is no statistically 
significant difference between responders and non-responders.   
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Table 4.3 Responder/Non-responder Comparison  
 
 
Number Of 
Restricted 
& Non-
Formulary 
Drugs Per 
Week 
Percent Of 
Restricted 
& Non-
Formulary 
Submitted 
For 
Coverage 
Percent Of 
Submitted 
Initiated By 
Pharmacy 
Vs. 
Prescribing 
MD 
Percent 
Submitted 
At Request 
Of MD 
Average 
Number Of 
Prescriptions 
Per Week 
Hours 
Pharmacy 
Open Per 
Week 
Z -1.772 -.254 -.016 -.842 -1.161 -.465 
p - Value .076 .799 .987 .400 .246 .642 
 
 
4.4 Stakeholders and the EDS Program 
 
Table 4.4 Saskatchewan Health’s EDS Program 
 
 Strongly Somewhat Neutral Somewhat Strongly Total 
Question Agree/Agree Agree  Disagree Disagree/ 
Disagree 
Responses 
 
 N 
 (%) 
N  
(%) 
N 
 (%) 
N  
(%) 
N  
(%) 
N 
 (%) 
 
1. The EDS program benefits 
patients by expanding the 
number of prescription drugs 
covered by the provincial Drug 
Plan. 
 
173 
(62.9) 
 
67 
(24.4) 
 
8 
(2.9) 
 
11 
(4.0) 
 
15 
(5.5) 
 
274 
(99.6) 
2. The EDS program benefits 
patients by making their 
prescription drug more 
affordable. 
132 
(48.0) 
87 
(31.6) 
12 
(4.4) 
19 
(6.9) 
24 
(8.7) 
274 
(99.6) 
3. The EDS program benefits 
physicians by providing them 
more drug therapy choices for 
their patients. 
101 
(36.7) 
80 
(29.1) 
22 
(8.0) 
30 
(10.9) 
40 
(14.5) 
273 
(99.3) 
4. The EDS program benefits the 
Drug Plan by allowing potentially 
costly drug therapies to be 
available in a more controlled 
fashion. 
176 
(64.0) 
51 
(18.5) 
19 
(6.9) 
12 
(4.4) 
16 
(5.8) 
274 
(99.6) 
5. The EDS program benefits the 
health care system by promoting 
more appropriate utilization of 
drugs. 
106 
(38.5) 
84 
(30.5) 
19 
(6.9) 
34 
(12.4) 
31 
(11.3) 
274 
(99.6) 
6. The EDS program benefits 
pharmacists by providing them 
with an opportunity to be more 
actively involved in securing the 
most appropriate drug therapy 
for their patients. 
 
41 
(14.9) 
 
51 
(18.5) 
 
36 
(13.1) 
 
46 
(16.7) 
 
100 
(36.4) 
 
274 
(99.6) 
 
Section A of the questionnaire referred to the five stakeholders 
identified as being involved in the EDS program: patients, the Drug Plan, the 
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health care system, physicians, and pharmacists.  Respondents were asked 
to what extent they agreed or disagreed with each statement.  Frequency 
distributions were carried out for each of the six questions within this section 
and are displayed in Table 4.4.  For post-hoc analysis, statistical significance 
was set at p < 0.05. 
When asked whether the EDS program benefits patients by expanding 
the number of prescription drugs covered by the provincial Drug Plan, 62.9% 
of respondents Agreed or Strongly Agreed with the statement. Bonferroni 
analysis revealed a statistically significant difference in terms of hours the 
responding pharmacy was open.  Pharmacies open more than 80 hours per 
week (44.4%) were less likely to agree with the statement compared to 
pharmacies open up to 60 hours per week (70.8%) (χ2 = 17.094; p < 0.002) 
(Figure 4.1). 
Slightly less than half of respondents (48.0%) Agreed or Strongly 
Agreed that the EDS program benefits patients by making their prescription 
drug more affordable.  Bonferroni analysis exposed statistically significant 
differences in responses based on community size, number of prescriptions 
filled per week, hours respondents’ pharmacy was open per week, and the 
number of restricted and non-formulary prescriptions submitted for coverage. 
Respondents in Saskatoon/Regina (40.6%) were less likely to agree 
with the statement than those in a community size of less than 5,000 people 
(59.8%) (χ2 = 10.509; p < 0.005) (Figure 4.2).   
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Figure 4.1 Benefits Patients Increased Number of Drugs by Hours Open 
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Figure 4.2 Benefits Patients More Affordable Drugs by Community Size 
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Pharmacies filling 501-750 prescriptions per week (60.7%) were more 
likely to agree with the statement than those filling more than 1000 
prescriptions per week (38.2%) (χ2 = 10.250; p < 0.036).  Pharmacies open 
more than 80 hours per week (27.0%) were less likely to agree with the 
statement than those open 40.5-60 hours per week (59.3%) (χ2 = 20.865; p = 
0.00) (Figure 4.3).   
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Figure 4.3 Benefits Patients More Affordable Drugs by Hours Open 
 
 
 Pharmacies that submitted between 26-50% of restricted and non-
formulary prescriptions (35.7%) were less likely to agree with the statement 
than those submitting 86-100% (61.6%) (χ2 = 11.009; p < 0.026). 
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Participants were next asked whether the EDS program benefits 
physicians by providing them more drug therapy choices for their patients; 
36.7% of respondents Agreed or Strongly Agreed with this statement.  
Bonferroni analysis revealed a statistically significant difference with the 
number of hours the respondents’ pharmacy was open per week.  
Pharmacies open 50.5-60 hours per week (55.6%) were more likely to agree 
with the statement than those open more than 80 hours per week (25.8%) (χ2 
= 11.556; p < 0.021) (Figure 4.4).   
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Figure 4.4 Benefits Physician More Drugs Choices by Hours Open 
 
 
 A total of 64% of respondents Agreed or Strongly Agreed that the EDS 
program benefits the Drug Plan by allowing potentially costly drug therapies 
to be available in a more controlled fashion.  Bonferroni analysis revealed a 
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statistically significant difference between pharmacies in terms of the 
percentage of EDS requests that were submitted by the pharmacy versus the 
prescribing physician.   Pharmacies where 0-50% of EDS requests (43.8%) 
were submitted by the pharmacy versus the prescribing physician were less 
likely to agree with the statement than those where 51-80% were (66.7%) (χ2 
= 10.892; p < 0.028) (Figure 4.5).    
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Figure 4.5 Benefits Drug Plan More Control by Percent Pharmacy Submitted 
 
 
 There were 38.5% of respondents who Agreed or Strongly Agreed that 
the EDS program benefits the health care system by promoting more 
appropriate utilization of drugs.  Bonferroni analysis revealed a statistically 
significant difference between pharmacies in terms of community size.  
Pharmacies situated in a region where the community size was less than 
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5,000 people (46.7%) were more likely to agree with the statement than those 
with 5,000-150,000 people (26.2%) (χ2 = 7.055; p < 0.029) (Figure 4.6).   
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Figure 4.6 Benefits Health Care System by Community Size 
 
 
 Only 14.9% of respondents Agreed or Strongly Agreed that the EDS 
program benefits pharmacists by providing them with an opportunity to be 
more actively involved in securing the most appropriate drug therapy for their 
patients, while 36.4% of respondents Disagreed or Strongly Disagreed.  
Bonferroni analysis exposed a statistically significant difference between 
pharmacies with regard to the percentage of requests submitted at the 
request of the prescribing physician.  Pharmacies where 26-40% of EDS 
requests (27.7%) were submitted at the request of the prescribing physician 
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were more likely to agree with the statement than those where 0-10% (12.8%) 
and 61-100% were (10.0%) (χ2 = 11.422; p < 0.022) (Figure 4.7).   
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Figure 4.7 Benefits Pharmacist by Percent Submitted at Request of Physician 
 
 
4.4.1 Factor Analysis - Stakeholders and the EDS Program Constructs 
 Section A exposed one construct.  Reliability statistics for Cronbach’s 
Alpha based on standardized items was 0.805.  The construct is based on the 
four questions of the questionnaire that dealt with the three identified human 
stakeholders of the EDS program: patients, pharmacists and physicians.  In 
particular, patients were identified as stakeholders due to the number of 
prescription drugs covered and costs associated with the EDS program.  
While physicians were included as stakeholders as the EDS program 
theoretically provides them with more drug therapy choices, and pharmacists 
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were stakeholders by becoming more actively involved in securing 
appropriate drug therapy for patients.  See Table 4.5. 
Analysis using one-way ANOVA resulted in one factor having a 
statistically significant difference of p < 0.05.  There was a significant 
difference between pharmacies in terms of the type of pharmacy between 
independent and grocery stores (p < 0.036). 
Table 4.5 Human Stakeholder Construct 
 
 
Scale Mean 
if Item 
Deleted 
Scale 
Variance if 
Item Deleted 
Corrected 
Item-Total 
Correlation 
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Benefits Patients By # 
Of Drugs Available 10.68 14.761 .680 .520 .719 
Benefits Patients By 
Making Drugs More 
Affordable 
10.32 14.321 .612 .476 .742 
Benefits MD By More 
Drug Therapy Choices 9.82 13.023 .659 .435 .717 
Benefits Pharmacists By 
Being Actively Involved 
In Drug Therapy 
8.62 13.708 .511 .290 .801 
 
 
 
4.5 Participation in the EDS Program 
 
Section B of the questionnaire focused on how often the responding 
pharmacy dealt with prescriptions for EDS drugs.  A summary of responses 
are displayed in Table 4.6. 
The first item asked on average, how many new prescriptions for 
restricted or non-formulary medications does your pharmacy receive per 
week?  Just over half (54.1%) of pharmacies reported between 0 and 20 
restricted or non-formulary prescriptions per week.  Each pharmacy received, 
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on average, 36 restricted or non-formulary prescriptions per week, accounting 
for 4.88% of all prescriptions.  Pharmacies reported receiving anywhere from 
a minimum of one request per week, to a maximum of 400 requests per 
week.  
Table 4.6 Participation in Saskatchewan Health’s EDS Program 
 
 0 - 10 11 - 20 21 - 40 41 - 75 76 + 
Total 
Responses 
Question 
 
 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
1. On average, how 
many new 
prescriptions for 
restricted or non-
formulary medications 
does your pharmacy 
receive per week? 
87 
(31.6) 
 
62 
(22.5) 
 
56 
(20.4) 
 
31 
(11.3) 
 
39 
(14.2) 
 
275 
(100.0) 
 
 
 
0 – 25% 26 – 50% 51 – 75% 76 – 85% 86 – 100% 
Total 
Responses 
Question 
 
 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
2. On average, what 
percent of these 
restricted or non-
formulary medications 
are submitted for 
coverage under the 
EDS program? 
 
58  
(21.1) 
 
 
 
56  
(20.4) 
 
 
 
50  
(18.2) 
 
 
 
37  
(13.5) 
 
 
 
74  
(26.9) 
 
 
 
275 
(100.0) 
 
 
 
 
0 – 50% 51 – 80% 81 – 90% 91 – 95% 96 – 100% 
Total 
Responses 
Question 
 
 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
3. On average, what 
percent of the EDS 
submissions are 
initiated by your 
pharmacy rather than 
by the prescribing 
physician? 
48  
(17.5) 
 
63  
(22.9) 
 
82  
(29.8) 
 
45  
(16.4) 
 
37  
(13.5) 
 
275 
(100.0) 
 
 
 
0 – 10% 11 – 25% 26 – 40% 41 – 60% 61 – 100% 
Total 
Responses 
Question 
 
 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
 
N 
(%) 
4. On average, what 
percent of EDS 
submissions initiated 
by your pharmacy are 
the result of a request 
by the prescribing 
physician? 
117 
(42.5) 
 
41  
(14.9) 
 
47  
(17.1) 
 
30  
(10.9) 
 
40  
(14.5) 
 
275 
(100.0) 
 
 
 
 In relation to the previous response, respondents were asked on 
average, what percent of these restricted or non-formulary medications are 
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submitted for coverage under the EDS program?  An average of 59% were 
submitted for coverage.  This translated into 21.2 prescriptions per week 
submitted for coverage, with pharmacies submitting between 2% and 100% 
of restricted and non-formulary prescriptions for coverage.   
 Continuing with the progression of questions, respondents were asked, 
on average, what percent of the EDS submissions are initiated by your 
pharmacy rather than by the prescribing physician?  An average of 79% of 
EDS requests submitted were initiated by the pharmacy as opposed to the 
prescribing physician.  This translated into approximately 16.65 prescriptions 
per week submitted for EDS coverage by the pharmacy instead of the 
prescribing physician, with pharmacies reporting between 5% and 100% of 
EDS request being initiated by the pharmacy. 
 The final area of interest asked, on average, what percent of EDS 
submissions initiated by your pharmacy are the result of a request by the 
prescribing physician?  An average of 29.1% of EDS claims submitted by 
pharmacies were at the request of the prescribing physician.  Therefore, each 
responding store submitted 4.85 EDS submissions per week at the request of 
the prescribing physician, where responding pharmacies reported submitting 
between 0% and 100% of EDS submissions at the request of the prescribing 
physician.   
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4.6 Factors Associated with an EDS Request 
 
Section C of the questionnaire consisted of items used to identify 
factors that might influence whether a pharmacy initiated an EDS request on 
behalf of the patient.  Respondents were asked to rate the importance of 
each factor on whether to initiate an EDS request.  Results of analysis using 
frequency distributions are displayed in Table 4.7.  For post-hoc analysis, 
statistical significance was set at p < 0.05. 
Table 4.7 Factors Associated with the Initiation of an EDS Request  
 
 
Very Somewhat Neutral Somewhat Very Total 
 
Question 
Important/ 
Important 
Important  Unimportant Unimportant/  
Unimportant 
Responses 
 
N  
(%) 
N  
(%) 
N  
(%) 
N  
(%) 
N  
(%) 
N  
(%) 
 
1. The time 
needed to submit 
an EDS request. 
107 
(38.9) 
43 
(15.6) 
25 
(9.1) 
21 
(7.6) 
79 
(28.7) 
275 
(100.0) 
2. The ability of 
the patient to pay 
for the 
prescription. 
202 
(73.5) 
32 
(11.6) 
11 
(4.0) 
12 
(4.4) 
18 
(6.5) 
275 
(100.0) 
3. The patient 
has exceeded 
the Drug Plan 
deductible. 
181 
(65.8) 
49 
(17.8) 
17 
(6.2) 
9 
(3.3) 
19 
(6.9) 
275 
(100.0) 
4. The likelihood 
that the patient 
will eventually 
exceed the Drug 
Plan deductible. 
163 
(59.3) 
 
60 
(21.8) 
 
21 
(7.6) 
 
12 
(4.4) 
 
19 
(6.9) 
 
275 
(100.0) 
5. Your familiarity 
with the 
administrative 
processes of the 
EDS program. 
123 
(44.7) 
 
37 
(13.5) 
 
54 
(19.6) 
 
10 
(3.6) 
 
50 
(18.2) 
 
274 
(99.6) 
 
6. Ability to 
obtain all the 
information 
needed to make 
an EDS request. 
211 
(76.7) 
 
30 
(10.9) 
 
10 
(3.6) 
 
6 
(2.2) 
 
18 
(6.5) 
 
275 
(100.0) 
 
7. Ability to track 
the status of your 
EDS request 
once it has been 
submitted. 
141 
(51.3) 
 
54 
(19.6) 
 
38 
(13.8) 
 
2 
(2.2) 
 
36 
(13.1) 
 
275 
(100.0) 
 
8. Your ability to 
contact the 
prescribing 
physician. 
193 
(70.2) 
47 
(17.1) 
14 
(5.1) 
2 
(0.7) 
19 
(6.9) 
275 
(100.0) 
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 Only 38.9% of respondents reported that the time needed to submit an 
EDS request was an Important or Very Important factor in applying for EDS.  
Bonferroni analysis revealed a statistically significant difference between 
responding pharmacies with regard to the number of EDS submissions 
resulting from a request by the prescribing physician.  Respondents’ whose 
pharmacy submitted 11-25% of EDS submissions (19.5%) at the request of 
the prescribing physician were less likely to find the statement important than 
those where 26-60% were (49.4%) (χ2 = 15.685; p < 0.003) (Figure 4.8). 
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Figure 4.8 Factor Time by Percent Submitted at Request of Physician 
 
 
 Almost three-quarters of respondents (73.5%) reported that the ability 
of the patient to pay for the prescription was an Important or Very Important 
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factor in whether they will submit an EDS request.  There was no statistically 
significant difference between groups.   
 Two-thirds of respondents (65.8%) indicated whether the patient has 
exceeded the Drug Plan deductible to be an Important or Very Important 
factor.  There was no statistically significant difference between groups.   
 In terms of the likelihood that the patient will eventually exceed the 
Drug Plan deductible, 59.3% of respondents reported this to be an Important 
or Very Important factor.  There was no statistically significant difference 
between groups.   
 Less than half of respondents (44.7%) revealed that his or her 
familiarity with the administrative processes of the EDS program was an 
Important or Very Important factor.  There was no statistically significant 
difference between groups.   
 Over three-quarters of respondents (76.7%) indicated his or her ability 
to obtain all the information needed to make an EDS request was an 
Important or Very Important factor.  There was no statistically significant 
difference between respondents.   
 Slightly more than half of respondents (51.3%) reported that his or her 
ability to track the status of your EDS request once it has been submitted to 
be an Important or Very Important factor.  There was no statistically 
significant difference between respondents.   
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 Almost three-quarters of respondents (70.2%) found his or her ability to 
contact the prescribing physician to be an Important or Very Important factor.  
Bonferroni analysis revealed a statistically significant difference between 
respondents’ in terms of proximity to the prescribing physician.  Responding 
pharmacies where the prescribing physician was in the Same Location 
(54.9%) as the pharmacy were less likely rate the factor as important than 
those that were Removed (82.1%) (χ2 = 18.408; p = 0.000) (Figure 4.9). 
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Figure 4.9 Factor Contact Physician by Proximity of Prescribing Physician  
 
 There were eight separate questions on factors affecting whether a 
pharmacy will apply for EDS or not, yet only two factors, time and ability to 
contact the prescribing physician, displayed statistically significant differences 
between respondents.  This highlights the uniform nature of responses when 
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pharmacies consider whether to apply for EDS despite the diverse nature of 
community-pharmacy practice.   
 
4.6.1 Factor Analysis – Factors Associated EDS Requests Constructs 
 
Reliability statistics for Cronbach’s Alpha based on standardized items 
was 0.831.  The construct is based on the five questions of the questionnaire 
that dealt with issues pertaining directly to the pharmacist.  In particular, the 
factors included the: time needed to submit an EDS, pharmacists’ familiarity 
with the administrative processes, ability to obtain the required information, 
ability to track the status of the EDS request, and ability to contact the 
prescribing physician.  See Table 4.8. 
Table 4.8 Pharmacist Centred Issues Construct 
 
 
Scale Mean 
if Item 
Deleted 
Scale 
Variance if 
Item 
Deleted 
Corrected 
Item-Total 
Correlation
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Time Needed To Submit 
EDS 10.58 25.425 .572 .347 .804 
Pharmacist Familiarity 
With Administrative 
Processes 
10.96 28.021 .543 .301 .805 
Ability To Obtain 
Information Required 12.13 28.976 .674 .544 .771 
Ability To Track The 
Status Of EDS Request 11.38 26.536 .689 .479 .760 
Ability To Contact The 
Prescribing MD 11.98 29.604 .641 .505 .780 
 
 
Analysis using one-way ANOVA resulted in one factor having a 
statistically significant difference of p < 0.05.  There was a significant 
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difference between pharmacies with regard to the area of pharmacy between 
mixed and those situated in residential and commercial areas (p < 0.002). 
Reliability statistics for Cronbach’s Alpha based on standardized items 
was 0.756.  The construct is based on the three questions of the 
questionnaire that were patient centred concerns.  In particular, the factors 
included the: ability of the patient to pay for the prescription, patient had 
exceeded the deductible, and patient will eventually exceed the deductible.  
See Table 4.9. Analysis using one-way ANOVA resulted in no statistically 
significant difference between respondents; p < 0.05.     
Table 4.9 Patient Centred Issues Construct 
 
 
Scale Mean 
if Item 
Deleted 
Scale 
Variance if 
Item Deleted 
Corrected 
Item-Total 
Correlation
Squared 
Multiple 
Correlation 
Cronbach's 
Alpha if Item 
Deleted 
Ability Of Patient To 
Pay For Rx 4.99 7.536 .397 .158 .873 
Patient Has Exceeded 
Deductible 4.81 5.882 .692 .609 .541 
Patient Will Eventually 
Exceed Deductible 4.58 6.040 .688 .606 .548 
 
 
 
4.7 EDS Procedures 
Section D of the questionnaire was seeking to understand the 
experiences in pharmacies since the EDS program came into effect.  
Responses are displayed in Table 4.10 as analyzed using frequency 
distributions.  For post-hoc analysis, statistical significance was set at p < 
0.05. 
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Table 4.10 Appropriateness of Procedures used in Obtaining EDS 
 
 Always Usually Sometimes Rarely Never Total 
 
Question 
 
N        
(%) 
N          
(%) 
N           
(%) 
N        
(%) 
N        
(%) 
Responses 
N            
(%) 
 
 
1. Do you find it difficult to 
apply for EDS? 
 
 
14 
(5.1) 
47 
(17.1) 
137 
(49.8) 
66 
(24.0) 
11 
(4.0) 
275 
(100.0) 
2. Do you have access to 
all the information required 
by the Drug Plan (e.g. 
diagnosis relevant to use 
of drug)? 
 
15 
(5.5) 
 
 
70 
(25.5) 
 
 
78 
(28.4) 
 
 
99 
(36.0) 
 
 
13 
(4.7) 
 
 
275 
(100.0) 
 
3. When you submit an 
EDS request, do you 
receive notification from 
the Drug Plan as to 
whether the request is 
accepted or rejected? 
 
3  
(1.1) 
 
 
 
17 
(6.2) 
 
 
 
21  
(7.6) 
 
 
 
77 
(28.0) 
 
 
 
157 
(57.1) 
 
 
 
275 
(100.0) 
 
 
 Always Usually Sometimes Rarely Do Not  Total 
Question     Receive Responses 
 
 
N        
(%) 
N          
(%) 
N           
(%) 
N        
(%) 
N        
(%) 
N            
(%) 
4. If you receive 
notification from the Drug 
Plan as to whether the 
EDS request is accepted 
or rejected, is that 
notification provided in a 
timely manner (within two 
days of submission)? 
 
2  
(0.7) 
 
 
 
28 
(10.2) 
 
 
 
34 
(12.4) 
 
 
 
66 
(24.0) 
 
 
 
137 
(49.8) 
 
 
 
267 
(97.1) 
 
 
 
 
A total of 22.2% of respondents Usually or Always reported it to be 
difficult to apply for EDS.  There was no statistically significant difference 
between respondents.   
Only 31.0% of respondents Usually or Always have access to all the 
information required by the Drug Plan.  Bonferroni analysis exposed a 
statistically significant difference between respondents in terms of hours the 
pharmacy was open.  Pharmacies open 50.5 – 60 hours per week (42.6%) 
were more likely to have access to the information required than those open 
more than 60 hours per week (21.5%) (χ2 = 13.956; p < 0.007) (Figure 4.10).   
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Figure 4.10 Access to Information by Hours Open 
 
 
Respondents were asked when you submit an EDS request, do you 
receive notification from the Drug Plan as to whether the request is accepted 
or rejected, 7.3% of respondents Usually or Always receive notification; while 
85.1% of respondents Rarely or Never receive notification.  Bonferroni 
analysis revealed a statistically significant difference in terms of the 
community size the pharmacy was situated in.  Pharmacies located in 
Saskatoon/Regina (4.7%) were less likely to receive notification than those in 
regions where the community size was less than 5,000 people (9.4%) (χ2 = 
10.169; p < 0.006) (Figure 4.11).   
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Figure 4.11 Notification of Status by Community Size 
 
 Respondents were questioned on if they receive notification from the 
Drug Plan as to whether the EDS request is accepted or rejected, is that 
notification provided in a timely manner?  A total of 10.9% reported Usually or 
Always receiving notification in a timely manner, while 49.8% Do Not Receive 
notification.  There was no statistically significant difference between 
respondents. 
 
4.8 Pharmacy Dynamics 
 
Section E of the questionnaire was formed to gain an appreciation for 
the dynamics that existed in the responding pharmacy and the circumstances 
surrounding an EDS request.  Respondents were asked to what extent they 
agreed or disagreed with each statement.  Frequency distributions were 
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carried out for each of the four questions within this section and are displayed 
in Table 4.11.  For post-hoc analysis, statistical significance was set at p < 
0.05. 
Table 4.11 Pharmacy Dynamics 
 
 Strongly Somewhat Neutral Somewhat Strongly Total 
Question 
Agree/ 
Agree Agree  Disagree 
Disagree/ 
Disagree Responses 
 
N  
(%) 
N 
 (%) 
N  
(%) 
N  
(%) 
N  
(%) 
N  
(%) 
1. Pharmacists in your 
store have adequate 
information on the 
administrative nature of 
the EDS program. 
207 
(75.3) 
 
44 
(16.0) 
 
13 
(4.7) 
 
7 
(2.5) 
 
3 
(1.1) 
 
274 
(99.6) 
 
2. Pharmacists in your 
store feel that initiating 
an EDS request is an 
important service for 
their patients. 
218 
(79.3) 
 
35 
(12.7) 
 
12 
(4.4) 
 
4 
(1.5) 
 
6 
(2.2) 
 
275 
(100.0) 
 
3. Changing the policy in 
1999 to allow 
pharmacists to initiate an 
EDS request on behalf of 
patients has been 
beneficial to patient 
health care. 
 
195 
(70.9) 
 
 
 
43 
(15.6) 
 
 
 
19 
(6.9) 
 
 
 
6 
(2.2) 
 
 
 
12 
(4.4) 
 
 
 
275 
(100.0) 
 
 
4. The EDS program 
contributes significantly 
to the administrative 
workload of pharmacists. 
238 
(86.5) 
 
25 
(9.1) 
 
7 
(2.5) 
 
2 
(0.7) 
 
3 
(1.1) 
 
275 
(100.0) 
 
 
 
Just over three-quarters of respondents (75.3%) Agreed or Strongly 
Agreed that pharmacists in your store have adequate information on the 
administrative nature of the EDS program.  Bonferroni analysis revealed a 
statistically significant difference in terms of the number of prescriptions filled.  
Pharmacies that filled 0 – 500 prescriptions per week (63.2%) were less likely 
to agree with the statement than those that filled 501-750 (92.9%) and more 
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than 1000 prescriptions per week (76.6%) (χ2 = 20.475; p = 0.000) (Figure 
4.12). 
Strongly
Disagree/Disagree
Somewhat DisagreeNeutralSomewhat AgreeStrongly
Agree/Agree
100.0%
80.0%
60.0%
40.0%
20.0%
0.0%
1001 +
751 - 1000
501 - 750
251 - 500
0 - 250
Average # Of Rx Per
Week
 
Figure 4.12 Adequate Information by Prescription Volume 
 
 
 A total of 79.3% of respondents Agreed or Strongly Agreed that 
pharmacists in your store feel that initiating an EDS request is an important 
service for their patients.  A statistically significant difference was revealed via 
Bonferroni analysis with regard to the percentage of EDS requests submitted 
by the pharmacy instead of the prescribing physician.  Pharmacies where 0-
50% of EDS requests (60.4%) were submitted by the pharmacy as opposed 
to the prescribing physician were less likely to agree with the statement than 
those where 81-90% (79.3%) and 96-100% were (97.3%) (χ2 = 20.320; p = 
0.000) (Figure 4.13). 
   82
Strongly
Disagree/Disagree
Somewhat DisagreeNeutralSomewhat AgreeStrongly
Agree/Agree
100.0%
80.0%
60.0%
40.0%
20.0%
0.0%
96 - 100
91 - 95
81 - 90
51 - 80
0 - 50
% Of Submitted
Initiated By Pharmacy
Vs. Prescribing MD
 
Figure 4.13 Important Service for Patients by Percent Pharmacy Submitted 
 
 
 There were 70.9% of respondents who Agreed or Strongly Agreed that 
changing the policy in 1999 to allow pharmacists to initiate an EDS request 
on behalf of patients has been beneficial to patient health care.  Bonferroni 
analysis revealed a statistically significant difference between the percentage 
of EDS requests submitted by the pharmacy instead of the prescribing 
physician.  Pharmacies where 0-50% of EDS requests (50.0%) were 
submitted by the pharmacy as opposed to the prescribing physician were less 
likely to agree with the statement than those where 96-100% were (78.4%) 
(χ2 = 12.476; p < 0.014) (Figure 4.14).   
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Figure 4.14 Policy Change Benefits Patients by Percent Pharmacy Submitted 
 
 
 A large majority of respondents (86.5%) Agreed or Strongly Agreed 
that the EDS program contributes significantly to the administrative workload 
of pharmacists.  Only 1.8% of respondents Somewhat Disagreed or 
Disagreed with the statement, and no respondents Strongly Disagreed.  
Bonferroni analysis revealed statistically significant differences in terms of the 
volume of prescriptions filled per week and the number of EDS requests 
submitted by the pharmacy instead of the prescribing physician.   
Pharmacies that filled 0-250 prescriptions per week (73.9%) were less 
likely to agree with the statement than those that filled more than 500 
prescriptions per week (91.8%) (χ2 = 12.873; p < 0.012) (Figure 4.15). 
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Figure 4.15 Increased Workload by Prescription Volume 
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Figure 4.16 Increased Workload by Percent Pharmacy Submitted 
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Pharmacies submitting 0-50% of EDS request (68.8%) versus the 
prescribing physician were less likely to agree with the statement compared 
to those where more than 50% were (90.3%) (χ2 = 19.536; p < 0.001) (Figure 
4.16). 
 
4.9 Maximum Allowable Cost 
Table 4.12 Maximum Allowable Cost 
 
 Strongly  Somewhat  Too Early Somewhat  Strongly  Total 
Question 
Agree/ 
Agree Agree To Say Disagree 
Disagree/ 
Disagree Responses 
 
N  
(%) 
N  
(%) 
N  
(%) 
N  
(%) 
N  
(%) 
N  
(%) 
1. Saskatchewan 
Health has 
provided adequate 
information to 
pharmacists in your 
store on the 
administrative 
nature of the MAC 
policy. 
 
139 
(50.5) 
 
 
 
71 
(25.8) 
 
 
 
25 
(9.1) 
 
 
 
11 
(4.0) 
 
 
 
29 
(10.5) 
 
 
 
275 
(100.0) 
 
 
2. The staff in your 
pharmacy are 
sufficiently 
prepared to deal 
with questions on 
MAC. 
168 
(61.1) 
 
63 
(22.9) 
 
21 
(7.6) 
 
15 
(5.5) 
 
8 
(2.9) 
 
275 
(100.0) 
 
5. The MAC policy 
is impairing the 
ability of my 
patients to receive 
appropriate drug 
therapy. 
37 
(13.5) 
 
75 
(27.3) 
 
111 
(40.4) 
 
21 
(7.6) 
 
30 
(10.9) 
 
274 
(99.6) 
 
 Greatly  Somewhat  Not Somewhat  Greatly  Total 
Question 
Increased/ 
Increased Increased Changed Decreased 
Decreased/ 
Decreased Responses 
 
N  
(%) 
N  
(%) 
N  
(%) 
N  
(%) 
N  
(%) 
N  
(%) 
3. Since the MAC 
policy came into 
effect, the amount 
of time your staff 
spends explaining 
the Drug Plan to 
patients has: 
182 
(66.2) 
 
64 
(23.3) 
 
25 
(9.1) 
 
1 
(0.4) 
 
2 
(0.7) 
 
274  
(99.6) 
 
4. Since the MAC 
policy came into 
effect, the number 
of EDS requests 
initiated by your 
pharmacy has: 
83 
(30.2) 
 
69 
(25.1) 
 
122 
(44.4) 
 
0 
(0.0) 
 
1 
(0.4) 
 
275 
(100.0) 
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Section F of the questionnaire was formed to obtain initial perceptions 
of the MAC policy.  Results of frequency distribution analysis are displayed in 
Table 4.12.  For post-hoc analysis, statistical significance was set at p < 0.05. 
Half of respondents (50.5%) Agreed or Strongly Agreed that 
Saskatchewan Health has provided adequate information to pharmacists in 
your store on the administrative nature of the MAC policy.  There was no 
statistically significant difference between groups.   
A total of 61.1% of respondents Agreed or Strongly Agreed that the 
staff in your pharmacy are sufficiently prepared to deal with questions on 
MAC.  There was no statistically significant difference between groups. 
When asking respondents since the MAC policy came into effect, the 
amount of time your staff spends explaining the Drug Plan to patients has, 
66.2% of respondents reported that the time their staff spent explaining the 
Drug Plan to patients had Increased or Greatly Increased since the Policy 
came into effect.  There was no statistically significant difference between 
groups. 
When addressing the issue of since the MAC policy came into effect, 
the number of EDS requests initiated by your pharmacy has, 30.2% of 
respondents indicated that the number of EDS requests has Increased or 
Greatly Increased since the Policy came into effect.  Bonferroni analysis 
revealed a statistically significant difference in terms of prescription volume.  
Pharmacies that filled 251-500 prescriptions per week (19.7%) were less 
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likely to report an increase in EDS requests than those that filled 751-1000 
per week (46.8%) (χ2 = 9.693; p < 0.046) (Figure 4.17).   
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Figure 4.17 Change in EDS Requests by Prescription Volume 
 
 
Only 13.5% of respondents Agreed or Strongly Agreed that the MAC 
policy is impairing the ability of my patients to receive appropriate drug 
therapy; while 40.4% of respondents felt it was too early to assess whether 
this was true.  There was no statistically significant difference between 
groups.   
 
4.10 Qualitative Themes 
 
 As indicated in Section 3.4.1, the qualitative themes of the study and 
responses are displayed in Appendices J and K.   
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Eight general themes were developed for the EDS responses 
(Appendix J), with one theme changing for responses pertaining to MAC 
(Appendix K); these themes are displayed with an explanation, along with all 
responses.   
The themes were not mutually exclusive, as some responses were 
coded into more than one category, and are therefore displayed in 
Appendices J and K in no particular order or theme.  Responses from the 
open-ended questions were used to add to the discussion that is to follow, 
and will not be alluded to in the results section.   
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5. DISCUSSION 
 Results of this study are revealing, but as with survey-based research 
should be approached with some caution.  The intention of this study was not 
to gain hard, objective results one might gain through other methods, such as 
exploring administrative databases.  Instead, the results can be used to build 
upon in future research pertaining to pharmacy practice.   
 This study is based on four research questions, which were formed to 
gain a greater appreciation of pharmacy practice with regard to the EDS and 
MAC policies, as well as to potentially generate hypotheses for future 
research.  Therefore, there are no hypotheses to accept or reject.  This 
section begins with a discussion on the four research questions and sub-
questions.  This is followed by the conclusion and recommendations.   
 
5.1 Research Question 1 
 
In the opinion of community-pharmacists, which stakeholders benefit 
from Saskatchewan Health’s Exception Drug Status (EDS) program? 
 
As identified through the literature, the principal stakeholders in prior 
authorization programs are: patients, pharmacists, physicians, drug plans, 
and the health care system as a whole [21, 22, 25, 39, 74].  And while all 
these stakeholders differ as to their interest in the program, the respondents 
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(pharmacists) indicated the Drug Plan and patients benefited more from the 
program than pharmacists, physicians, or the health care system as a whole.  
Specifically, patients were seen to benefit from having more prescription 
drugs covered by the Drug Plan than would be the case if EDS were not in 
place.   
While one may view the inclusion of some prescription drugs on the 
formulary via the EDS program as beneficial, in reality many patients would 
not receive any benefit from this inclusion unless they met the 3.4% of 
adjusted income deductible.  Even though there are varying levels of 
coverage under the Drug Plan, depending on the beneficiary, the majority fall 
within this structure [6].  This may have been the perspective in the minds of 
respondents who did not agree, relatively, that the EDS program was 
beneficial for patients in terms of making the drug more affordable, compared 
to the benefit of including more drugs on the formulary.   
Respondents were less likely to agree, relative to other stakeholders, 
that the EDS program was beneficial to the health care system by promoting 
more appropriate utilization of drugs, physicians by providing them with more 
drug therapy choices, or pharmacists by providing them the opportunity to be 
more actively involved in securing drug therapy for patients.  These findings 
are interesting as it suggests that some pharmacists may have an 
appreciation and orientation to other stakeholders within the health care 
system, and not just to their own profession.  One would expect pharmacists 
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to find administrative programs, such as EDS, unbeneficial to their own 
profession.   
There was a difference in terms of the hours a pharmacy was open per 
week.  The differences in opinion by respondents’ in pharmacies open more 
than 80 hours a week may reflect the dissatisfaction with the EDS program.  
This dissatisfaction may arise as the result of the reduced access to 
information that is inherent in the current EDS program.  The restricted hours 
Drug Plan representatives are available, compared to pharmacies open more 
than 80 hours per week, and the hours physician offices are open, both limit a 
pharmacies access to the required information.   
 
5.2 Research Question 2 
 
To what extent do pharmacies in Saskatchewan participate in the EDS 
program? 
 
 Section B of the questionnaire was used to address the above 
research question.  Results are displayed in Table 4.6.  Each of the four 
questions in this section were used as independent factors for analysis 
purposes.  Therefore, these factors are also alluded to in the other three 
research questions, as comparators if there was a statistically significant 
difference between respondents based on the questions in Section B. 
 While the average number of restricted and non-formulary 
prescriptions received per pharmacy was 36, the range highlights the diverse 
nature of community pharmacies in Saskatchewan.  Pharmacies reported 
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receiving between one and 400 restricted and non-formulary prescriptions per 
week, with a mode of 10 and a median of 20.   
These numbers reveal that even though on average community 
pharmacies receive 36 non-formulary and restricted prescriptions per week, 
half of all pharmacies receive fewer than 20 such requests per week.   
Therefore, pharmacies that handle a greater volume of requests bring up the 
average for all.  Because data was not captured with regard to the type of 
patients’ community pharmacies primarily serve, such as seniors who tend to 
obtain a disproportionate amount of prescriptions in comparison to other 
demographics, it is not feasible to assume that pharmacies in one 
demographic area contributed to the higher volume of restricted and non-
formulary prescriptions.   
 In terms of the percentage of restricted and non-formulary 
prescriptions submitted for EDS coverage, an average of 59% were 
submitted.  There was a range of responses with some pharmacies 
submitting 2% of restricted and non-formulary requests, and others that 
submitted 100%.  The mode was 40%, with a median of 60%. 
 Due to the methods used to capture data for this study being almost 
exclusively quantitative, one is not able to make assertions on why only 59% 
of restricted and non-formulary prescriptions were submitted for coverage.  
However, assumptions can be derived on why the remaining 41% of such 
prescriptions were not submitted for coverage.   
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As reported in the results section, communication between the 
prescriber and pharmacist are important in whether a pharmacy will apply for 
EDS.  Therefore, one might assume that part of the reason why not all 
restricted and non-formulary prescriptions are submitted for coverage is the 
lack of communication and in turn information available to the pharmacy.  
Other reasons may centre on the patient not receiving coverage even if the 
request was approved, due to not reaching the deductible, or the fact that the 
prescription is not covered under the formulary or through EDS.   
 Since the policy change in 1999, pharmacists, by default, have taken 
some of the administrative burden of the EDS program from physicians.  
Pharmacies reported submitting an average of 79% of all EDS requests.  The 
range of responses went from a low of 5%, to a high of 100%.  While the 
mode and median were identical at 90%.  Therefore, pharmacies submitting a 
small percentage of EDS requests tended to bring down the average overall, 
since over half of all respondents reported submitting 90% of EDS requests.   
 The reported numbers are not objective due to the way in which data 
was collected, but perceptions are that over three-quarters of all EDS 
requests are submitted by the pharmacy.  This is a significant shift in 
administrative burden from physicians to pharmacists in just over 5 years 
from the time the policy changed to the time of the study.   
 A direct sign of physicians offloading the administrative workload 
associated with the EDS program is requesting that the pharmacy initiate the 
request.  Pharmacies reported that an average of 29% of EDS requests 
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submitted by their pharmacy were at the request of the prescribing physician.  
There was the maximum range of responses from 0% to 100% of EDS 
submissions by the pharmacy coming at the request of the prescribing 
physician.  The mode was 10%, while the median was 20%.   
 Again, due to the nature of the study being survey-based, these 
numbers do not communicate the entire story.  One might be interested to 
explore the communication processes that occur between the physician and 
pharmacist when the physician has asked the pharmacist to initiate the 
request.  It is just speculation, but one would assume that the sharing of 
information would be more forthright from the physician if he or she was 
asking the pharmacist to apply for EDS, versus the physician who did not.  In 
essence, the physician is asking for a favour from the pharmacists, and in 
turn may be more likely to provide the required information. 
 
5.3 Research Question 3 
 
Under what circumstances will a pharmacist initiate an EDS request?  
 
 The above research question was addressed in Section C of the 
questionnaire.  Table 4.7 displays the respondents’ responses.   
 The most surprising and interesting finding with regard to this research 
question revolve around the issue of time.  Out of the eight questions in this 
section, time was the least important, relatively speaking, with only 38.9% of 
respondents reporting it to be an Important or Very Important factor.  In 
relation to the other factors that impact whether a pharmacist will submit an 
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EDS request, time is secondary.  Therefore, one would assume that 
pharmacists are willing to take the time needed to apply for EDS, but other 
factors will affect time as well, such as the ability to obtain the required 
information and contacting the prescribing physician. 
 In relation to the strongest factors when determining if a pharmacists 
will initiate an EDS request, more than 70% of respondents indicated three 
factors to be Important or Very Important: the ability of the patient to pay for 
the prescription (73.5%), ability to obtain all the information needed to make 
the request (76.7%), and the ability to contact the prescribing physician 
(70.2%).   
 The ability of the patient to pay for the prescription is key in deciding 
whether to apply for EDS coverage.  If the patient is unable to afford the 
medication, even if EDS is approved, it is a misuse of resources to apply for 
EDS coverage with regard to the pharmacist, physician, and Drug Plan.  Of 
course, this does not take into consideration the direct and indirect effects of 
the patient not receiving pharmaceutical therapy, such as the possible need 
to treat the patient in an in-patient setting, resulting in a greater cost to the 
system, or the patients’ condition deteriorating resulting in a lower quality-of-
life.   
 The other two areas that emerged as Important or Very Important are 
interconnected: the ability to obtain information and the ability to contact the 
prescribing physician.  Pharmacists are faced with having the authority to 
apply for EDS on behalf of patients, yet are restricted in the access to 
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relevant and vital information.  The introduction of the Pharmacy Information 
Project (PIP), which is being developed as “a solution to link community 
physicians, pharmacies and hospitals, giving confidential shared access to 
patient medication histories [84]” may help alleviate some of the restrictions 
currently in place.  However, this project may bring with it another set of 
concerns, such as an unwillingness to input patient information into the 
system.   
With regard to ability to contact the prescribing physician, respondents’ 
whose pharmacies were in the same location as the prescribing physician 
were less likely to find their ability to contact the physician a factor than those 
who were removed.  This may be the result of having easier accessibility to 
the prescribing physicians where the dispensary is in the same location 
resulting in a more personal relationship than would be possible with more 
removed geographic locations. 
 
5.3.1 Research Question 3a 
 
Is the initiation of an EDS request part of the continuum of care 
pharmacists provide to their patients?   
 
 This research question was looked at in questions 2 and 3 in Section E 
of the questionnaire.   
 With almost all respondents agreeing (92.0%) that initiating a request 
is an important service to their patients, one is reminded that pharmacists 
believe the EDS program is beneficial to patients.  As well, a large majority of 
respondents agreed (86.5%) that patient health care has benefited by 
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authorizing pharmacists to initiate EDS requests.  These viewpoints would be 
expected to be strengthened if and when the underlying issues of 
communication and workload were addressed.   
Respondents in pharmacies that submitted fewer than 50% of EDS 
requests were less likely to agree with the statements than those who 
submitted close to 100%.  This is not surprising as one who submits a greater 
percentage of requests would naturally be more likely to agree that the 
service is important to patients and the patients’ health care because of his or 
her professional experience with patients who use the program.  Therefore, 
pharmacies that submit a higher percentage of requests may do so because 
they see the EDS program as beneficial to patient health care and as a result 
are providing an important service that was not part of pharmacy practice until 
1999.   
 
5.3.2 Research Question 3b 
 
Do pharmacists have access to all the information necessary to initiate 
an EDS request? 
 
 Section D of the questionnaire was used to address the above 
research question, with question 2 asking the question specifically.   
 Only 31% of respondents Always or Usually have access to all the 
information required.  The fact that pharmacists are more likely not to have 
the information required rather than have the information is troubling.  The 
idea behind authorizing pharmacists to apply for EDS on behalf of patients 
was to increase access to drugs for patients.  However, if the pharmacist 
   98
does not have the necessary information to make that request, the 
authorization may in fact lengthen the process.  In light of this, the 
introduction of the PIP system by Saskatchewan Health may resolve some of 
the issues around access to patient information.  However, it is only 
speculation to assume that this system would increase access to information 
without causing unanticipated problems. 
A statistically significant difference was revealed between respondents’ 
whose pharmacy was open 50.5-60 hours per week being more likely to have 
access to the information required than pharmacies open more than 60 hours 
per week.  This difference may be attributable to pharmacies open longer 
hours filling prescriptions after physicians’ offices have closed, making it more 
difficult to obtain the information required if it was not provided.  As well, Drug 
Plan representatives that handle EDS requests are not available to provide 
needed information or authorize requests at all times. 
 
5.3.3 Research Question 3c 
 
Is additional administrative workload a factor when initiating an EDS 
request? 
 
 The above research question was asked in a blunt manner in question 
4 of Section E of the questionnaire.  However, questions 1 and 5 – 8 of 
Section C addressed the question indirectly. 
 The response to question 4 in Section E was strong, with 95.6% of 
respondents agreeing that the EDS program contributes significantly to their 
workload.  Statistically significant differences were reported as responding 
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pharmacies that filled 0-250 prescriptions per week were less likely to agree 
with the statement that those that filled more than 500 prescriptions per week.  
Also, pharmacies that submitted 0-50% of EDS requests as opposed to the 
prescribing physician were less likely to agree with the statement than those 
who submit more than 50% of EDS requests. 
 Not surprisingly, these two differences between pharmacies reveal that 
the lower the prescription volume and number of EDS requests, the less 
pharmacists see the EDS program as contributing to their administrative 
workload.   
 While the time required when submitting an EDS request was less 
important than other factors in determining whether a pharmacy would initiate 
a request, the ability to obtain the information required and contacting the 
prescribing physician were important.  Again, it appears that respondents do 
not necessarily mind the time required submitting an EDS request, yet they 
do find their ability to obtain the information from the physician important.  
Therefore, the ability to communicate with the prescribing physician appears 
to be a deciding factor on whether the pharmacist will initiate a request.   
 
5.4 Research Question 4 
 
How is the new Maximum Allowable Cost (MAC) policy affecting the 
administrative workload of pharmacists?   
 
 The above question is a combination of questions 3 and 4 in Section F 
of the questionnaire, which are addressed in research questions 4a and 4c. 
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5.4.1 Research Question 4a 
 
Has the number of EDS requests initiated by pharmacies changed 
since the implementation of MAC? 
 
 Research Question 4a is addressed via question 4 in Section F.  A 
total of 55.3% of respondents saw an increase in the number of EDS 
requests since the MAC policy came into effect.  Pharmacies that filled 251-
500 prescriptions per week were less likely to report an increase in 
comparison to pharmacies that filled 751-1000 prescriptions per week.   
 The idea behind an increase in EDS requests following the 
implementation of the MAC policy may result from increasing the restrictions 
on pharmaceutical therapy.  And while over half of the responding 
pharmacies reported an increase, this increase may fade as pharmacists, 
physicians and patients become familiar with the policy and begin to work 
within the parameters of MAC.  However, in the future this will depend on the 
number of new beneficiaries that are prescribed a MAC drug who may not be 
familiar with the policy. 
EDS requests may have increased, yet in order for the patient to 
receive EDS coverage, they would have had to meet the regular criteria for 
obtaining EDS coverage.  Therefore, unless the patient had tried other drugs 
that fall within the MAC ceiling for coverage, they would either have to try the 
agents for which there is coverage, or pay the difference between what has 
been prescribed, and the MAC insured portion ($1.51 per tablet or capsule).  
As well, formulary restrictions, such as MAC, can result in both intended and 
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unintended therapeutic substitutions [7].  Further analyses of patient 
outcomes on the trends since the implementation are required to attempt to 
fully understand the impact, positive and negative, of the policy.   
 
5.4.2 Research Question 4b 
 
Do pharmacists have sufficient information on MAC to allow them to 
adequately explain the policy to patients? 
 
 This question was addressed in questions 1 and 2 of Section F.  While 
over three-quarters (76.3%) of respondents were provided with adequate 
information on the MAC policy, there were additional comments which added 
to the interpretation through the open-ended opportunity to respond.  Some 
respondents reported receiving information on the Policy after patients; 
catching many off guard and exhibiting inefficient communication by the Drug 
Plan (see Appendix K).   
The Government of Saskatchewan presented the 2004-2005 provincial 
budget on March 31st, 2004.  Within this budget was the announcement of the 
MAC policy being implemented on July 1st, 2004.  In order for policies to be 
properly implemented, it is essential to communicate vital information to those 
charged with administering the policies.  However, the Government knew it 
would be implementing this policy, yet it appears that the Government did not 
prepare some pharmacists well enough in advance on the administration of 
the program.   
  A large majority (84.0%) of respondents reported that pharmacists in 
their pharmacies were prepared for questions on MAC.  It is unclear as to 
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whether pharmacists were prepared for questions when the Policy was 
implemented, or whether this happened sometime after implementation.  
MAC is not a novel idea, and may have been a policy that pharmacists were 
aware of before implementation.     
 
5.4.3 Research Question 4c 
 
Since the implementation of MAC, have pharmacists been spending 
more time with patients explaining the Drug Plan?  
 
 Question 3 in Section F of the questionnaire addressed the above 
question.  A total of 89.5% of responding pharmacies reported an increase in 
the time spent explaining the Drug Plan since the implementation of MAC.  
The Drug Plan may not have provided patients with the appropriate 
information and/or did not communicate it in a manner that facilitated the 
appropriate understanding, leaving pharmacists to explain the Policy to 
patients.  Once patients’ understanding of the Policy was established, one 
would assume that the time spent explaining the Drug Plan would decrease.  
However, a policy is often important to a patient only when it applies to them 
so there will be a continuing need to explain the policy to new patients when it 
applies to them. 
 
5.5 Study Limitations 
 
 First, the nature of the study relies on pharmacist recall.  Therefore, the 
results must be interpreted as such, as no comparative analysis between 
responses in this study with other objective measures was conducted.  
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Previous research has shown that community pharmacists are accurate when 
asked to recall workload within ten percent in comparison to objective 
numbers [5].  As well, trying to control for certain factors, such as prescription 
volume or hours worked, can cause researchers to miss aspects that 
contribute to pharmacist workload [69]. 
 The study took place in the province of Saskatchewan and may not be 
applicable to other jurisdictions.  Saskatchewan is unique in that pharmacists 
are authorized to initiate EDS requests, and therefore may further limit the 
transferability of the results; with the possible exception of Newfoundland and 
Labrador who also grant authority to pharmacists when applying for prior 
authorization.  However, the research does add to the available literature by 
allowing those interested an account of community-pharmacy managers’ 
perceptions towards restrictive policies like EDS and MAC.  Not only will this 
aid policy makers in the province, but it may serve as an information piece in 
other jurisdictions contemplating implementation of pharmacist initiated prior 
authorization and/or a reference-based pricing strategy.   
 There has not been any research on the subject matter of this study 
done in the province of Saskatchewan.  Therefore, there is no baseline data 
to compare the results to.  However, this research was carried out, in part, to 
gain baseline knowledge and can be used as a basis for future comparisons.  
This is especially apparent with regard to the MAC policy that was in place for 
between three-and-a-half and five-and-a-half months at the time of data 
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collection.  Therefore, future opinion seeking research can be compared 
against the baseline knowledge gained via this research.   
 
5.6 Conclusion 
 
Pharmacists appear to have an appreciation of the health care system 
that extends beyond their own profession, and understand the way policies 
such as EDS affect other stakeholders.  However, the findings highlight the 
need to improve aspects of the Program to increase its efficiency and 
effectiveness.   
On the whole, pharmacists appear to find the EDS program beneficial 
to patients.  Pharmacists seem to be putting aside their own dissatisfaction 
with the Program so that patients can benefit.  And while this reinforces the 
professionalism of pharmacists, one can only sustain the displeasure and 
lack of cooperation for so long.  There may come a time when the profession 
of pharmacy in Saskatchewan agrees collectively to reduce or abolish 
providing administrative duties, such as EDS, unless their concerns are 
addressed.  Individual pharmacies are restricted in voicing their concerns, 
through such means as not initiating EDS requests, due to the prospect of 
having their license revoked, but this may change if the profession acts as a 
whole.   
Where contention towards the Program emerges is with the inefficient 
manner in which pharmacists are required to apply for EDS, and the 
inaccessibility to required patient information, which can be burdensome and 
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prolong the administrative process.  Like many issues in health care and 
other social programs, money is many times thrown into a system to 
theoretically help solve the problem.  Although money is required to institute 
measures that expedite and streamline the manner in which pharmacists 
apply for EDS, while enhancing the communication of pertinent information, 
paying pharmacists an administrative fee is not likely to improve the 
processes without addressing the underlying sources of discontent.   
 With regard to the MAC program, pharmacists appear to recognize the 
need and benefits of such a policy.  However, there should be clearer 
communication between the Drug Plan and pharmacists when future changes 
take place so that pharmacists can prepare for the change, to the benefit of 
all stakeholders.  Pharmacists continue to be the most accessible health care 
professional, and it is in the best interest of the Drug Plan to ensure that 
pharmacists are sufficiently consulted and informed on the policies that 
directly concern their profession.   
 
5.7 Recommendations 
 
Results of this study show dissatisfaction by community pharmacists 
with certain aspects of the EDS program and the new MAC policy.  The 
following are suggestions based on the literature review and results of the 
study to possibly help improve the acceptance by community pharmacists for 
these policies.  As well, suggestions from the open-ended responses 
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(Appendices J and K) made a substantial contribution to the 
recommendations that follow. 
o Implementation of an online, automated adjudication system for EDS 
claims that is accessible by all health professionals who are authorized 
to submit claims [1, 66]; failing that an increase the amount of staff at 
the Drug Plan who handle EDS requests and/or longer working hours 
to decrease the turn around time. 
o Prescription pads specifically made for EDS drugs which have space, 
either on the front or the back, to place the diagnosis on, as well as 
previous therapies tried [Appendix J]. 
o Remuneration for the time it takes pharmacists and physicians to 
submit an EDS request, regardless of whether the request is accepted 
or rejected [Appendix J].   
o Access for pharmacists to patient records in order to find out what the 
diagnosis is, and what prior therapy has been tried.  This would reduce 
the time spent trying to obtain this information.  The PIP program may 
address this issue [84]. 
o Some form of notification, preferably online or at the point-of-service 
terminal, as to whether the EDS submission was accepted or rejected; 
especially if it is the pharmacist initiating the request [Appendix J].   
Currently only the patient and physician are receiving notification. 
o More authority for pharmacists to make a professional judgment on 
patient diagnosis and past therapies tried [Appendix J].  This especially 
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holds true when the patient solely uses the pharmacy in question, and 
when the patient is on a chronic medication and the EDS claim is to 
renew coverage. 
o Educate physicians on what information pharmacists require from them 
to initiate an EDS request, as well as on Drug Plan coverage and when 
the patient begins to receive benefits (once the 3.4% threshold is 
reached) [Appendix J].  This may reduce the incidents when a patient 
is under the impression that they will have the EDS drug paid for if the 
request is approved due to unintentionally misguided information from 
the physician. 
o Have an emergency supply of medications when EDS is being applied 
for to cover 48 or 72 hours of the drug to tie the patient over while the 
request is being processed [33].  This supply may need to be restricted 
for certain medications, like antibiotics, for obvious clinical reasons 
o Before implementing other changes to the Drug Plan, such as MAC, 
inform the pharmacist well before the patient [Appendix K]. 
o Reinforce to pharmacists and physicians that the EDS policy is not just 
to save money, but is also linked to clinical guidelines to reduce the 
likelihood of inappropriate prescribing.  There may also be a benefit to 
educate on the reasoning behind formularies in general, as most 
appear to simply see management techniques like formularies as cost 
control strategies, and nothing more [22, 24, 27].  Although the RxFiles 
is an ‘arms length’ program of the Drug Plan, this group may be in the 
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best position to educate health professionals on formularies and the 
underlying policies.   
o Implement some form of educational campaign targeted to users of the 
Drug Plan on how the Plan works, such as when they will receive 
benefits, why a formulary is in place, etc. [Appendix J and K]. 
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A – Saskatchewan Health’s Exception Drug Status (EDS) Program 
Various stakeholders, from patients, pharmacists and physicians, to those who develop 
the Drug Plan are cited to have an interest in the EDS Program.  To what extent do you 
agree or disagree with the following statements? 
 
1. The EDS program benefits patients by expanding the number of prescription drugs 
covered by the provincial Drug Plan. 
Strongly 
Agree 
 
Agree 
Somewhat 
Agree 
 
Neutral 
Somewhat 
Disagree 
 
Disagree 
Strongly 
Disagree 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
2. The EDS program benefits patients by making their prescription drug more affordable. 
Strongly 
Agree 
 
Agree 
Somewhat 
Agree 
 
Neutral 
Somewhat 
Disagree 
 
Disagree 
Strongly 
Disagree 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
3. The EDS program benefits physicians by providing them more drug therapy choices 
for their patients.  
Strongly 
Agree 
 
Agree 
Somewhat 
Agree 
 
Neutral 
Somewhat 
Disagree 
 
Disagree 
Strongly 
Disagree 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
4. The EDS program benefits the Drug Plan by allowing potentially costly drug therapies 
to be available in a more controlled fashion. 
 Strongly 
Agree 
 
Agree 
Somewhat 
Agree 
 
Neutral 
Somewhat 
Disagree 
 
Disagree 
Strongly 
Disagree 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
5. The EDS program benefits the health care system by promoting more appropriate 
utilization of drugs.  
Strongly 
Agree 
 
Agree 
Somewhat 
Agree 
 
Neutral 
Somewhat 
Disagree 
 
Disagree 
Strongly 
Disagree 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
6. The EDS program benefits pharmacists by providing them with an opportunity to be 
more actively involved in securing the most appropriate drug therapy for their patients.  
Strongly 
Agree 
 
Agree 
Somewhat 
Agree 
 
Neutral 
Somewhat 
Disagree 
 
Disagree 
Strongly 
Disagree 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
B – Participation in Saskatchewan Health’s EDS Program 
Questions in this section relate to how often your pharmacy deals directly with the EDS 
program. 
 
1. On average, how many new prescriptions for restricted or non-formulary medications 
does your pharmacy receive per week?       
__________ Per Week 
2. On average, what percent of these restricted or non-formulary medications are 
submitted for coverage under the EDS program? (Please circle appropriate percentage) 
 
I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I 
0            10           20           30            40           50            60           70           80            90         100 
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3. On average, what percent of the EDS submissions are initiated by your pharmacy rather 
than by the prescribing physician? (Please circle appropriate percentage) 
 
I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I 
0            10           20           30            40           50            60           70           80            90         100 
 
4. On average, what percent of EDS submissions initiated by your pharmacy are the result 
of a request by the prescribing physician? (Please circle appropriate percentage) 
 
I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I 
0            10           20           30            40           50            60           70           80            90         100 
 
C – Factors Surrounding the Initiation of an EDS Request 
Rate the importance of the following factors in determining whether your pharmacy will 
initiate an EDS request for a new prescription for a restricted or non-formulary medication 
for which the physician has not initiated an EDS request. 
 
1. The time needed to submit an EDS request.  
Very 
Important 
 
Important 
Somewhat 
Important 
 
Neutral 
Somewhat 
Unimportant 
 
Unimportant 
 
Very Unimportant 
[    ] [    ] 
 
[    ] [    ] [    ] [    ] [    ] 
2. The ability of the patient to pay for the prescription. 
Very 
Important 
 
Important 
Somewhat 
Important 
 
Neutral 
Somewhat 
Unimportant 
 
Unimportant 
 
Very Unimportant 
[    ] [    ] 
 
[    ] [    ] [    ] [    ] [    ] 
3. The patient has exceeded the Drug Plan deductible. 
Very 
Important 
 
Important 
Somewhat 
Important 
 
Neutral 
Somewhat 
Unimportant 
 
Unimportant 
 
Very Unimportant 
[    ] [    ] 
 
[    ] [    ] [    ] [    ] [    ] 
4. The likelihood that the patient will eventually exceed the Drug Plan deductible. 
Very 
Important 
 
Important 
Somewhat 
Important 
 
Neutral 
Somewhat 
Unimportant 
 
Unimportant 
 
Very Unimportant 
[    ] [    ] 
 
[    ] [    ] [    ] [    ] [    ] 
5. Your familiarity with the administrative processes of the EDS program.  
Very 
Important 
 
Important 
Somewhat 
Important 
 
Neutral 
Somewhat 
Unimportant 
 
Unimportant 
 
Very Unimportant 
[    ] [    ] 
 
[    ] [    ] [    ] [    ] [    ] 
6. Ability to obtain all the information needed to make an EDS request.  
Very 
Important 
 
Important 
Somewhat 
Important 
 
Neutral 
Somewhat 
Unimportant 
 
Unimportant 
 
Very Unimportant 
[    ] [    ] 
 
[    ] [    ] [    ] [    ] [    ] 
7. Ability to track the status of your EDS request once it has been submitted. 
Very 
Important 
 
Important 
Somewhat 
Important 
 
Neutral 
Somewhat 
Unimportant 
 
Unimportant 
 
Very Unimportant 
[    ] [    ] 
 
[    ] [    ] [    ] [    ] [    ] 
8. Your ability to contact the prescribing physician. 
Very 
Important 
 
Important 
Somewhat 
Important 
 
Neutral 
Somewhat 
Unimportant 
 
Unimportant 
 
Very Unimportant 
[    ] [    ] 
 
[    ] [    ] [    ] [    ] [    ] 
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D - Appropriateness of Procedures used for Obtaining EDS 
Since 1999, pharmacists have been authorized to submit an EDS request.  We are 
interested in gaining an understanding of your experiences since pharmacists were 
granted this authority.   
1. Do you find it difficult to apply for EDS?  
Always Usually Sometimes Rarely Never 
[    ] [    ] [    ] [    ] 
 
[    ] 
 
2. Do you have access to all the information required by the Drug Plan (e.g. diagnosis 
relevant to use of drug)? 
Always Usually Sometimes Rarely Never 
[    ] [    ] [    ] [    ] 
 
[    ] 
 
3. When you submit an EDS request, do you receive notification from the Drug Plan as to 
whether the request is accepted or rejected?  
Always Usually Sometimes Rarely Never 
[    ] [    ] [    ] [    ] 
 
[    ] 
 
4. If you receive notification from the Drug Plan as to whether the EDS request is accepted 
or rejected, is that notification provided in a timely manner (within two days of 
submission)?  
Always Usually Sometimes Rarely Do Not Receive 
[    ] [    ] [    ] [    ] 
 
[    ] 
 
 
E- About the EDS Program 
We are looking to gain an appreciation for the dynamics that exist in your pharmacy.  The 
following questions deal with the circumstances surrounding an EDS request.  
 
1. Pharmacists in your store have adequate information on the administrative nature of the 
EDS program. 
Strongly 
Agree 
 
Agree 
Somewhat 
Agree 
 
Neutral 
Somewhat 
Disagree 
 
Disagree 
Strongly 
Disagree 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
 
2. Pharmacists in your store feel that initiating an EDS request is an important service for 
their patients. 
Strongly 
Agree 
 
Agree 
Somewhat 
Agree 
 
Neutral 
Somewhat 
Disagree 
 
Disagree 
Strongly 
Disagree 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
 
3. Changing the policy in 1999 to allow pharmacists to initiate an EDS request on behalf of 
patients has been beneficial to patient health care.  
Strongly 
Agree 
 
Agree 
Somewhat 
Agree 
 
Neutral 
Somewhat 
Disagree 
 
Disagree 
Strongly 
Disagree 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
 
4. The EDS program contributes significantly to the administrative workload of 
pharmacists.  
Strongly 
Agree 
 
Agree 
Somewhat 
Agree 
 
Neutral 
Somewhat 
Disagree 
 
Disagree 
Strongly 
Disagree 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
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F – Maximum Allowable Cost 
Starting July 1, 2004, Saskatchewan Health began to phase in a Maximum Allowable Cost 
(MAC) policy into the Drug Plan, beginning with Proton Pump Inhibitors (PPIs).  We are 
interested in gaining an understanding of the experiences in your pharmacy to date with 
this new policy.   
 
1. Saskatchewan Health has provided adequate information to pharmacists in your store 
on the administrative nature of the MAC policy. 
Strongly 
Agree 
 
Agree 
Somewhat 
Agree 
Too Early  
To Say 
Somewhat 
Disagree 
 
Disagree 
Strongly 
Disagree 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
 
2. The staff in your pharmacy are sufficiently prepared to deal with questions on MAC. 
Strongly 
Agree 
 
Agree 
Somewhat 
Agree 
Too Early  
To Say 
Somewhat 
Disagree 
 
Disagree 
Strongly 
Disagree 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
 
3. Since the MAC policy came into effect, the amount of time your staff spends explaining 
the Drug Plan to patients has: 
Greatly 
Increased 
 
Increased 
Somewhat 
Increased 
Not 
Changed 
Somewhat 
Decreased 
 
Decreased 
Greatly 
Decreased 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
 
4. Since the MAC policy came into effect, the number of EDS requests initiated by your 
pharmacy has: 
Greatly 
Increased 
 
Increased 
Somewhat 
Increased 
Not 
Changed 
Somewhat 
Decreased 
 
Decreased 
Greatly 
Decreased 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
 
5. The MAC policy is impairing the ability of my patients to receive appropriate drug therapy. 
Strongly 
Agree 
 
Agree 
Somewhat 
Agree 
Too Early  
To Say 
Somewhat 
Disagree 
 
Disagree 
Strongly 
Disagree 
[    ] [    ] [    ] [    ] [    ] [    ] [    ] 
 
G – The Pharmacy  
 
Location and Type of Pharmacy (Check all that apply) 
Area: 
  [   ] Commercial                            [   ] Residential              [   ] Mixed 
 
Location: 
  [   ] Stand Alone Building  [   ] Strip Mall  [   ] Enclosed Mall 
  [   ] Medical Building/Complex     [   ] Other: _____________________ 
 
Type of Pharmacy:  
 [   ] Independent  [   ] Banner   [   ] Chain  
 [   ] Franchise   [   ] Grocery Store  [   ] Department Store 
 [   ] Mass Merchandiser              [   ] Other: ______________________ 
 
 
Pharmacists employed at your location 
 Total Number (Full and Part-time): ______   Full Time Equivalents: _______ 
 
Pharmacy technicians employed at your location 
 Total Number (Full and Part-time): ______ Full Time Equivalents: _______ 
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Proximity of the majority of physicians prescribing to your patients (indicate one that best 
applies) 
  [   ] Same Location (same building or mall) 
  [   ] Next Door (on the same block or just across the street) 
  [   ] Close By (within easy walking distance) 
  [   ] Somewhat Removed (short driving distance in same town)  
  [   ] Distant (one hour or less drive to different town or city) 
  [   ] Remote (one than one hour drive to another town or city)   
 
Average number of prescriptions filled per week. (Can be a single number or a range, e.g. 
250 – 300)       ______________ Per Week 
 
Hours the dispensary is open:    ______________ Per Week 
 
H – The Pharmacist Completing the Questionnaire  
 
Gender:    Female (   ) Male (   ) Age (years): ________   
Current position (Job Title): _______________________________ 
How many years in your current position? ____________________ 
 
I – Do you have suggestions or comments on how the EDS program and/or MAC 
policy could be improved? (Please feel free to attach additional pages): 
 
 
 
 
 
 
 
J – Additional Comments (Please feel free to attach additional pages): 
 
 
 
 
 
 
 
 
Thank you for participating in this study.
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October 18th, 2004 
 
 
«Title» «UsualName» «Pharmacy_Manager_Last_Name» 
«Pharmacy_Name» 
«Street» 
«City», «Province» «PostalCode» 
 
Dear «Title» «Pharmacy_Manager_Last_Name»: 
 
Within the next week you will receive in the mail a request to complete a brief 
questionnaire for an important research project being conducted at the College of 
Pharmacy & Nutrition at the University of Saskatchewan.   
 
The questionnaire we are asking you to complete concerns your experiences with the 
Exception Drug Status (EDS) program and how it has affected your workload.  There will 
also be a brief section on your experiences to date with the Maximum Allowable Cost 
(MAC) policy recently implemented by Saskatchewan Health.   
 
Should you have any concerns about this research do not hesitate to contact the principal 
investigator (Roy Dobson) by e-mail (roy.dobson@usask.ca), facsimile (306-966-6377) or 
phone (306-966-6363).   
 
Thank you for your time and consideration.  It’s only through people like you who are 
willing to help in our research that we are able to gain a greater appreciation for how these 
programs are perceived by pharmacists, as well as how they affect the workload of your 
pharmacy.   
 
 
Sincerely, 
 
 
 
 
Jason Perepelkin, BA, BComm  Roy Dobson, BScPharm, MBA, PhD  
Graduate Student    Assistant Professor of Pharmacy 
College of Pharmacy & Nutrition  College of Pharmacy & Nutrition 
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October 25th, 2004 
 
 
«Title» «UsualName» «Pharmacy_Manager_Last_Name» 
«Pharmacy_Name» 
«Street» 
«City», «Province» «PostalCode» 
 
Re: Pharmacists and the Exception Drug Status Program 
 
Dear «Title» «Pharmacy_Manager_Last_Name»: 
 
The purpose of this study is to gain pharmacists perceptions on Saskatchewan Health’s 
Exception Drug Status (EDS) program and the new Maximum Allowable Cost (MAC) 
policy.  The questionnaire includes questions on: who benefits from the EDS program; 
factors surrounding an EDS request; the appropriateness of the procedures in place to 
initiate an EDS request; the dynamics of your pharmacy; as well as initial thoughts about 
the MAC policy.  The questionnaire should take less than 15 minutes to complete.   
  
Your participation is important.  However, it is completely voluntary and you do not have to 
complete the questionnaire if you do not wish to; you may also refuse to answer individual 
questions.  You may withdraw from the study at any time.  The code number on the 
questionnaire is designed to give the investigators the ability to track questionnaires while 
keeping your identity strictly confidential.  Once the data collection is complete, the list that 
links code numbers to names will be destroyed.  Only the principal investigator (Roy 
Dobson) and co-investigator (Jason Perepelkin) will have access to the data arising from 
this study.  All information will be stored in secure facilities at the University of 
Saskatchewan.  Results will be aggregated to ensure that the identities of individual 
respondents are safeguarded.  Results will be reported in the student-researcher’s Thesis, 
refereed periodicals and at conferences and meetings associated with pharmacists and 
health care organization. 
 
Should you have any concerns about this research do not hesitate to contact the principal 
investigator (Roy Dobson) by e-mail (roy.dobson@usask.ca), facsimile (306-966-6377) or 
phone (306-966-6363).  You completing and returning this questionnaire constitutes consent 
for the researchers to use the data for the purposes of conducting the study as approved by 
the University of Saskatchewan Behavioural Research Ethics Board on August 27th, 2004.  
Should you have any questions regarding your rights as a participant in this study you may 
call the Office of Research Services at the University of Saskatchewan (306-966-2084).  Out 
of town participants may call collect.   
 
If you feel that another pharmacist in your practice would be more knowledgeable about the 
subject matter of this questionnaire, please feel free to have that person complete it. 
 
Sincerely, 
 
 
Jason Perepelkin, BA, BComm  Roy Dobson, BScPharm, MBA, PhD  
Graduate Student    Assistant Professor of Pharmacy 
College of Pharmacy & Nutrition  College of Pharmacy & Nutrition 
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November 8th, 2004 
 
 
«Title» «UsualName» «Pharmacy_Manager_Last_Name» 
«Pharmacy_Name» 
«Street» 
«City», «Province» «PostalCode» 
 
Re: Pharmacists and the Exception Drug Status Program 
 
Dear «Title» «Pharmacy_Manager_Last_Name»: 
 
You recently received a request to complete a questionnaire on Saskatchewan Health’s 
Exception Drug Status (EDS) program and Maximum Allowable Cost (MAC) policy.  If you 
have already completed and returned the questionnaire, thank you.  If you have not yet 
completed the questionnaire, we would ask that you complete it as soon as possible and 
to return it in the pre-stamped envelope provided.  Your participation is important and we 
look forward to receiving a completed questionnaire from you. 
 
As you know, the purpose of this study is to gain pharmacists perceptions on the EDS 
program, as well as the MAC policy.  In addition to informing members of the pharmacy 
profession about pharmacists’ perception on these programs, the information obtained 
from you and other participants in the study will help to better inform those charged with 
planning and implementing changes in the delivery of the programs.   
 
Should you have any concerns about this research do not hesitate to contact the principal 
investigator (Roy Dobson) by e-mail (roy.dobson@usask.ca), facsimile (306-966-6377) or 
phone (306-966-6363).   
 
 
Sincerely, 
 
 
 
Roy Dobson, BScPharm, MBA, PhD  
Assistant Professor of Pharmacy 
College of Pharmacy and Nutrition 
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November 22nd, 2004 
 
«Title» «UsualName» «Pharmacy_Manager_Last_Name» 
«Pharmacy_Name» 
«Street» 
«City», «Province» «PostalCode» 
 
Re: Pharmacists and the Exception Drug Status Program 
 
Dear «Title» «Pharmacy_Manager_Last_Name»: 
 
You recently received a request to complete a questionnaire on Saskatchewan 
Health’s Exception Drug Status (EDS) program and Maximum Allowable Cost (MAC) 
policy.  If you have already completed and returned the questionnaire, thank you.  If 
you have not yet completed the questionnaire, we would ask that you complete it as 
soon as possible.  We have included an additional questionnaire and pre-stamped 
envelope in case you misplaced the original.  Your participation is important and we 
look forward to receiving a completed questionnaire from you. 
 
As you know, the purpose of this study is to gain pharmacists perceptions on the EDS 
program, as well as the MAC policy.  In addition to informing members of the 
pharmacy profession about pharmacists’ perception on these programs, the 
information obtained from you and other participants in the study will help to better 
inform those charged with planning and implementing changes in the delivery of the 
programs.   
 
Should you have any concerns about this research do not hesitate to contact the 
principal investigator (Roy Dobson) by e-mail (roy.dobson@usask.ca), facsimile (306-
966-6377) or phone (306-966-6363).  You completing and returning this questionnaire 
constitutes consent for the researchers to use the data for the purposes of conducting 
the study as approved by the University of Saskatchewan Behavioural Research Ethics 
Board on August 27th, 2004.  Should you have any questions regarding your rights as a 
participant in this study you may call the Office of Research Services at the University of 
Saskatchewan (306-966-2084).  Out of town participants may call collect.   
 
If you feel that another pharmacist in your practice would be more knowledgeable about 
the subject matter of this questionnaire, please feel free to have that person complete it. 
 
 
Sincerely, 
 
 
 
Jason Perepelkin, BA, BComm  Roy Dobson, BScPharm, MBA, PhD  
Graduate Student    Assistant Professor of Pharmacy 
College of Pharmacy & Nutrition  College of Pharmacy & Nutrition 
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A – Participation in Saskatchewan Health’s EDS Program 
Questions in this section relate to how often your pharmacy deals directly with the EDS 
program. 
 
1. On average, how many new prescriptions for restricted or non-formulary medications does 
your pharmacy receive per week?       
__________ Per Week 
 
2. On average, what percent of these restricted or non-formulary medications are submitted 
for coverage under the EDS program? (Please circle appropriate percentage) 
 
I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I 
0            10           20           30            40           50            60           70           80            90         100 
 
3. On average, what percent of the EDS submissions are initiated by your pharmacy rather 
than by the prescribing physician? (Please circle appropriate percentage) 
 
I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I 
0            10           20           30            40           50            60           70           80            90         100 
 
4. On average, what percent of EDS submissions initiated by your pharmacy are the result of 
a request by the prescribing physician? (Please circle appropriate percentage) 
 
I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I-----I 
0            10           20           30            40           50            60           70           80            90         100 
 
B – The Pharmacy  
 
Proximity of the majority of physicians prescribing to your patients (indicate one that best 
applies) 
  [   ] Same Location (same building or mall) 
  [   ] Next Door (on the same block or just across the street) 
  [   ] Close By (within easy walking distance) 
  [   ] Somewhat Removed (short driving distance in same town)  
  [   ] Distant (one hour or less drive to different town or city) 
  [   ] Remote (one than one hour drive to another town or city)   
 
Average number of prescriptions filled per week. (Can be a single number or a range, e.g. 
250 – 300)                  ______________ Per Week 
 
Hours the dispensary is open:               ______________ Per Week 
 
C – The Pharmacist Completing the Questionnaire  
 
Gender:    Female (   ) Male (   ) Age (years): ________   
Current position (Job Title): ________________________________ 
 
 
Thank you for participating in this study. 
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March 7th, 2005 
            
 
«Title» «UsualName» «Pharmacy_Manager_Last_Name» 
«Pharmacy_Name» 
«Street» 
«City», «Province» «PostalCode» 
 
Re:  Pharmacists and the Exception Drug Status Program  
 
Dear «Title» «Pharmacy_Manager_Last_Name»: 
 
We respect your decision not to complete the questionnaire, “Pharmacists Experience with 
the Exception Drug Status (EDS) Program in Saskatchewan.”  However, we would ask 
you to take a couple of minutes and complete the enclosed non-responder questionnaire 
and return it in the pre-stamped envelope provided?  The data you provide will only be 
used to evaluate the validity of the questionnaires completed by your colleagues.  This is 
our last request of you.   
 
Your participation is important.  However, it is completely voluntary.  The code number on 
the questionnaire is designed to give the investigators the ability to track questionnaires 
while keeping your identity strictly confidential.  Results will be aggregated to ensure that 
the identities of individual respondents are safeguarded.  Only the principal investigator 
(Roy Dobson) and co-investigator (Jason Perepelkin) will have access to the data arising 
from this study.  All information will be stored in secure facilities at the University of 
Saskatchewan.  
 
You completing and returning this questionnaire constitutes consent for the researchers to 
use the data for the purposes of conducting the study as approved by the University of 
Saskatchewan Behavioural Research Ethics Board on January 6th, 2005.  Should you have 
any questions regarding your rights as a participant in this study you may call the Office of 
Research Services at the University of Saskatchewan (306-966-2084).  Out of town 
participants may call collect.   
 
Should you have any concerns about this research do not hesitate to contact the principal 
investigator (Roy Dobson) by e-mail (roy.dobson@usask.ca), facsimile (306-966-6377) or 
phone (306-966-6363).   
 
If you feel that another pharmacist in your practice would be more knowledgeable about the 
subject matter of this questionnaire, please feel free to have that person complete it. 
 
 
Sincerely, 
 
 
 
 
Jason Perepelkin, BA, BComm   Roy Dobson, BScPharm, MBA, PhD  
Graduate Student     Assistant Professor of Pharmacy 
College of Pharmacy & Nutrition   College of Pharmacy & Nutrition 
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EDS Themes  
? Process [PRO] – issues pertaining to system being too slow, not 
receiving notification of acceptance or rejection, etc. 
? Automation [AUTO] – responses centred on an online and/or automated 
adjudication system to handle requests. 
? Administrative [ADMIN] – the subject of administrative burden, having to 
balance regular duties with EDS, etc. 
? Remuneration [REMUN] – focus on being compensated for initiating 
EDS requests 
? Education [ED] – concern with the lack of understanding regarding the 
EDS process by physicians and patients, as well as suggestions to 
educate the two 
? Cooperation [COOP] – distress over the lack of cooperation seen from 
physicians and the Drug Plan on matters relating to EDS 
? Communication [COMM] – centring on lack of, or insufficient  
communication between Drug Plan and pharmacists, Drug Plan and 
physicians, Drug Plan and patients, physicians and patients, and/or 
physicians and pharmacists 
? Coverage [COV] – anxiety over the issue of what is and isn’t covered, 
when patients benefits start to take effect, why a drug is labelled EDS, 
third-party plans, etc. 
 
Responses 
o EDS is too slow – they are often 3 – 5 days behind. [PRO] 
o Pharmacists seem to accept more & more administrative work to administer 
government plans, as well as private for free.  Doctors get paid for every fax 
we send, but we get paid $0.  We chase for EDS information from doctors, 
spend countless hours explaining MAC & EDS for no pay and yet we 
continue to have to fit it into an already busy work day.  Countless audits & 
requests by NIHB require valuable time best spent elsewhere. [ADMIN] 
[REMUN] [PRO] 
o Provide physicians more information about what Exception Drug Status 
means in regards to drug costs, etc.  Many doctors assume that by applying 
for EDS means the patients’ drug cost for the medication is $0. [ED] 
o If EDS criteria is met for one drug in a class (i.e. PPIs, Cox-2) it should be 
extended to all drugs in that class and not require renewing. [PRO] [COV] 
o The EDS program is quite workable; however, more doctor involvement 
would make it more efficient. [COOP] [COMM] 
o Get SHIN running province wide – allow SPDP to access patient diagnosis, 
etc. [PRO] 
o Use funds collected for previously failed ‘trial prescription program’ to 
reimburse pharmacists for time spent on EDS requests. [REMUN] 
o We [should] get paid a fee for every EDS request made on our patients’ 
behalf. [REMUN] 
o Implement a fee for this service. [REMUN] 
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o If SHIN were available, it would possibly save time in determining EDS 
criteria. [PRO] 
o I feel the turn around time is sometimes lacking, which then creates us 
another job as to checking whether or not coverage is granted. [PRO] 
[COMM] 
o I understand physicians are being paid for fax requests & as well being paid 
or lobbying to be paid for EDS – why are pharmacists doing the work 
requesting, checking, obtaining diagnosis from physicians & for patients & 
we are not paid or being considered for payment for services?  In fact, a 
pharmacy some years ago was disciplined for charging the patient for this 
service – I am tired of being expected to educate the public & check on 
physicians (which provide positive outcomes) for NO PAYMENT. [PRO] 
[ADMIN] [REMUN] [COMM] 
o Provide information sessions to all physicians.  I don’t think they understand 
it all & are misleading the patients & then it is up to us, pharmacists, to try 
and sort out the situation & this takes more time for us than if the doctor had 
not told the patient anything or better yet had given them the right 
information! [ED] [COMM] 
o I cannot let this pass without a comment(s).  We spend an inordinate 
amount of time on EDS.  The doctor & patient EXPECT us to do it.  The 
most offensive and abused plan is that with SAHO.  If ANY of our SAHO 
patients get a rejection slip, they immediately turn heaven & earth upside 
down to get coverage.  EVERY trick in the book is evident – and many times 
the truth is stretched!  The rejection slip from SAHO blatantly states – take 
this to your pharmacists to get EDS – then re-submit.  No where does it say 
you must meet certain criteria – to this end I have made countless phone 
calls – to no AVAIL.  One case: we got coverage (or someone did) for 
Duragesic; it expired (turns out only for 50 UG); re-applied and had to phone 
twice, advised to give it to her; 3rd phone call – in system – give it to her; 4th 
phone call – wrong strength; 4 faxes; 3 hours time; got the stuff – not paid 
for and we have to keep track of this?; and backdated, and it’s a triple Rx – 
and ??? one patient only!  This is the tip of the iceberg! [PRO] [ADMIN] 
[COMM] 
o More drugs that are automatically approved due to the age or medical 
condition, i.e. Cox-2 > 65, palliative care. [COV] 
o Perhaps when SHIN comes into effect process can be streamlined. [PRO] 
o Patients need to jump through hoops – decrease if possible, i.e. bi-polar 
patient must try Risperdal or Seroquel before Zyprexa. [PRO] 
o The drug company had heavily sampled Symbicort when it came out so 
patients with COPD often went straight to this medication without trying a 
long acting beta-agonist alone.  In order to qualify had to switch back or use 
2 separate products. [PRO] 
o EDS criteria don’t always keep up with current medical uses – some lag 
time. [COV] [COMM] 
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o Some of the more expensive antibiotics want direct proof of infection, i.e. 
“known to be resistant” determined via C&S – sometimes difficult to obtain 
good sample in pneumonia & would result in extra delay. [PRO] [ADMIN] 
o [The] drug plan could fax us when an EDS drug is either approved or not 
approved and the reason why; saves us calling about why a claim is not 
going through. [PRO] [ADMIN] [COMM] 
o Do something similar to Ontario – have a separate Rx pad for doctors with a 
reference number that can be entered; this online number automatically 
adjudicates the EDS claim instead of phoning in a diagnosis. [PRO] [AUTO] 
o EDS, 1st time for patient, should be applied for and approved by pharmacist 
and then verified by the Drug Plan.  We often have to renew EDS for drugs 
the patient has already had EDS for.  Quite often the Drug Plan will ask 
what the diagnosis is even though it is the same diagnosis and drug as [the] 
last time (waste of time!!!).  EDS should possibly be eliminated all together.  
With the new Adapt program, if a patient decides to fill a Rx that requires 
EDS we should be able to check off the criteria that applies to this particular 
drug and patient if it fits criteria, it is covered automatically.  Physicians can 
be asked to include that diagnosis on those Rx’s so that can also be 
checked off right away.  A separate box with yes or no answers to 
determine eligibility instantly would save a lot of time and paper. [PRO] 
[ADMIN] [COMM] 
o Pharmacists need to be paid for initiating EDS requests, i.e. at least $5 per 
request.  [REMUN] 
o I think the formulary should be the formulary and remove all exceptions.  To 
me this would provide a better idea of costs and make the people decide 
about affordability. I liken this to wants and needs.  Same with MAC; e.g. 
now we are having physicians requesting EDS for Nexium because Pariet 
did not work; I question the validity of the request. [PRO] [ADMIN] 
o Has to be improved to reduce the workload for pharmacists who wish to 
provide a superior service for customers. [ADMIN] 
o Make doctors more responsible for applying for EDS or make the process 
simpler for pharmacists.  We try to provide a superior service at our store to 
make medications more affordable for all our customer, welfare and low-
income earners, as well as patients with Drug Plans that require the 
medications be on the Drug Plan.  Have more people on the Drug Plan 
working Monday and Tuesday to clear back logs.  Have Drug Plan people 
follow-up with doctors to clarify diagnosis, etc. NOT pharmacists – it is 
adding an extra step to the process that is not necessary.  One call from the 
Drug Plan to the doctors’ office should clear up the query. [PRO] [ADMIN] 
[ED] [COOP] [COMM] 
o The worst part of applying for EDS is getting the diagnosis from the 
physicians.  Perhaps they could be encouraged to write it on the Rx more 
often.  The second worst part is explaining to patients why they don’t qualify 
– e.g. they can’t get Fosamax until they try Diflucan, or they can’t get Advair 
until they try Flovent.  The Drug Plan should notify patients, in writing, with 
an explanation of the rejection.  They could then take that letter to their 
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physician and attempt to meet the criteria.  Lastly, the new requirement for 
C & S testing for antibiotics is unreasonable. The reality is that while these 
drugs are frequently prescribed, often as the first choice antibiotic for a 
particular infection, C & S testing is rarely performed.  The Drug Plan should 
tell doctors that they must do C & S if they want to prescribe these 
antibiotics.  I’ve been yelled at on several occasions when I asked a doctor 
if they had done C & S – they see it as a waste of time and money, and 
they’re probably right.  It seems to me that the Drug Plan is simply using a 
lack of C & S as an excuse to avoid paying for an expensive antibiotic.  In 
the big picture, C & S testing costs far more than paying for a second line 
antibiotic.  The Drug Plan is attempting to off-load costs onto the labs, and 
onto patients, who have no control over what their doctor prescribes. [PRO] 
[ADMIN] [ED] [COV] [COMM] 
o Tedious and time consuming to get diagnosis/criteria met from the doctors.  
Frustrating as we do not get any additional benefit for this work. [PRO] 
[COMM] 
o Prometrium should be automatically covered (not equivalent to Provera). 
[COV] 
o I feel strongly that if the doctor feels the patient requires the medication, 
some obscure person CANNOT over-ride this.  Also, often the EDS is for an 
antibiotic which they need now, not in 7 days!!! [PRO] 
o Reimburse pharmacists for time spent on administering the program.  Some 
pharmacies are charging patients a fee to provide this service. [REMUN] 
o Pharmacists [should] get compensated for filling out and explaining EDS to 
patients. [REMUN] 
o [Should] notify pharmacists when there is a problem with an EDS they have 
applied for. [PRO] [COMM] 
o EDS for long-term drugs (e.g. Plavix) should not have to be renewed as this 
can be very time consuming – which doctor wrote the original, when, what 
was the diagnosis back then, etc. [PRO] [COV] 
o The approval has to be made within minutes, not days; the patient requires 
the medication then.  The process is totally useless for antibiotics unless 
you count (which you have to) on the pharmacist to ensure [the] patient is 
looked after.  Pharmacists spend way too much time describing the Drug 
Plan and explaining it to patients; we do not work for the Drug Plan.  No 
reimbursement for this. [PRO] [COV] [REMUN] 
o Communication is a one-way street with the Drug Plan.  We have our 
number if there is a problem with an EDS application but never hear from 
them if there is.  The letter is sent only to the patient and often the patient 
interprets it to mean that they don’t have to pay for it.  For the majority of 
patients EDS is useless.  Once it is in place they then have to apply for 
additional support which again takes weeks to hear about.  The letters sent 
to patients, most have a difficult time understanding. [COMM] [PRO] [ED] 
o The EDS program places the pharmacist between a rock and a hard place.  
Doctors do not share information, Drug Plan treats us with indifference and 
patients get angry. [COMM] [PRO] 
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o Some reimbursement for our time would be nice. [REMUN] 
o It is often difficult to obtain information from medical records departments in 
hospitals.  They usually refuse to release information to me, which can 
sometimes leave patients without EDS coverage. [COMM] [PRO] 
o Stream-line all manual portions [of EDS application] as much as possible. 
[AUTO] 
o Education to physicians [on EDS] to ensure they supply sufficient 
information to patients and pharmacists. [ED] 
o Extend inquiring capability [of pharmacists] to get specifics. [PRO] 
o Better education of physicians regarding writing diagnosis on prescription. 
[ED] 
o All the work in applying for EDS [is] done by pharmacists.  Physicians rarely 
do EDS prior to patient coming into the pharmacy.  Physicians should be 
required to automatically apply for EDS everytime they write a prescription 
for an EDS drug.  Physicians should be better informed on purpose of EDS 
program and how it benefits the patients regarding their drug costs. [PRO] 
[COMM] [ED] 
o It would be nice if the pharmacy could be faxed when EDS goes through 
(similar to NIHB requests for prior approval).  This would speed up filling 
these prescriptions and prevent multiple tries/phone calls to SK Health 
which is very time consuming. [COMM] [PRO] 
o I think doctors need to be more aware of what drugs require EDS.  Some 
seem almost surprised when we call for information.  Also, if doctors could 
be told to always include information like diagnosis, previous treatment 
failures, etc. it would make it easier for pharmacists to apply for EDS and 
reduce the number of phone calls and faxes to doctors requesting this 
information.  Plus then the doctors wouldn’t have to do the applying. [ED] 
[PRO] [COMM] 
o Doctors should provide [the] diagnosis without being asked AND give 
alternative drugs tried, etc. so we are NOT searching for this information. 
[PRO] [ADMIN] 
o Have software to do it online; no paperwork! [AUTO] 
o The EDS program needs to be revamped as it is to time consuming.  A 
pharmacist should be able to determine if therapy is appropriate by talking 
to patient only.  Contacting the physician is to time consuming for both 
health professionals.  Simple questions can determine if therapy is 
appropriate. [ADMIN] [PRO] 
o Educate physicians on the program and it’s requirements (our physicians do 
not do anything with this – their receptionist calls in requests and tries to find 
the diagnosis in the chart so often EDS is denied because not enough 
information is given). [ED] [PRO] 
o Educate the public or pay pharmacists for the time taken to explain the 
program. [ED] [REMUN] 
o Send the pharmacy a copy of the approval or rejection so that I can follow 
up with the doctor if the request is denied (as EDS requests that are denied 
are never looked at by our local physicians). [COMM] [PRO] [ADMIN] 
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o Improve how quickly requests are processed.  Often in our town patients’ 
are not able to afford full price and to submit receipts for reimbursement, so 
I am in the difficult position of billing for products after the EDS is approved 
or to with-hold the drug. [ADMIN] [PRO] 
o Follow up with physicians when prescribing is not appropriate. [COMM] 
o Thanks for doing this study – I think that many improvements need to be 
made to this program! 
o Pharmacists should be notified when a EDS request is approved or declined 
just as doctors are.  Sometimes the Drug Plan needs more information to 
complete the request approval but don’t ask us for it.  We have to call them 
to see why a request hasn’t been approved.  Extra work for us and delays 
for patients.  How about being able to make requests online and then 
notifying us online when requests are approved? [PRO] [COMM] [ADMIN] 
[AUTO] 
o I feel that many of the meds that are available for EDS would not be 
prescribed if the doctor did not feel that they would be beneficial to the 
patient.  I know of more then one instance where a patient was denied EDS 
but had extraordinary circumstances that that patient should be on the drug 
but did not “meet criteria” and therefore [was] denied assistance from the 
Drug Plan.  There are also people who demand EDS be gotten for them and 
somehow they always get it. [ADMIN] [COV] 
o Pharmacists could have the authority to switch patients to lower costs meds 
– like interchangeable or no substitution situations. [PRO] 
o Pharmacists should get a fee for EDS & MAC administration. [REMUN] 
o The lack of physician understanding of the EDS and MAC policies [is a 
barrier to proper administration].  Most do not provide a diagnosis on the 
prescription when they write for an EDS medication.  A pharmacist 
administrates an EDS submission and is required to make a fax or phone 
call to the physician to attain this information.  Thus, the pharmacists and 
physician have duplicated the administration time on the prescription. [ED] 
[COMM] [ADMIN] [PRO] 
o The cost of administration of these programs (EDS & MAC) to the pharmacy 
is huge.  The time consumption of the pharmacist to administer these 
programs has grown tremendously especially since 1999 without monetary 
compensation from the SPDP.  The reasons for this growth are prescribing 
trends and the majority of new therapies are only considered EDS benefits.  
The EDS program as administered by the Drug Plan believes that potential 
costly drug therapies will be available in a more controlled fashion therefore 
benefiting the health of the public.  It is my belief that these are money 
saving controls, not health wellness controls.  I have personally brought 
forward clients which required the EDS medication but did not specially 
meet any of the criteria exactly as wanted by the SPDP.  I would have to call 
Gail Bradley personally on behalf of the resident to explain why this client 
should be covered by the Plan.  There is a bias formed when it comes to the 
cost of medication and how much the literature would be used or not used 
to save the money.  One great example would be the bisphosphates.  
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Didrocal does not have the indication for the treatment of male osteoporosis 
and will not get that indication.  But the SPDP will not allow all males to 
have EDS on Actonel or Fosamax based on being male alone when these 2 
medications have the indication for male osteoporosis but are more 
expensive then Didrocal.  Is this more controlled fashion really benefiting the 
health of the patient or benefiting the SPDP pocketbook because Didrocal is 
less money?  Another example would be the use of respiratory 
fluoroquinolones.  They are only to be used in documented pneumonias.  
The Drug Plan is trying to get physicians to use the combo 2nd generation 
cephlasporins with a macrolide to help decrease over usage and resistance.  
Great we now have 2 EDS submissions to apply for the 2nd generation 
cephlasporins and the macrolide because erythromycin is not favoured over 
clarithromycin or azithromycin.  In the nursing home residents getting a 
chest x-ray is extremely difficult and expensive when they have to use an 
ambulance.  Yet there are some of these residents who should be on the 
respiratory fluoroquinolones but following criteria made by SPDP there are 
not exceptions until they get hospitalized. [ADMIN] [PRO] [REMUN] [COV] 
[COMM] 
o In the end pharmacists are great contributors to health outcomes.  We 
assist in the administration of the programs, help patients decrease 
medication costs, are educators of both the public and healthcare 
professionals on programs like EDS and MAC however we are not 
reimbursed by any 3rd party payer for these services.  In my opinion this 
needs to change.  The push for increased pharmacist involvement in patient 
care has grown and will continue to grow until we don’t have the resources 
available to pay for these extra administrative costs.  The pharmacies will 
not be able to afford these free services much longer, a dispensing fee only 
covers so much!!! [ADMIN] [PRO] [REMUN] 
o I think there should be some kind of compensation for EDS requests.  EDS 
requests can require significant time; requires professional judgement and 
knowledge (cannot be done by a technician). [REMUN] [PRO] 
o I fail to understand the rationale for requiring the pharmacist to confirm the 
diagnosis with a physician for every EDS request.  Should I not be able to 
know that my client has asthma if I have been dispensing asthma 
medication monthly [to the client] for 5 years? [PRO] [ADMIN] 
o EDS should be reserved for the exception, not the norm.  A MAC drug like 
Pariet should be on the Plan.  EDS for others (PPIs) with Pariet MAC 
pricing.  Same for Celebrex.  Also, a much shorter list of EDS drugs should 
be developed.  Either a shorter list or no list at all.  The Drug Plan takes as 
many as 7 days to authorize drugs.  They are severely understaffed and 
don’t work on weekends of evening when they might actually help patient 
care.  I just finished waiting 2 weeks for palliative care for a patient as well 
and the doctor phoned in 3 times and I phoned/faxed 3 times.  I am 
exceptionally disappointed with their service.  The Drug Plan is the weakest 
link in providing seamless care.  Limit EDS drugs, put more EDS drugs on 
the Plan, or drop the program.  The Drug Plan can’t do the job so please do 
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not hire more people (this is not cost saving to health care).  It is just 
robbing Peter to pay Paul.  Finally, if the pharmacist is doing all the 
information gathering, and patient counselling, doctor follow up, there 
should be a fee for our service.  You could easily replace the whole EDS 
wing of the Drug Plan if we could bill on the web with certain indications 
checked off and not require patients to be without medications or wait to be 
reimbursed via the Drug Plan.  You could spend money on one auditor to 
replace the EDS staff and have the pharmacy finish the job you already 
partially handed over. [COV] [PRO] [COMM] [ADMIN] [AUTO] 
o EDS should only be initiated by hospital pharmacists as they commonly 
have access to appropriate information.  Approximately 80% of EDS 
requests should be initiated by the physician, knowing they have all the 
appropriate information to make the request.  Unfortunately physicians are 
not only dumping the job on retail pharmacists, but they rarely provide the 
information necessary to make the request possible.  Many patients are 
being given improper information about EDS and how it works, by the 
physicians.  Unfortunately the patients are commonly the victims of this 
process.  Overall, I have yet to see the government properly educate the 
public on the ins and outs of Drug Plan policy.  The pharmacist seems to be 
the only accessible person the public has for their inquiries.  Unfortunately 
we DON’T HAVE TIME FOR THIS!  Things must change and SOON! [ED] 
[PRO] [COMM] [ADMIN] [COOP] 
o Doctor suggests pharmacist get EDS when patient is not qualified for SPDP 
help.  Doctors need to understand the reason for EDS. [ED] [COV] 
o Physicians and patients need to understand that coverage under EDS does 
not mean the drug is free.  This is a common misconception. [ED] [COMM] 
o Pharmacists need easier access to diagnosis and lab values to ensure EDS 
eligibility. [COMM] [COOP] 
o Prescriptions should have [an] area for physicians to write diagnosis. [PRO] 
o Physician samples cause most [of the] problems when continuation of 
therapy is required.  It discourages the proper sequence in order to get EDS 
coverage.  For example, samples of Symbicort – Symbicort will not be 
covered unless other products are used first.  The list goes on – Spiriva, 
Pariet, etc.  Often the prescriber will give the product (samples) he [/she] 
has rather than what the patient should be started on.  This is where a great 
deal of pharmacists’ time is spent – explaining [to patients] the physician 
samples and why coverage cannot be given or applied for. [PRO] [COV] 
[ADMIN] 
o The EDS that we apply for should at least be responded to as (1) problems 
with the application – physician, and/or (2) approved or not approved within 
2 days.  The same applies for MAC – we are constantly having to phone or 
try to adjudicate the claim for the patient – not having any idea if it has been 
accepted or not.  Please get someone on a fax machine to let us know! 
[COMM] [PRO] [ADMIN] 
o Feedback from Drug Plan to pharmacists as well as patients – i.e. fax back 
approval – could speed up the process. [COMM] [PRO] 
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o Phoned in EDS – respond too – rather than faxing. [COMM] 
o EDS program must be more transparent.  We were told to fax requests.  
This has NOT resulted in any improvement in speeding up approvals.  We 
never receive information regarding our requests. [PRO] [COMM] 
o I think preparations such as Duragesic should NOT require EDS approval.  
Patients in nursing homes or on palliative care need these pain relievers 
and it takes considerable time to obtain approval. [COV] [PRO] 
o Would be nice to be contacted once EDS has been accepted/denied; many 
times our customers bring in their letters once the accepted date has past – 
antibiotics especially. [COMM] [PRO] 
o Just eliminate the EDS portion [of the Drug Plan], and cover the 2 drugs 
they will pay for [in a category] and that’s it. [COV] [ADMIN] 
o I hate the EDS program; it makes so much extra work for us [pharmacists].  
The doctors have no idea most of the time of the process of stuff and write 
whatever.  Even if they know its EDS they get us to do the paperwork – a 
simple phone call for them and at least 2 faxes for us just for the information 
to fill it out.  Eliminate this program.  When we get it in place we have to 
refund the patient back and date the prescription – the paperwork is huge.  
It really annoys me that the Drug Plan just off-loaded this from physicians 
[onto pharmacists].  Sometimes we have to get EDS for a person because 
their third-party won’t pay for it unless it goes thru SPDP.  Paperwork for 
nothing.  I’d like to bill them but it’d just be more paperwork! [ADMIN] [PRO] 
[ED] [COMM] [COV] [REMUN] 
o The waste is in the bureaucracy.  Pharmacists should be the gate keepers 
for drug therapy.  An override code costing nothing would save thousands of 
dollars per year. [PRO] [ADMIN] [AUTO] 
o Currently, we apply for EDS without complaint.  The Saskatchewan Drug 
Plan EDS application is far better than NIHB or third-party plans.  My main 
complaint is that less than 0.1% of requests for EDS are turned down.  They 
only ones that are troublesome are the Alzheimer drugs where the Drug 
Plan is possibly depriving a patient of his/her last grasp at reality before 
he/she dies.  I think this is cruel and cold. [PRO] [COV] [ADMIN] 
o Improve wait time – 2 to 4 days is unacceptable. [COMM] [PRO] 
o Allow pharmacist to get diagnosis information from the patient. [PRO] 
[COMM] 
o Allow submissions electronically during claim adjudication. [AUTO] [PRO] 
o Please explain both policies (EDS & MAC) more clearly to physicians and 
patients.  Countless time I’ve been yelled at because a doctor will tell the 
patient the drug is paid for when EDS is approved, but they have no 
coverage.  The letter the patient gets us very unclear for EDS.  Remove 
some items from EDS that are extremely necessary or are not used for 
other purposes. [ED] [PRO] [COV] [ADMIN] 
o Take the EDS drugs off EDS and make them “open formulary.” [COV] 
o We waste a lot of time calling/faxing doctors and waiting for diagnosis.  I’m 
not sure how to improve that but it is something that needs to be looked at. 
[PRO] [COMM] 
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o EDS program needs a more efficient manner of notification of either 
rejection of approval – i.e. notification should be more readily forthcoming to 
the pharmacist.  “On-line” applications for dispensaries – i.e. at the time of 
dispensing – more efficient time-wise, etc. [COMM] [PRO] [AUTO] 
o [Drug Plan] must recognize the time it takes and pay us a fee for doing it.  
Government needs to understand that most EDS are because of other drug 
plans and they are doing the work.  Very few are turned down so there is 
really no purpose in the program.  The program is also not universal – if no 
one applies that person is not treated the same.  I think that in most cases 
[when] EDS is done no one benefits.  Most people do not get help from 
government.  I feel that this should be assessed before an EDS application 
is made.  If government wants us to administer their programs we need to 
be paid for it. [REMUN] [PRO] [COV] [ADMIN] 
o Pharmacist [should] get paid for service.  Government should look at how 
increasing drug coverage could save money on hospital stays.  Person 
could be treated at home. [REMUN] 
o Patients who already have EDS for Losec, Pantoloc, Prevacid, etc. should 
automatically be granted EDS for the alternative i.e. Omeprazole, Pariet – 
pharmacists or physicians should not have to reapply. [COV] [PRO] 
o Decrease the number of drugs available on EDS (the balance fully covered). 
[COV] 
o If a drug has 8 or more indications for EDS coverage perhaps it should be 
put on the drug plan. [COV] 
o Educate doctors on which medications are on the EDS program, the criteria 
for them, and [to] write [the] diagnosis and relevant information on the 
prescription.  This will speed up [the] process of EDS application, [make it] 
easier on the pharmacist, and more beneficial for [the] patient.  Or tell 
doctors to phone for EDS him/herself and write on the prescription that EDS 
has been applied [for].  This will reassure [the] patient knowing that 
coverage [may be] coming. [ED] [COMM] [PRO] 
o Compensate the pharmacy for applying [for] EDS on behalf of the patient 
where the doctor did not do anything.  They are compensated, but we do all 
the frustrating work, e.g. calling doctors (who are seldom available) for 
diagnosis, allergies or intolerances.  We have to do all the work, fill out [the] 
form and then follow-up whether it was successful or not, then call the 
patient, either because there is a refund, or more so, try to explain to [the] 
patient why it is not covered.  They take it out on us, not the doctor. 
[REMUN] [COMM] [ADMIN] 
o We should be able to use our professional judgement as to the diagnosis 
after looking at the profile. [PRO] 
o Less restrictions on guidelines in formulary and more input allowed from 
pharmacists who are more aware of situation than anyone – i.e. antibiotic 
acceptance from pharmacists’ recommendation.  We know best what 
medications patients can and cannot use. [COV] [PRO] [ADMIN] 
o It’s good that pharmacists can apply for EDS but we still don’t have the 
impact that physicians have in getting approval – particularly antibiotics. 
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o Pharmacists should be paid for every fax [when] applying for EDS. [COV] 
[PRO] 
o Online EDS with immediate approval for situations when the criteria are 
met. [AUTO [PRO] 
o Physicians [should be] indicating diagnosis on EDS prescriptions. [COMM] 
o The time lag for EDS for antibiotics is too long.  Some people will not take 
the prescription if it is not covered and a few days is too long to wait for an 
antibiotic. [COV] [COMM] [PRO] 
o Find it interesting how physicians constantly fight to be paid for any 
additional work they perform for their patients, where we as pharmacists are 
constantly increasing our workload thru pill packs, EDS submissions, 
increasing pharmaceutical care, aiding patients in applying for drug 
coverage with Saskatchewan Health, insurance claims, faxing for refills, 
phoning doctors and are reimbursed NOTHING!  We as an association 
need a backbone! [REMUN] [PRO] 
o At this location we find the EDS/MAC programs very time consuming.  
Some physicians are helpful by writing the diagnosis on the prescription but 
many do not so tracking down a diagnosis is very time consuming.  We are 
located in a low-income neighbourhood and the time it takes to get approval 
after the request is made is also time consuming because we are 
continually trying to re-bill prescriptions to see if coverage has gone thru.  
Most of out customers cannot afford to pay full price and then get 
reimbursed so we try to “loan” the a few pills and if the EDS is not accepted 
it is difficult for out customers to pay for what they have already taken.  We 
have a big issue with the “unpublished” EDS list.  We have no idea how to 
handle drugs that might be covered by EDS but we have no way of knowing 
one way or another.  We definitely feel we should be compensated for the 
time it takes to administer this program.  Physicians are now compensated 
for Alzheimer medication EDS applications.  I would argue that many times 
we spend just as much time making the call to the doctor for diagnosis, 
phoning in the request, trying to re-bill, phoning to see why it’s not going 
thru, and phoning the doctor for more information or a change in medication.  
The time it takes to administer this program is definitely adding to the stress 
of a busy workplace and taking away from the time we could be spending 
counselling patients on their medications. [ADMIN] [COMM] [PRO] [COV] 
[REMUN]  
o Have online approval immediately (see Manitoba’s plan) with reason codes 
online with documentation for audit purposes kept at the pharmacy 
regarding diagnosis, etc. [AUTO [PRO] 
o Get many of the antibiotics off EDS.  This is a waste of precious time.  
Reserve it for truly costly drugs, not as a deterrent to prescribing habits. 
[COV] [PRO] 
o Moved here from Alberta ? comparison? ? EDS is a nightmare to 
administer.  Make more efficient or pay us for it (our time)! [ADMIN] 
[REMUN] [PRO] 
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o Renew EDS for longer periods of time or completely disregard [the] need for 
renewal to decrease time spent. [COV] [ADMIN] [PRO] 
o Make it (EDS) part of computer software so [requests] could be done online 
somehow rather than paper. [AUTO] [PRO] 
o I’m not sure it (EDS) changes prescribing or not – often see doctor 
indicating whatever diagnosis to get EDS for their patient.  Those who can 
afford still pay –those who can’t, don’t. [PRO] [COV] 
o We get a lot of angry customers whose third-party plans won’t cover EDS 
medications without a form and so they expect us to apply 3 months later 
when they’ve gotten around to submitting receipts.  We have no way of 
knowing who might benefit or be eligible at the time. [COV] [PRO] [ADMIN] 
o Time consuming, especially when [the] pharmacist initiates the EDS 
because the form has to be faxed to the doctor, [and] then send it to SPDP.  
If there are problems with it SPDP faxes us with questions, which we don’t 
know then it’s faxed back to the doctor.  Better if the Drug Plan faxed the 
physician with their questions than us. [ADMIN] [COMM] [PRO] 
o Majority of the onus for EDS is on the pharmacist as the physician will not 
do it if he/she does not get paid.  Financial reimbursement is required for 
pharmacists to continue this process.  Very time consuming, i.e. paper work, 
faxing, phoning doctors for diagnosis, forwarding medication until EDS 
comes through, etc. [PRO] [COMM] [ADMIN] 
o The EDS program is taking up too much of our time to get diagnosis and 
other information, etc. [PRO] [COMM] 
o Increase the hours someone is at the EDS office.  EDS office staff should 
contact us if there is a problem ? we only find out if we call them.  If a 
pharmacy is calling, we should get a fax back when coverage is initiated.  
Patients call us repeatedly to put through [a] prescription to check coverage 
? real time waster. [ADMIN] [COMM] [PRO] 
o The whole EDS program is not saving money – at least 95% of my 
applications are approved.  The system puts extra workload on pharmacists 
and/or doctors, plus there must be extra staff at the Drug Plan so saving 
could be used as staff costs.  Patients must take other medications (i.e. 
Ranitidine, etc.) before getting a PPI.  Therefore the patient is 
inconvenienced and pre-requisite drugs are wasted because they did not 
work.  “EDS” system is a “make work project” – a complete waste of time. 
[ADMIN] [COV] [PRO] 
o Have the doctor fill in diagnosis on all prescriptions requiring EDS at the 
time of writing the prescription and all other pertinent information.  Have 
people at the Drug Plan who can believe a pharmacists word as equal to a 
physicians word regarding previous treatments i.e. not have to relay all 
requests for more information back to the doctor when you as a pharmacists 
know the answer.  [COMM] [PRO] [ADMIN] 
o Go online – be able to click on appropriate requirements and audit a 
percentage of requests instead of 100% of all requests handled by each 
pharmacist, doctor and corresponding worker at the Drug Plan. [AUTO] 
[PRO] [ADMIN] 
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o If this program saves the Drug Plan money, a percentage of that money 
should be paid back to the person doing the EDS submission.  Third-party 
payers who use the same EDS requirements for their formularies should 
also be required to pay a percentage back to the person doing the EDS 
submission. [REMUN] [COV] 
o Coverage should be by drug classes – not individual drugs i.e. all PPIs or all 
quinolones, etc. for the Saskatchewan Drug Plan and other third-party 
payers using [the] same EDS requirement. [COV] [PRO] 
o The single most frustrating part for me is that I cannot phone for EDS if I 
don’t know the diagnosis or what has been tried before. [COMM] [PRO] 
o EDS should not be required for palliative care patients. [COV] 
o Would be good to be informed on the acceptance of EDS for your patients. 
[COMM] 
o Allow a code to be transmitted online so that EDS dollar amount can be 
calculated at time of initial prescription pick up e.g. Code 1 – meets criteria 
for SPDP EDS – then when we process [the] prescription the correct dollar 
amount will be calculated.  Information documented on hard copy 
prescription subject to audit. [AUTO] [PRO] [COMM] 
o Expand criteria for certain antibiotics e.g. a patient with a past history of 
ineffectiveness of 2 other antibiotics for Sinusitis but not C&S done – has 
had success with Ceftin but EDS was refused – why does Saskatchewan 
Health have to pay for a C&S test when we know Ceftin works? [COV] 
[PRO] [ADMIN] 
o The administrative issues facing pharmacy have increased dramatically 
over the past 10 years; mostly to the benefit of third-party payers and 
government.  Pharmacy staff spend an inordinate amount of time explaining 
insurance programs to their patients without any financial recognition; this is 
unacceptable. [ADMIN] [PRO] [REMUN] 
o Reviewing the EDS criteria on a regular basis and making them reality 
based e.g. a C&S on a pneumonia patient is rarely done because they are 
often contaminated during the collection process. [COMM] [PRO] [ADMIN] 
o Most of our EDS requests are required in order to have the prescription 
covered by the patients’ private insurance (must be on the SPDP formulary 
to be a benefit for their plan) therefore more responsibility should be on the 
insurance company and the patient (i.e. insurance company should supply 
forms to their patients to [be] filled out and sent in on their own ? when 
approved let us know! [COV] [COMM] [ADMIN] 
o Getting prescriptions paid for often seems to take more time and effort than 
giving patients “pharmaceutical care.” [PRO] [COV] 
o It seems only a few physicians are aware that pharmacists can apply for 
EDS – why not get the word out so that they would get in the habit of writing 
[the] diagnosis on [the] prescription?  We often fax them for a diagnosis.  It 
takes a lot of time to explain the procedure to the patient, then fax, etc.  
Doctors get reimbursed for faxes all the time.  Paying pharmacists for this 
time is critical to making this whole procedure happen.  I work in a slower 
pharmacy and I enjoy giving this service but if I were busier there in now 
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way I would make all the EDS requests happen unless I have some funding 
to staff this.  [ED] [COMM] [REMUN] [PRO] [ADMIN] 
o The amount of time spent [on EDS] is ridiculous - #1 explain to [the] patient, 
#2 try to get [the] diagnosis, and #3 [the] wait time is too long.  Doctors need 
to be educated about EDS, [on] both requirements and criteria.   They seem 
to have no regard for their patient at all.  Or pharmacists should be able to 
have instant coverage if criteria are met. [PRO] [COMM] [ADMIN] [ED] 
o We should be paid for EDS submissions. [REMUN] 
o Physicians need to be educated very well about MAC, EDS, and Drug 
Plans. [ED] 
o The letter sent out to patients has to be reworded ? in this province they 
only get to the word “covered” and then they come [in] for their refund. [ED] 
[COMM] 
o My biggest beef is with the special support program – doesn’t seem to cover 
those who should be covered. [COV] 
o If we could have a reply from [the] Drug Plan within one or two days, 
whether approved or denied, would be very helpful. [COMM] 
o [Make it] mandatory [for] physicians [to] put down diagnosis. [COMM] 
o It would be beneficial if the Drug Plan could fax a confirmation or denial of 
EDS claims; would save us and them many phone calls. [COMM] [PRO] 
o Recently had a case where the patient ended up back in the hospital while 
waiting for Avelox to be approved or denied.  Applied for EDS October 14th 
(now October 26th); I have no idea what the Drug Plan has decided (i.e. will 
approve, not approve). [COMM] [PRO] 
o Please inform pharmacists if request is: (1) yes, (2) no, or (3) pending – 
within 24 hours!  Should be paid $5 per request [whether] approved or not 
approved. [COMM] [REMUN] 
o Please, please, please fax us a confirmation or rejection within 24 hours 
(Indian Affairs can).  Also, the Drug Plan should be chasing down the 
diagnosis by fax as is done by Indian Affairs! [COMM] [PRO] [ADMIN] 
o EDS – for example – if a patient has been on Metformin and Avandia is 
added, why couldn’t the Drug Plan check the profile, see that Metformin has 
been inadequate and grant EDS without a request?  Similarly, Ranitidine 
and PPIs. [PRO] 
o Drug Plan indicated rejection of an EDS application if not done verbally.  
They never acknowledge acceptance – whether verbal or written request is 
made. [COMM] [PRO] 
o Drug Plan should pay pharmacists for applying for EDS. [REMUN] 
o I have a client whose mother lives in the country (rural location) and neither 
her doctor of her pharmacist will request EDS or special coverage.  Actually 
I have applied for EDS for her on several occasions.  This pharmacist is not 
doing their job. [COMM] [COV] [ADMIN] 
o When an EDS request is made the pharmacy should be contacted within 3 
days if it is rejected.  ALL EDS eligible drugs should be listed in the 
formulary i.e. acetaminophen suppositories, etc. and automatic EDS for 
palliative care patients and other groups. [COMM] [COV] [PRO] 
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o Give pharmacists authority to approve EDS online in real time.  Pay us for 
our time! [AUTO] [COV] [PRO] [REMUN] 
o I feel that it is unfair that when doctors make EDS request that they are paid 
for it – yet we are not.  We have to spend time contacting the doctor for [the] 
diagnosis and then phoning it in and we are not compensated. [REMUN] 
[ADMIN] [COMM] [PRO] 
o Pay pharmacists to administer these programs at $2 per minute therefore 
$5 per claim. [REMUN] 
o It is difficult to be responsible for applying for EDS when we don’t have all 
the information.  It seems we are secretaries for the Drug Plan which eats 
up our time. [COMM] [ADMIN] [PRO] 
o The Drug Plan has too many items that they don’t cover.  If they would 
become a real drug plan, there would be a lot less EDS requests.  It 
appears to me that any drug that is expensive or good they don’t cover i.e. 
Clavulin, Ceftin, etc. [COV] [PRO] 
o My concern is the time spent gathering information, checking deductibles, 
filling out the form, reviewing criteria, discussing with patient, reimbursing 
patient if necessary, making notes on patient files and on hardcopy so we 
can remember what stage we are at with each request and not being paid to 
perform this time consuming task; something is wrong with this scenario.  I 
believe doctors receive something for their time but [it] must not be enough 
as most download to us the job of making the applications. [PRO] [ADMIN] 
[COMM] [REMUN] 
o Faster approval. [PRO] 
o Saskatchewan Health needs to do a better job of explaining these policies 
and take the onus off of the pharmacists to explain.  There are still 
numerous people that are not aware that the $850, every 6 months, family 
deductible is gone. [ED] [COMM] 
o EDS requests are regularly lost at the Drug Plan.  Also if a request is 
deemed to not have adequate information, no one informs you of that.  And 
as of October 26th, they were two weeks behind [in] processing some 
requests (Aricept). [PRO] [COMM] 
o I simply fax [the] doctor and tell him/her to apply to [the] Drug Plan for EDS 
when it would benefit the patient.  Therefore, the doctor collects the $4 for 
my fax…but then has to do the work.  If they don’t pay me then I rarely do 
everything.  I used too but too much work for nothing. [REMUN] [PRO] 
[ADMIN] 
o Software program to facilitate requests by software vendors and SPDP.  
Emergency trial program. [AUTO] [COV] 
o Physicians are paid for administrative work; why are pharmacists not paid?  
Veteran Affairs pays for this type of service – very much appreciated. 
[REMUN] [ADMIN] 
o Physicians should be more aware of the programs and provide appropriate 
information on the written prescription to reduce the time wasted calling 
them back for information. [ED] [COMM] [PRO] [ADMIN] 
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o The pharmacy should receive a fax as soon as the EDS has been 
approved. [COMM] 
o [The Drug Plan] should be more up-to-date in their criteria i.e. Zyprexa is on 
the hospital formulary but not the community formulary.  Also with Fosamax 
and Didrocal.  All [the Drug Plan] cares about is their own budget and not 
the whole picture. [COV] [COMM] [PRO] 
o About the EDS [program], physicians should indicate the diagnosis and 
other relevant information on the prescription; that way the pharmacist does 
not have to phone the doctor.  Also, it would beneficial to the patient if the 
EDS application was processed faster by the Drug Plan (i.e. within the same 
day). [COMM] [PRO] 
o Pharmacists should be paid for this service as it is a means for SPDP to 
save or cut costs.  Politicians talk about the “value” of pharmacists but no 
one mentions reimbursement for a valued service.  Electronic integration 
with SPDP should be considered – i.e. submission should be done via 
internet instead of fax alone. [REMUN] [AUTO] [PRO] [ADMIN] 
o Scrap it totally – allow physicians to prescribe – have guts and stop listing 
everything but have the best on the formulary or the first based on 
evidence-based medicine. [COV] [PRO] [ADMIN] 
o 2 year old refused coverage (Plan 2) for Prevacid after hospital discharge 
re: esophagitis, severe from acid reflux (docs thought patient has asthma).  
Money saved on puffers could have been used to cover the Prevacid 
completely but no provision made for children or any exceptions or unusual 
circumstances. [COV] [PRO] [COMM] 
o Physicians should not tell patient that EDS coverage means that 
prescriptions are free.  Also, have more staffing arranged for Thursday and 
Friday for EDS coverage, e.g. if an antibiotic is prescribed, the patient 
usually has to wait for 5 days.  Have EDS approved in a more timely 
manner.  Also, physicians are not aware of the MAC policy.  Also if the 
physician wants pharmacists to apply for EDS, please indicate all the 
appropriate information on the prescription.  So we don’t have to keep 
phoning the doctor. [ED] [COMM] [PRO] [ADMIN] 
o Need Drug Plan feedback; never know status of EDS. [COMM] 
o Doctors do not understand EDS.  They think it means patients will get 
medication for free.  I spend much time with irate customers who think the 
drug should be cheaper because the doctor said so.  MUST EDUCATE 
PHYSICIANS!  Doctors think a drug should be covered simply because they 
want to use it.  They do not understand nor care about approved indications. 
[ED] [COMM] [COV] 
o Must simplify process.  The burden on the pharmacy for EDS is often 
overwhelming.  Very few physicians in this area do it themselves, they rely 
on the pharmacy to do it for them.  Physicians now get paid for faxed refills, 
and quite frankly, pharmacists should get some sort of payment for the 
administrative burden of doing an EDS.  This is one more service which our 
profession is doing for nothing, and out time could be better spent 
elsewhere.  The patients put significant pressure on the pharmacists to get 
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EDS, and if they do not qualify for it because the doctor has not used the 
drug for an approved indication, the patient is upset and it is too late to 
change the drug, because it takes one to two weeks to get a response from 
the Drug Plan, even if you fax.  By this time, the patient is taking the drug, 
hoping they will get a refund if EDS is approved. [PRO] [REMUN] [ADMIN] 
[COMM] 
o I had called in an “emergency” EDS request for a cancer patient who 
needed Duragesic patches.  This patient was on palliative care.  They Drug 
Plan said they were back logged and it would take several days.  This was 
NOT acceptable with the patient’s circumstances and pain levels.  I 
understand having to wait for other circumstances, such as a PPI drug, but 
this was a situation that required immediate attention and did not receive it.  
There is no such thing as “emergency” EDS requests. [PRO] [COMM] 
[COV] 
o Doctors prescribe what they want.  If a patient presents with “gerd” they 
seldom start with an H2RA, they jump straight to PPIs.  Very seldom do they 
prescribe Amoxicillin for a simple sinus infection, they go straight to Biaxin 
or Zithromax.  Physicians in this area want the Drug Plan to cover drugs 
because they have decided it is the best one and they want it.  They get 
annoyed if we ask if they’ve tried something else on the Drug Plan first, or 
tell them the condition is not an approved one. [COV] [COMM] [PRO] 
o Longer or indefinite EDS coverage for certain maintenance drugs. [COV] 
o Notify the applying agency (pharmacy) if there is a problem with the 
application instead of simply doing nothing. [COMM] 
o Apply a lot more common sense and treat each application on its individual 
merits rather than the strict “cookie cutter” approach used now.  i.e. work in 
the best interests of the patient rather than SPDP. [PRO] [COV] 
o When a diagnosis is obvious (e.g. Actos or Avandia for a diabetic or H. P. 
Pac for H. Pylori) why do we need to contact the doctor for a diagnosis 
(make-work project?) as per the Drug Plan rules? [PRO] [ADMIN] [COMM] 
o Whether approved or rejected – the faxed EDS form should always be 
returned to the pharmacy which sent in the form in a reasonable time frame. 
[PRO] [COMM] 
o Many EDS application are for medications which patients receive who have 
other insurance benefits.  If they get the EDS approved then the other 
insurance program cuts in for payment. [COV] [PRO] [ADMIN] 
o Explain to patients that EDS does not equal 100% “free” medicine.  Only 
100% coverage under their plan.  Some patients think if the Drug Plan 
covers something, it means that the cost is covered by government. [ED] 
[COMM] 
o Can EDS be extended to cover “classes” of drugs?  For Example, a patient 
is put on Fosamax, and receives EDS.  However, experiences side effects 
and switches to Actonel.  Have to apply for EDS again.  Also, some third-
party plans that cover only formulary medications assume EDS is 
automatically granted whenever it is applied for.  For example, patient gets 
a prescription for Zithromax (first prescription).  Sends receipt to work 
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insurance, and receives letter telling them they require EDS to receive 
money back.  Most letters are written as if EDS will be automatically granted 
whether the patient has actually met conditions of EDS or not (in this case, 
didn’t try other antibiotic first).  It is then up to the pharmacist to explain why 
the patient shouldn’t expect any money back, making us look bad and not 
their plan. [COV] [COMM] [PRO] [ADMIN] 
o We should be reimbursed for our time and effort and expertise.  We are 
saving the SPDP and third-party insurance money – they need us in the link 
– we should be reimbursed. [REMUN] [PRO] 
o Put all EDS drugs on Plan and encourage doctors to use discretion in 
prescribing them.  It is impossible (nearly) to get a diagnosis in a timely 
fashion – very annoying! [COV] [PRO] [COMM] 
o Increase turn around time for EDS requests.  Too long of a wait. [PRO] 
o Better communication when more information is needed or requests are 
denied.  We currently get NOTHING from the Drug Plan to say when 
requests are approved/denied.  We can wait days to try and process and 
EDS claim only to find out, by phoning, that there was a problem.  Perhaps 
they could institute a priority policy to get acute care medications approved 
in a more timely fashion (i.e. same day!!). [COMM] [COV] [PRO] [ADMIN] 
o I think doctors need to be better informed on both EDS and MAC.  The 
number of patients who have been told their medication will be “fully 
covered” once they get EDS is astonishing and we spend a lot of time 
explaining the process to very upset patients.  All the pharmacists here feel 
that if the onus to apply for EDS is put on us (which it is) the doctors should 
be required to provide us with the information needed in a timely matter.  
Often we spend weeks trying to get the information because the doctor can’t 
be bothered to get back to us. [ED] [COMM] [PRO] [ADMIN] 
o EDS program is prone to abuse.  Many are the times when a physician will 
request EDS simply to have his/her choice covered. [PRO] [COV] 
o Seems to be too much work that should be done by the doctor not the 
pharmacists as they have the needed information not us.  Being done 
mainly for low income people or people with third-party plans as a 
requirement that their third-party plan pays for the drug.  Lots of times we 
don’t even bother to apply as patients’ deductible is $99,000 and their third-
party plan pays for it even if not a SPDP benefit.  Give it back to the doctors! 
[ADMIN] [PRO] [COMM] 
o Most people believe they don’t have to pay for it if on EDS. [COMM] [ED] 
o Too much work to credit return prescription and re-bill and give patient 
refund when it is backdated.  [PRO] [ADMIN] 
o If program is to continue [the] public must be better educated as trying to 
explain it to them is a major waste of time and aggravation. [ED] [COMM] 
o Make the doctors do it again.  They are much more apt to write expensive 
drugs now that the pharmacist has to do everything.  If they had to do it, 
they would give cheaper drugs.  The doctors also don’t understand how the 
special support program or EDS works – a lot of them actually think the drug 
is either free or very cheap if they request EDS. [ED] [PRO] [ADMIN] [COV] 
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o Doctors need to look at the EDS criteria before they prescribe to ensure 
patients will be eligible.  It is not good enough to scribble on a prescription 
“apply for EDS” if the patient isn’t going to meet the proper criteria.  Doctors 
need to be educated that even though a patient may receive EDS on a 
particular drug, it does not mean it will automatically be cheaper for them.  
Doctors need to understand that this is only true if a patient actually has 
coverage from the Drug Plan – most do not! [COMM] [PRO] [ED] [COV] 
o Educate doctors to put necessary information for criteria on EDS on 
prescription. [ED] [COMM] 
o Once someone is approved for EDS for a drug that is treating a non-curable 
condition, e.g. osteoporosis, COPD, reflux with erosive esophgitis, etc. there 
should not be a time line on EDS coverage.  It is frustrating having to re-
apply for the same drug for the same person and condition ever 1, 2, or 3 
years when their condition is non-curable and the will require treatment 
indefinitely.  [PRO] [COMM] [ADMIN] [COV] 
o Patient in a correctional facility should be exempt because they are unable 
to receive drugs that are not covered (they do not have the ability to pay) 
and therefore cannot receive a drug if they do not meet the criteria but 
would still benefit. [COV] [PRO] 
o Anytime doctors write for an EDS drug, they should give a diagnosis or any 
criteria needed to phone a EDS request in.  If they won’t phone the EDS in 
then they should supply us with the information we need.  As the 
pharmacist, you feel an obligation to help your patient save money.  They 
(patients) have no idea how EDS works. [COMM] [ED] [PRO] [ADMIN] 
o The EDS request takes the pharmacist a lot of time.  You have to be like a 
private detective and track down the doctor to get all of your information to 
make the request.  This takes time and money to do.  Money being spent on 
wages and phone calls.  Time you don’t have.  A lot of time these requests 
just pile up by the phone in hope that the doctor would call a prescription in.  
When he/she calls a prescription in you hope you can get all the information 
you need from him/her to finish your EDS request. [PRO] [COMM] [ADMIN] 
o The problem we have is we have a SAHO insurance company that needs 
EDS to settle in order for them to pay the patient.  These people are no 
where near their deductible but we have to bother the doctor for the 
information needed to make the request, bother the pharmacist to make the 
request, bother the Drug Plan to process the request, just so the SAHO 
insurance company can process a insurance claim.  No other insurance 
company requires this but a health organization insurance company.  This 
puts more strain on an already overworked system.  The only way the 
insurance company got the SAHO insurance is the government moved the 
company to Saskatchewan from down east and gave them the business.  
[COV] [ADMIN] 
o It is one thing for the Drug Plan to allow us to apply for EDS (and not 
compensate us for doing their (?whose?) job), it is a whole other thing when 
we are asked to track down a diagnosis, to track down applicable patient 
information to meet EDS criteria and then to continually try to submit the 
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same claim to see if it has been accepted.  If not accepted, eventually we 
must call the Drug Plan to find out why it was rejected and explain this to the 
patient.  If claim is accepted we still have a paper trail to fix, in resending the 
original claim and refunding part to the client, changing our end-of-day 
reports and payer totals ? or the alternative, explaining to the patient how 
to get reimbursed from Saskatchewan Health…  This is the time consuming 
part. [ADMIN] [PRO] [REMUN] 
o I am tired of working for the Saskatchewan Drug Plan gratis (as well as for 
other payers).  I did not go into pharmacy to explain insurance policies and 
jump through hoop after hoop to try to obtain the best possible health care 
for my clients.  I feel that EDS & MAC are the Drug Plan’s way of making 
coverage so difficult to obtain that people no longer bother with it.  What a 
short sighted vision! [COV] [PRO] [ADMIN] 
o I suggest that when an EDS drug is initially filled, that it is processed 
through the Drug Plan.  At this point, the Drug Plan can contact the 
prescriber for the information they seek.  Once they find out the EDS criteria 
is not met, at that point they can cancel patients EDS and contact both 
doctor and patient to explain all of this.  They will soon find out how time 
consuming and cumbersome all of this is, and costly to the Drug Plan! 
[PRO] [ADMIN] 
o Need better and more timely response mechanisms in place. [AUTO] 
[COMM] 
o One big problem with EDS occurs with insurance companies who tie their 
benefits to SPDP.  Sometime months after the fact we are requested to 
apply for EDS so that insurance companies will accept the claim for 
reimbursement – big hassle for no compensation. [COV] [PRO] 
o Fax back to pharmacy when approved (letter) so we can re-bill or send to 
third-party payers. [COMM] 
o Notify doctors to write diagnosis on all prescriptions (esp. EDS 
medications). [ED] 
o If I, a pharmacist, phone in for immediate coverage and choose that 
particular selection in the phone cue and the patient meets the criteria in the 
formulary can we get the coverage immediately or within a few minutes, 
would make adjudication process with third-party payers easier instead of 
re-billing/refunding.  Otherwise we don’t have the choice of immediate 
coverage that isn’t immediate. [PRO] [AUTO] [COMM] 
o Education of the physicians.  Most of them expect you to initiate EDS but 
they do not include enough information and a lot of time is wasted trying to 
get this information from them! [ED] [COMM] 
o Scrap them!  Drug should either be on or off the Drug Plan.  No in-between 
(EDS)! [COV] 
o The EDS program could be improved if [the] pharmacist was allowed to 
assume diagnosis (e.g. if patient is on Metformin, Glyburide, buying test 
strips, lancets, and says they are diabetic, are we not safe in assuming (or 
knowing) they have diabetes without phoning the doctor for confirmation 
when he/she orders Avandia?).  The same for asthmatics on Flovent and 
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Salbutamol with uncontrolled asthma when needing EDS on Advair. [PRO] 
[COV] 
o EDS program is necessary but pharmacists should receive reimbursement 
for doing it.  It is too time consuming for is to spend all this time for free. 
[REMUN] [ADMIN] 
o Physicians need to be educated on how the Drug Plan works (what 
medications are formulary, what are not, what are EDS and that criteria 
must be met in order to get EDS, deductibles, special support plan, etc.).  
Very few physicians have a good grasp of how the Plan works.  Many are of 
the opinion that getting EDS means that the drug is paid for by the Drug 
Plan.  Physician “detailing” done by someone from the Drug Plan or by a 
pharmacist would be time well spent. [ED] [COMM] 
o Patient understanding of EDS is poor.  Letters from Saskatchewan Health 
do not help – patients do not understand why they still have to pay or meet 
a deductible when they get a letter of approval for EDS which says that the 
drug is “covered.”  The letter should be reworded to make it more clearly 
understood that EDS does not necessarily mean the medication will be paid 
for. [ED] [COMM] 
o Educate the doctors – patients come out of the hospital or clinic with a script 
for one of the “SOC” PPIs and hardly ever a diagnosis or trial with Pariet or 
Apo-omeprazole.  Likewise with antibiotics – they ask the patient if he/she 
has a plan but not all plans cover the expensive antibiotics and we end up 
calling the doctor to change the prescription, or give diagnosis and call the 
Drug Plan then the patient has to decide whether they want to pay for it and 
chance not getting reimbursed.  We have had people simply shred the 
prescription at our counter and say to never mind they’ll either see another 
doctor or tough it out or their doctor always is prescribing the “expensive 
stuff” and they are going to look for another doctor. [ED] [COMM] [PRO] 
o I feel that the EDS program is making unreasonable comments when a 
rejection fax is received.  For example, “was a C & S done (for an 
antibiotic)?” or “was a culture sensitivity done?” – not a usual question when 
I take up the doctor’s time for a diagnosis.  [PRO] [COMM] 
o Much more work must be performed by the pharmacist when an EDS 
application has to be done.  The pharmacist should receive remuneration 
from the Drug Plan and/or patient, and the credit for making the application!  
Let me tell you the doctors’ offices are very glad not to have to do these 
EDS’ any longer! [REMUN] [PRO] [ADMIN] 
o As a pharmacy we probably do the most applications for EDS’ as any 
pharmacy our size in this province.  I’m proud of that, but feel it is such an 
integral part of the Saskatchewan Drug Plan and health care network, that 
pharmacists must receive pay for this!  Many third-party drug insurance 
companies demand EDS applications and imply they will be automatically 
approved – not so! [REMUN] [COV] 
o Why do Celebrex and Bextra require EDS when they are the same price as 
Arthrotec? [COV] 
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o I believe that since pharmacists now apply for EDS doctors have lost touch 
with what requires EDS.  For me to apply now often requires 2 or 3 phone 
calls before I can fill out the fax form. [COMM] [ED] [PRO] 
o I estimate that 30 – 40% of our EDS requests are for people who the SPDP 
does not pay any portion of their prescriptions but their private plan requires 
us to apply for EDS and transmit to SPDP before they will pay. [COV] [ED] 
o We could receive an administrative fee to reflect the large amounts of time 
spent explaining, interpreting, faxing, long distance phone calls, etc.  There 
is no incentive to physicians to do this, although they have information at 
[their] fingertips.  Both the EDS and MAC programs are excessively 
burdening pharmacists and resulting in less time available for patient care 
and higher job stress levels.  There must be a lot of money saved ? some 
of this should be used to cover out staffing costs. [REMUN] [ADMIN] 
[COOP] [PRO] 
o Cancel EDS.  Either drug to be formulary, or not.  Ultimately the costs 
incurred to [the] province is likely higher with EDS considering most patients 
are put on first line agents with intent of using EDS drug after words.  
Province ends up paying for both drugs plus administrative cost of Drug 
Plan employees. [COV] [PRO] 
o If the Drug Plan wishes for pharmacies to continue to have to apply for EDS 
they should pay us.  Very time consuming to not only apply for EDS but 
essentially process the same prescription twice (initially upon patient arrival 
and then again once prescription approved, or not, for EDS).  Time and 
money – we should be getting paid. [REMUN] [PRO] [ADMIN] 
o The EDS program is just another form of two-tier health care.  Allowing 
pharmacists to apply for EDS is just a download of work from doctors to us.  
We waste a lot of time calling doctors for diagnosis because they don’t 
indicate it on the prescription.  Apparently they think that their time is 
infinitely more important than the pharmacists.  We are tired of taking crap 
from physicians, be it their EDS load, their incorrect dosing and medication 
errors, or simply their bad/unreadable writing.  Maybe they should spend a 
shift in our shoes. [COV] [ADMIN] [COMM] [COOP] [PRO] 
o Problems are the accessibility of doctors – cannot reach right away if at all, 
no doctor diagnosis on most scripts and doctors do not know the 
requirements for EDS drugs; therefore educate doctors and make them 
more accountable.  This service must be paid for.  A pharmacists time is 
worth something! [COMM] [COOP] [ED] [REMUN] 
o Time is money – we are very conscientious about completing forms at time 
of patient presenting prescription.  Multiple EDS forms when we are busy 
are extremely time consuming.  I must admit feeling exasperated when I 
have multiple requests hack-to-back for EDS renewals.  We often intervene 
to get medication changed because the patient cannot afford – this results 
in considerable time and perhaps improvement in patient care (?) but does 
not result in an EDS application.  I would estimate we intervene 
approximately 10 times per week. [REMUN] [PRO] [ADMIN] 
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o Sometimes it is difficult to obtain the official diagnosis from the prescriber.  I 
believe as a health care professional we should be able to indicate a 
diagnosis such as GERD especially if the patient meets all of the criteria 
and we are sure of what the patient is being treated for. [COMM] [PRO] 
o EDS program could be improved by having the Drug Plan send us 
(mail/email) a list of our claims which have been approved or not approved. 
[COMM] [PRO] 
o Doctors could be more informed about the program and told to write [the] 
diagnosis on the prescriptions for EDS drugs. [ED] [COMM] 
o Less drugs on EDS program – take TOO MUCH time. [COV] [ADMIN] 
o Doctors need more education on documenting and EDS requirements. [ED] 
o We spend a great deal of time applying for EDS.  Many private drug plans 
now require non-formulary drugs to be placed on the drug plan.  It is a 
length[y] procedure in many instance[s] to obtain [the] diagnosis, [and] past 
drug therapy if not filled at our pharmacy.  It would be of great assistance if 
the individuals at the SPDP would be able to guide us with past drug 
therapy as elder[ly] patients often do not know what [they] last received, etc.  
I also feel that the application for EDS should be able to be billed for 
pharmacy reimbursement. [COV] [PRO] [ADMIN] [REMUN] 
o Better educate the physicians to either submit the EDS request or write the 
information needed on [the] script so that we may do it at the pharmacy 
(without having to phone and track it down and waste our time). [ED] [PRO] 
o The biggest obstacle is trying to obtain the diagnosis from the doctor when 
applying for EDS.  Often the doctor will write EDS on the prescription but no 
diagnosis. [COMM] [ADMIN] 
o The EDS form takes less than 5 minutes to fill out, but getting a hold of a 
busy doctor is most time consuming. [COMM] 
o Better communication between SPDP and pharmacy. [COMM] 
o EDS requests should be handled in a quicker manner and if someone does 
not meet criteria (or pending) the pharmacy should be contacted with 
details. [PRO] [COMM]  
o EDS approval or rejection INCLUDING dates should be provided to 
pharmacy. [COMM] 
o Drug Plan warning online that EDS is soon to expire. [COV] [COMM] 
o Re-evaluate EDS drugs – for example, Imitrex – criteria is migraine, is this 
necessary? [COV] 
o Educate doctors – encourage them to include diagnosis on prescriptions. 
[ED] [COMM] 
o Biggest problem is third-party payers who insist on EDS – always after the 
fact. [COV] 
o Pharmacy [should] be notified if approved – we sometimes know if rejected. 
[COMM] 
o Doctors [do] not always cooperate in completing information required. 
[COOP] [COMM] 
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o Each drug requiring EDS should have it’s own request form complete with 
criteria to assist the doctors in knowing what information is required as more 
are “much too busy” to read the formulary. [PRO] [ADMIN] 
o I feel most doctors use the high end drugs because of marketing from the 
innovative manufacturers rather than from need.  It seems they will not 
apply for EDS because they don’t get paid but still won’t fill in required 
information unless we fax and then they get paid for the fax!  I wonder what 
motivates them? [COV] [COMM] 
o Physicians should be more aware of criteria for EDS; pharmacists should 
NOT have to tell physicians what the criteria is. [ED] 
o Physicians should be more accessible to pharmacists.  If we are expected 
to apply for EDS we should not have to spend a lot of time begging for 
diagnoses and criteria which is what we are doing now. [COMM] [COOP] 
o Patients should take more responsibility in this matter – after all it’s their 
pocket book and they best know what they can or can not afford.  They 
should be asking their physician to provide the pharmacist with diagnoses, 
criteria, etc. if they feel a drug us going to be a financial burden for them. 
[COV] [COMM] 
o It’s wonderful to have all these benefits to the patient and the government, 
again being carried on the backs of pharmacists.  We are not allowed to 
change for the service we provide and we are not given any help in this 
matter either. [REMUN] [ADMIN] 
o There’s a safety issue involved.  In order to apply for EDS we fax a form to 
the doctor to be filled out by him/her.  This must also include a list of criteria 
because doctors are very busy and they can’t look in the formulary 
themselves.  Then begins the wait for a reply.  Meanwhile a stack of faxed 
EDS forms piles up on the dispensary counter along with faxed 
prescriptions waiting for signatures.  Then some of them come back 
completed incorrectly or incompletely.  Search through the pile, find the 
corresponding one and shred it or refax it.  Meanwhile the phones are still 
ringing and people need questions answered.  It makes for unsafe working 
conditions as far as making a mistake on someone’s prescription is 
concerned.  The more we have piled on our plate the less time we have to 
do what is most important and that is make sure the prescription is filled 
appropriately and correctly. [PRO] [COMM] [ADMIN] 
o Give us [the] ability to get “instant” approval on short-term medications – for 
example Cipro, eye drops, etc.  Our pharmacy usually gives out and 
“guesses” on EDS approval and charges the patient as such.  Some DO 
NOT give out drug without EDS or make patient pay full cost. [COV] [PRO] 
o SPDP EDS is very prompt 48 – 72 hours most times.  When the 72 hours 
window is passed, it is frustrating and usually requires a call.  Even though 
they request our store information, we are not called back if there is a 
problem or missing information.  On a positive note, the EDS staff has been 
excellent in getting quick approvals if asked when it impacts a emergency 
assistance or an appeal of special support.  Gail Bradley seems to 
understand community pharmacy well. [COMM] [PRO] 
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o Physicians should be responsible for applying for the EDS & MAC policy for 
their patients.  Why should pharmacists manage the doctors’ prescribing 
habits? [PRO] [ADMIN] 
o A lot of work – poor support from SPDP.  Patients and physicians expect 
pharmacists to do a lot.  If a patient is not granted the EDS, pharmacists are 
the ones to blame! [COOP] [PRO] [COMM] 
o Online submission where you only have to click on relevant information. 
[AUTO] [PRO] 
o Coordinate with software vendors to be able to submit online directly from 
patient profile.  All patient information would already be on form from profile, 
then click areas relevant to that drug and hit send (Then I woke up and 
realized it was all just a dream!). [AUTO] [PRO] 
o A lot of trouble getting Reminyl coverage. [COV] 
o EDS program never calls to let us know of acceptance or refusal.  Average 
time for approval 3 – 5 days (more so for Aricept, Reminyl). [COMM] [PRO] 
o Notification if EDS is accepted rather than just rejected would be nice if EDS 
request was initiated by a pharmacy. [COMM] [PRO] 
o It is sometimes very difficult and time consuming to obtain diagnosis and 
alternative agents tried.  Too much time is spent on this requirement. [PRO] 
[ADMIN] [COMM] 
o EDS requests take too long to be approved or not. [PRO] [ADMIN] 
o Physicians do not understand the SPDP.  They assume that if we apply and 
receive EDS that the prescription is “cheaper” for them.  Patients need to 
have a special support program in place as well.  Physicians need to 
understand the Drug Plan first before the EDS program will make any sense 
to them. [ED] [COMM] 
o There is no universal drug plan in this province.  Only those people with 
disproportionate drug costs to income may receive benefit. [COV] 
o Private third-party drug plans from benefit packages at work should not be 
able to restrict coverage based on the Drug Plans use of EDS to save 
money. [COV] 
o 80% of the time we apply because [the] patient has third-party private 
coverage and a deductible that will never be met.  I don’t mind doing this if 
we were allowed to charge a service fee.  However [the] Drug Plan has said 
they will void our contract if we charge for this service. [COV] [REMUN] 
[ADMIN] 
o Faster turn around time for EDS requests… has been over one week due to 
backlog and insufficient staff to process requests.  Some patients decide to 
wait for approval rather than pay up front and wait for refund.  This is usually 
not in the patient’s best health interest. [PRO] [COV] 
o Perhaps an intervention code that would allow a 4 day supply of the EDS 
drug while the request is being processed would help.  Patient could 
consider their options after 4 days – if refused continue therapy at own 
expense or see doctor to change prescription (this option however means 
another physician visit). [COV] [PRO] 
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o Physicians should cease and desist with telling patients that EDS reduces 
the cost of their medication! [ED] [COMM] 
o It would be extremely helpful if the physicians, [who] would like us to apply 
for EDS, included on the prescription the diagnosis and criteria. [COMM] 
[COOP] 
o Need to increase public awareness and knowledge regarding EDS program 
and/or MAC policy. [ED] [COMM] 
o Need to increase doctors’ awareness and knowledge (patients often receive 
incorrect information regarding EDS & MAC). [ED] 
o It is time consuming. [ADMIN] 
o Physicians get paid for faxes and I believe EDS requests while pharmacists 
don’t. [REMUN] 
o Less items should be on EDS – rather just part of the formulary. [COV]  
o EDS processing times need to be increased; 2 – 3 day waits are 
unacceptable.  Should be in real-time – i.e. same day approval. [PRO] 
o Should fax back store or go to fax system for doctors – most of our time is 
used finding out if EDS has been applied for – if doctor phones it in it could 
get “bumped” off the system if it is full. [PRO] [COMM] [ADMIN] 
o Response to rejected claims because the patient is waiting and we always 
must indicate second or third calls. [PRO] [COMM] 
o Criteria for EDS is not always clearly indicated or followed as written in 
formulary – very frustrating. [COV] [COMM] 
o For some reason doctors EDS requests seem to get preferential treatment 
(done faster and less problems with not meeting criteria). [COMM] [COV] 
o EDS should be integrated into the online adjudication system and should be 
followed up by the Drug Plan rather than by the discretion of the patient’s 
physician or pharmacist.  If they get a prescription for an EDS eligible 
product, the system should flag it and initiate the EDS process by contacting 
the physician to confirm the diagnosis, etc.  This is the only way this process 
can satisfy the concept of universality.  [AUTO] [PRO] [COMM] 
o Many EDS applications are done to satisfy third-party insurers rather than to 
lower the cost (get some coverage by the SPDP). [COV] 
o Pharmacists should be able to give a few days emergency coverage under 
certain criteria. [COV] 
o Antibiotics are difficult to have on restricted coverage because therapy 
needs to be initiated immediately and the time it can take to contact the 
prescriber for a diagnosis, call the Drug Plan to apply for coverage and wait 
until it is accepted can be far too long especially if it is a prescription 
received on a Friday evening (can sometimes have to wait almost a week 
before gaining therapy). [COV] [PRO] [ADMIN] 
o If someone’s request has been rejected please get back to [the] pharmacy 
as soon as possible. [COMM] [PRO] 
o Sometimes the processing time is long ? more than one week to get 
coverage. [PRO] 
o Notification to pharmacist of approval/denial of requests initiated by 
pharmacist. [PRO] [COMM]         
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MAC Themes  
? Process [PRO] – issues pertaining to how the program is run 
? Administrative [ADMIN] – the subject of administrative burden, having to 
balance regular duties with MAC, explaining the policy, etc. 
? Remuneration [REMUN] – focus on being compensated for initiating 
administering MAC  
? Education [ED] – concern with the lack of understanding regarding the 
MAC process by physicians and patients, as well as suggestions to 
educate the two, and how patients received notification of MAC before 
pharmacists 
? Cooperation [COOP] – distress over the lack of cooperation seen from 
the Drug Plan on matters relating to MAC and its implementation 
? Communication [COMM] – centring on lack of, or insufficient  
communication between Drug Plan and pharmacists 
? Coverage [COV] – anxiety over the issue of what is and isn’t covered, 
when patients benefits start to take effect, patients being stabilized on 
one medication and are forced to try another  
? Future Concerns [FUT] – issue of what may happen in the future when 
MAC is expanded to more complex categories 
 
Responses 
o Consult and inform pharmacists of proposed changes. [COMM] 
o The MAC policy undermines the format of the formulary and I can see 
where the drug plan is going with their reasoning (soon other drug 
categories will be included).  In the short time the MAC policy has been in 
place, we have had at least two (2) cases where relief was not achieved 
when a lesser priced drug other than Losec was taken.  We are a rather 
small pharmacy outlet, but if our percentage of clients holds true in the 
industry, many patients will not be receiving adequate care.  The MAC 
policy drugs, if in the formaulary, would not be considered interchangeable, 
what the drug plan is implying is somewhat similar to administering a 
‘Valium’ in place of an ‘Ativan’. [COV] 
o Make all MAC choices a tiered process, then if failure allow EDS for 3rd tier 
choices. [COV] 
o Instead of applying for EDS on PPIs, make their coverage automatic, but 
limited to the price of the MAC like BC. [COV] [PRO] 
o MAC policy disadvantages those people who even though they are in the 
minority, get less benefit or are unable to tolerate the suggested drug 
covered on the MAC policy.  Suggest [the] drug plan move very slowly 
before adding more drugs. [COV] [FUT] 
o MAC program information was mailed to patients before the pharmacists 
received their information packages, so we had people bringing in letters 
and phoning us and we had no background or information about the 
program.  I was very, very angry, that if we were to field questions, we had 
not been notified well in advance of their implementation.  Poor, poor 
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support from [the] Drug Plan, who always makes us deal with the 
consequences of their decisions. [COMM] [ADMIN] 
o When the MAC policy came into place, people’s EDS that had expired 
should have been automatically extended to generics Apo-omeprazole and 
Pariet without us applying again.  Certainly should have not had to include 
diagnosis again.  They should have this information.  It was enough that we 
had to fax everyone’s physician to ask if the switch was appropriate for that 
patient once changed by the physician to less expensive alternatives, the 
EDS should have been an automatic thing.  I feel it was poor planning and a 
waste of administrative dollars to not help each other out.  Think of how it 
affects us!!! [COV] [PRO] [ADMIN] [COMM] 
o Pharmacists have done most of the explaining of the MAC policy, and I am 
sure physicians have had to explain a lot too.  The minimum ? the Drug 
Plan.  We are doing the administrative work for them and get nothing.  
When a drug is approved, such as Ciprofloxacin, and the patient gets a full 
page of all generic equivalents and strengths, they have 5 – 10 minutes 
worth of questions.  Quit listing all these drugs; minimum amount of 
information would be appreciated! [COMM] [PRO] [ADMIN] [COV] 
o OK, switch the patients, but if they simply cannot take the alternatives, allow 
the switch back – for example, we have a patient on multiple drugs including 
Pantoloc.  She has a history of allergies plus condition such as an ulcer, 
depression, seizures and diabetes.  The switch to Omeprazole caused 
severe vomiting which lead to 3 days in hospital (HUGE COST).  Change to 
Pariet – back in hospital (2 days).  Coincidence?  Maybe, but probably not.  
NOW WHAT?  She is on social assistance and cannot afford Pantoloc! 
Cripes!!! [COV] [PRO] 
o MAC policy seems to be a make work project, job creation for civil servants. 
[ADMIN] 
o Most patients (actually all patients) who come in and have to get switched 
because of [the] MAC policy do not understand it.  They just nod their heads 
and say “if you say so” or “I guess if it is cheaper.”  But they all say that 
Pariet or Omeprazole works just fine (they just don’t want to pay the extra to 
cover the cost). [COV] [COMM] [ED] 
o [Should have] provided more information to pharmacists before changes are 
made, not after. [COMM] [ED] 
o The first I heard about the MAC policy was from a patient.  I was hurriedly 
reading the letter they handed me trying to sort out what it was saying while 
they were asking me questions.  My information letter from the Drug Plan 
came later that day. [COMM] [ED] 
o The MAC policy is idiotic.  To allow one person to continue to have full 
coverage for a product and another not based only when the latest EDS has 
been approved is not fair, nor equitable. [COV] 
o The letter sent to patients about MAC needs to be written so patients can 
understand [it]. [COMM] [ED] 
o Making Losec and Apo-omeprazole interchangeable, as AstraZeneca stated 
they were when they first introduced the tablets, would be great. [COV] 
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o So far I feel the MAC program is a good decision. [COV] 
o MAC policy a bit confusing.  I’m still not clear whether people who need 
Pantoloc, for example, can get full coverage for it if Pariet doesn’t work.  
Pantoloc is considered to be stronger despite what the MAC policy says. 
[ED] [COMM] [COV] 
o Put Pariet and Apo-omeprazole on the plan and have only the more 
expensive PPIs on EDS. [COV] 
o I think that once physicians are in the habit of prescribing low cost PPIs, 
there will be less work for pharmacists. [PRO] [ADMIN] 
o I find that there are many customers going back to the more expensive PPIs 
because the cheaper one didn’t work.  This is occurring much more often 
then I expected. [COV] 
o Our local hospital uses the hospital formulary, which includes all PPIs.  We 
need to have some consistency between hospitals and community.  I have 
noticed that Pantoloc is always used in hospital and we must always contact 
the doctor to explain that the MAC policy doesn’t fully cover Pantoloc and 
therefore more administrative time is needed for the pharmacist to have to 
explain both to the doctor and the patient to get the new prescription 
changed and then apply for EDS. [COV] [PRO] [ADMIN] 
o 2 days notice is inexcusable for implementing a new policy.  At the 
beginning lots of questions about it.  As of now no questions, since summer 
actually.  [COMM] [ED] 
o MAC policy is still in it infancy, so the jury is still out. [FUT] 
o The MAC policy should not be absolute.  Some patients are not receiving 
optimal therapy because they are being forced to take a drug based on cost, 
not on the individuals’ therapeutic needs. [COV] [PRO] 
o Discontinue. [COV] 
o All PPIs should be included on [the] regular formulary with MAC applying – 
would save an awful lot on faxing. [COV] [PRO] 
o The MAC program is preventing some patients from getting the medications 
that really are more effective.  They’ve tried some other medications before, 
and only a specific one will be effective. [COV] [PRO] 
o Too early to determine the impact of MAC. [FUT] 
o If MAC is being expanded – please notify pharmacists prior to 
announcement. [FUT] [COMM] 
o Very scared about MAC and the amount of time required for explaining 
things. [COMM] [ED] 
o Pharmacists should be able to do therapeutic interchange by protocol in 
order to facilitate the MAC program.  Both MAC and EDS would work better 
if pharmacists had the information and could make the application without 
spending so much time contacting doctors.  We need to be able to be paid a 
reasonable administrative fee for our time to provide this service. [COV] 
[COMM] [REMUN] 
o Do not agree with the MAC policy.  I think it will become a problem when 
they expand to other groups. [COV] [FUT] 
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o MORE information to the public – most of the early response indicates the 
secondary or less expensive drug is doing an adequate job. [ED] [COMM] 
[COV] 
o The MAC policy is a good program and a cost saver to the public, however 
the public needs to be better informed as to how it works. [ED] [COMM] 
o Way more notice should have been sent out to pharmacists first – patients 
were getting their information before pharmacists had a chance to really 
know the policy of MAC. [ED] [COMM] 
o Include RBSP and SMA in early discussions of new MAC policy. [COV] 
[COMM] [COOP] 
o Allow pharmacist the ability to switch to MAC from non-MAC drug with 
guidelines provided by SMA. [COV] [PRO] 
o The MAC information was very poorly sent out.  We received it like 3 days 
before it was to be implemented. [COMM] 
o I do not agree that all PPIs are equal in efficacy and side effects and I think 
that when this policy is expanded to more classes of drugs, our problems 
will get worse. [COV] [FUT] 
o I’m not sure how pharmacists get hooked into this EDS request job but it’s 
another job in addition to explaining MAC to patients and faxing doctors for 
renewals.  We don’t get paid for any of this.  When most pharmacies are 
open 8 hours per day and you spend 15 to 20 minutes per person 
explaining MAC to them, how much time do you have left to fill 
prescriptions, patient counselling, etc.?  With all the information that was 
sent out to patients about MAC, they still ended up at the pharmacy to get 
an explanation of how it worked. [PRO] [ADMIN] [REMUN] [ED] [COMM] 
o The Drug Plan did a lousy job with the MAC – giving bad information to the 
patients created a lot of confusion and pharmacists should have had more 
notice. [ED] [COMM] 
o Suggestions of less expensive alternatives have been something we have 
always done in the past after discussion with patient and if cost is an issue 
to them of their payer.  We then send a faxed recommendation for trial drug 
to the doctor along with cost comparison.  At this point, after patient 
involvement, it still remains the doctors’ choice.  I feel this is a much better 
way as it doesn’t question the doctor’s authority or “impose” a drug choice 
on doctor or patient.  This method is received more positively than the MAC. 
[COV] [PRO] [ADMIN] [COOP] 
o I would suggest more academic detailing such as RxFiles does (to doctors 
and pharmacists).  Teach more pharmacists about drug categories and 
assertiveness in involvement in patient therapy.  A small compensation to 
pharmacists as incentive to reduce Saskatchewan Drug Plan costs and 
document for compensation might prove useful.  Currently there is no 
incentive to get involved in patient care other than personal satisfaction and 
that only lasts so long in a stretched and overburdened system.  Current 
compensation for pharmacists such as trial drugs. EDS, special support 
forms, manual claims, etc. are simply not worth the effort monetarily. [ED] 
[REMUN] [COMM]  
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o It (MAC) will be much more time consuming when folks’ current EDS run 
out!  Then the major explanations will start.  I plan to give a brief explanation 
and refer the patient directly to SPDP. [ED] [COMM] [COV] 
o MAC implementation was horrid.  Patients received notification before we as 
pharmacists had any idea.  We found out through patients and the 
newspapers.  This really didn’t make us feel like spending hours explaining 
and recommending this incentive to patients!  Perhaps this should have 
been passed by those of us in the front lines first!?!  We were extremely 
disappointed in SPDP over that and are still resentful! [ED] [COMM] 
o MAC program seems cost effective but will be very difficult to administrate 
once more drug categories get included. [COV] [PRO] [ADMIN] [FUT] 
o We had already done considerable work with pharmacy initiated PPI 
substitution so MAC was not a problem for PPI. [PRO] 
o MAC is a good program; should be expanded – Cox-2 Inhibitors are an 
example of over prescribing. [COV] 
o We should have more notice when policy changes so we can better educate 
patients. [COMM] [ED] 
o There should be provision for the higher cost medications on the MAC list to 
be covered under EDS if the lower cost ones don’t work as well for the 
individual patient. [COV] [PRO] 
o Information [should be] sent to pharmacies at least 4 weeks prior to 
changes.  Pharmacy input on changes before they occur. [COMM] [COOP] 
o Allow EDS for patients in which the lower priced PPIs don’t work. [COV] 
[PRO] 
o If adding a new category, inform pharmacists before patients.  We are 
concerned about future categories… that they may be to the detriment of 
patients. [COMM] [FUT] 
o We need more public information to explain to people how the MAC 
program is in their best interest. [ED] [COMM] 
o I’m not sure where the MAC program is going but it creates more workload 
? can the pharmacist get reimbursed for the time spent on interventions? 
[FUT] [PRO] [ADMIN] 
o We spend too much time explaining government policies.  Many people truly 
find a difference with the different PPIs and shouldn’t have to pay extra. 
[COV] [COMM] [ADMIN] 
o MAC policy not explained to patients well and ended up being pharmacists’ 
responsibility to ensure patient understanding.  Very frustrating when I have 
to do the Drug Plan’s work and the we (pharmacists) get stone walled and 
treated as second class during negotiations for new contract and 
reimbursement opportunities – for example blister packs. [COMM] [ED] 
[ADMIN] 
o I appreciate the theory of MAC pricing – is it possible to combine RxFiles 
articles with information mail outs by Drug Plan as I find [the] RxFiles to be 
unbiased and informative? [ED] [COMM] 
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APPENDIX L  
Provincial and Territorial Drug Plan Websites 
Provincial Drug Plan Name Review Committee Website 
British Columbia (Ministry of Health 
Services) PharmaCare 
Drug Benefit Committee of 
PharmaCare www.healthservices.gov.bc.ca 
Alberta (Health & Wellness) Drug Benefit List Expert Committee on Drug Evaluation & Therapeutics www.health.gov.ab.ca 
Saskatchewan (Department of Health) Saskatchewan Drug Formulary 
Drug Quality Assessment Committee 
(DQAC) & Saskatchewan Formulary 
Committee 
www.health.gov.sk.ca 
Manitoba (Department of Health) Manitoba Drug Benefits & Interchangeability Formulary 
Manitoba Drug Standards & 
Therapeutics Committee www.gov.mb.ca/health/mdbif/index.html 
Ontario (Ministry of Health & Long-
term Care) 
Ontario Drug Benefit 
Formulary/Comparative Drug Index 
Drug Quality & Therapeutics 
Committee (DQTC) www.health.gov.on.ca 
Quebec (Department of Health & 
Social Services) 
Basic Presecription Drug Insurance 
Plan - (Régime général d’assurance 
médicaments, RGAM) 
Conseil Consultatif de Pharmacologie www.msss.gouv.qc.ca 
New Brunswick (Health & Wellness) New Brunswick Prescription Drug Program Formulary 
Atlantic Expert Advisory Committee 
(AEAC) www.gnb.ca/0051/index-e.asp 
Nova Scotia (Health) Nova Scotia Formulary Formulary Management Committee www.gov.ns.ca/health 
Prince Edward Island (Department of 
Health & Social Services) 
PEI Drug Cost Assistance Programs 
Formulary PEI Pharmacy Advisory Committee www.gov.pe.ca/hss/index.php3 
Newfoundland & Labrador 
(Department of Health & Community 
Services) 
Newfoundland & Labrador 
Interchangeable Drug Products 
Formulary 
Expert Advisory Committee www.gov.nf.ca/health 
Territorial Drug Plan Name Review Committee Website 
Yukon (Department of Health & Social 
Services) Yukon Drug Programs Formulary 
SK Drug Quality Assessment 
Committee & Yukon Formulary 
Working Group 
www.hss.gov.yk.ca 
Northwest Territories (Department of 
Health & Social Services) NWT PharmaCare Formulary  www.hlthss.gov.nt.ca 
Nunavut (Department of Health & 
Social Services)   www.gov.nu.ca/hsssite/hssmain.shtml 
 
 
 
 
 
